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Chapter 1
This thesis describes a series of experiments on the role of neurotrophic factors in spinal pain 
transmission. The details of these studies are found in the Chapters 2-5. As an introduction to 
these studies a general overview will be given of the organization of the pain system and the 
involvement of neurotrophic factors in sensory transmission, followed by a short description of the 
aim of this thesis.  
ORGANIZATION OF THE PAIN SYSTEM
According to the definition of the International Association for the Study of Pain (IASP), pain 
is an unpleasant sensory and emotional experience associated with actual or potential tissue 
damage, or described in terms of such damage. This definition implies that in order to perceive a 
stimulus as painful, both the sensory (Fig. 1) and the affective-motivational (Fig. 2) components 
of pain have to be experienced. In other words nociception or the detection of tissue damage is 
not the same as pain, because pain includes not only the detection of tissue damage but also 
the conscious perception of this damage as an unpleasant experience. Much progress in our 
understanding of the affective-motivational component of pain has been made in recent years 
(Tracey, 2005), especially by means of functional imaging studies, but a detailed description of 
these studies is beyond the scope of this introduction. Yet most of our knowledge regarding the 
organization of the pain system relates to the nociceptive component of pain and this is also the 
main subject of this thesis, with a focus on the spinal cord.
Pain and temperature are perceived by a system, which is anatomically and functionally distinct 
from the mechanosensory system, the latter being responsible for the perception of mechanical 
stimuli, e.g. discriminative touch, vibration, pressure, cutaneous tension, joint position and many 
other types of proprioceptive information. In virtually all tissues of the body, with the notable 
exception of the central nervous system, the sensation of pain is initiated by various types of nerve 
endings collectively termed nociceptors. Nociceptors appear as bare, relatively unspecialized nerve 
cell endings. They are able to transduce a variety of (potentially) damaging stimuli (including 
heat, cold, mechanical and chemical inputs), into receptor potentials which may then trigger 
action potentials. The cell bodies of nociceptors are located in dorsal root ganglia (DRG) or in 
the trigeminal ganglion and give rise to one axonal process which divides into two branches, one 
projecting to the periphery and one projecting centrally into the spinal cord or brainstem. There 
are two major subclasses of nociceptors: Aδ and C nociceptors. Aδ nociceptors are characterized 
by their thinly myelinated fibers and respond either to potentially damaging mechanical (Aδ 
mechanosensitive nociceptors) or to mechanothermal (Aδ mechanothermal nociceptors) stimuli. 
C nociceptors on the other hand are characterized by unmyelinated fibers that often respond to 
mechanical, thermal as well as chemical nociceptive stimuli and are therefore called polymodal 
nociceptors. Since Aδ fibers are myelinated, they convey action potentials faster than C fibers. In 
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human volunteers, by selectively blocking Aδ fibers using a pressure cuff, it was found that Aδ 
fibers are responsible for the so called first pain, a sharp and short lasting pain, while C fibers are 
responsible for the second pain, a delayed, diffuse type of pain, often outlasting the duration of the 
stimulus. C nociceptors are further subdivided into a peptidergic and a non-peptidergic subgroup 
of C nociceptors (Snider and McMahon, 1998) (Fig. 3). These two groups are further characterized 
by expressing different neurotrophic receptors and show different central termination areas.
Peptidergic nociceptors, in addition to the classical neurotransmitter glutamate, contain one 
or more neuropeptides such as Substance P (SubP), Calcitonin Gene-Related Peptide (CGRP), 
galanin, somatostatin and others. They also express TrkA, the receptor for Nerve Growth Factor 
(NGF) (Michael et al., 1997), and use Brain-Derived Neurotrophic Factor (BDNF) as a transmitter 
(see later). Non-peptidergic nociceptive neurons only use glutamate as transmitter. They are 
further characterized by expression of the plant lectin isolectin B4 (IB4) and contain the receptor 
components for Glial cell line-Derived Neurotrophic Factor, i.e. RET and GFRα-1, which are also 
discussed later (Molliver et al., 1997).
In the spinal cord, the peptidergic nociceptors terminate in lamina I and the outer layer of 
lamina II (IIouter), the most superficial layers of the spinal dorsal horn according to (Rexed, 
1952). Here they synaptically contact various types of neurons, including nociceptive specific 
neurons in lamina I that project to the brainstem and thalamus. Many of these neurons express 
Neurokinin-1 (NK-1), the receptor for SubP. It has been shown (Mantyh et al., 1997) that following 
selective ablation of these NK-1 neurons by a toxin, saporin, that was conjugated to SubP, baseline 
thermal and mechanical (pain) thresholds remained unaltered, but the hypersensitivity induced 
by a capsaicin injection (the pungent substance present in chili peppers) was almost completely 
abolished. Furthermore, these neurons were found to downregulate the K+-Cl- exporter channel 
KCC2, following peripheral nerve damage, resulting in increased excitability (Coull et al., 2003). 
It was therefore concluded that the peptidergic nociceptors-NK-1 neuronal system is important 
in both inflammatory and neuropathic pain conditions (Mantyh and Hunt, 2004). The non-
peptidergic nociceptors terminate preferentially in the outer region of lamina IIinner, which is also 
called lamina IImiddle. Lamina IIinner contains relatively few neurons, one type of them being 
interneurons expressing Protein Kinase C γ (PKCγ). These neurons were generally believed to be 
innervated by the non-peptidergic nociceptors and to play an important role in neuropathic pain, 
since mice lacking PKCγ displayed reduced neuropathic pain behavior (Julius and Basbaum, 2001; 
Malmberg et al., 1997). Recent evidence however has cast doubt on this widely held assumption 
(Braz et al., 2005; Zylka, 2005; Zylka et al., 2005). Braz and coworkers demonstrated that non-
peptidergic nociceptors bypass PKCγ neurons and terminate on other interneurons in lamina II. 
These neurons, in turn, project to neurons in lamina V that project directly to brain regions, such 
as the amygdala, the ventromedial nucleus of the hypothalamus and the bed nucleus of the stria 
terminalis, that may be involved in the affective-motivational component of pain. These authors 
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therefore concluded that there may be two systems that are responsible for the perception of pain, 
one is the peptidergic nociceptors-NK-1 neurons-thalamus system (spinothalamic system) that 
subserves the sensory-discriminative aspects of pain (e.g. where is the pain stimulus located, is 
the stimulus thermal or mechanical?) and the other the non-peptidergic nociceptors-lamina II-V 
projection neurons system that subserves the affective-motivational aspects of pain (e.g. how 
unpleasant is the pain?). Although this hypothesis needs to be further substantiated and although 
there are other pathways subserving affective-motivational aspects of pain, such as the NK-
1 neurons-parabrachial area-amygdala/hypothalamus system and the NK-1 neurons-thalamus-
insula/anterior cingulate cortex system, the general idea is in accordance with the “labeled lines 
hypothesis” of pain perception (Craig, 2002; Craig, 2003; Hunt and Mantyh, 2001), i.e. the 
idea that specific sensory stimuli are conveyed separately by specific anatomical and functional 
systems. The separate neuronal systems that process itch (McMahon and Koltzenburg, 1992), C-
fiber touch (Olausson et al., 2002) and specific viscero-sensory inputs (Craig, 2003) also fit within 
this scheme. The labeled line hypothesis contrasts with the traditional view that the intensity and 
quality of the pain is coded by pattern activity of spinal cord wide dynamic range neurons, which 
receive both nociceptive and non-nociceptive (touch) information. This view dates back from the 
time of the gate control theory (Melzack and Wall, 1965)(Fig. 4), which basically proposed a 
gating system in the spinal cord, which closes in response to normal stimulation of fast conducting 
“touch” fibers, but opens when a large number of slow conducting “pain” fibers transmit sensory 
signals of a high intensity. The gate can be closed again if these signals are countered by renewed 
stimulation of the fast conducting touch fibers. According to the gate control theory it is the firing 
intensity and pattern of nociceptor activity and the subsequent activation of wide dynamic range 
neurons that determines the nature of the pain that is experienced. Although the general idea 
that there is an interaction between afferent inputs in the spinal cord has proven highly fruitful, 
the most elementary parts of the theory could not be confirmed, like e.g. presynaptic inhibition 
of primary afferent fibers. Increasing evidence for the existence of separate modules for different 
types of nociceptive information has now put the gate control theory into the background.
Following a painful stimulus associated with tissue damage, stimuli in the area of the injury 
and in the surrounding region that would ordinarily be perceived as slightly painful will now 
be perceived as significantly more so. This phenomenon is called hyperalgesia or sensitization. 
Two forms of sensitization exist: peripheral and central sensitization. Peripheral sensitization is 
caused by a decreased threshold of nociceptors for nociceptive stimuli. Peripheral sensitization 
generally takes place in inflammatory pain conditions and is caused by a variety of substances 
released by inflammatory cells and nerve terminals, the so-called “inflammatory soup”. Examples 
include extracellular protons, adenosine triphosphate (ATP), bradykinin, histamine, serotonin, 
prostaglandins, tumor necrosis factor α (TNFα), interleukin 1β (IL-1β) and nerve growth factor 
(McMahon et al., 2005). These substances can act directly on receptors expressed by nociceptive 
fibers, e.g. bradykinin receptors, TrkA (Koltzenburg et al., 1999; McMahon et al., 1995), and 
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ion-channels, e.g. the transient receptor potential vanilloid type 1 (TRPV1) (Caterina et al., 2000; 
Koltzenburg, 2004) and the purinergic P2X3 receptor. These substances may also act indirectly 
through inflammatory cells, by enhancing the inflammatory response (Leon et al., 1994; Shu 
and Mendell, 1999). Receptor activation during inflammation will ultimately result in lowering 
of the membrane potential, thus increasing the likelihood that an action potential is triggered. An 
increase in the frequency of action potentials will contribute to a painful perception and at the 
same time enhance the release of neuropeptides from the peripheral endings of nociceptors, a 
process which is called neurogenic inflammation (Herbert and Holzer, 2002a; Herbert and Holzer, 
2002b). A well known example of peripheral sensitization is the increased sensitivity to heat 
following a sunburn, which is confined to the area of the sunburn.
Central sensitization on the other hand refers to an immediate onset, activity dependent increase 
in the excitability of neurons in the dorsal horn of the spinal cord, following high levels of activity in 
the nociceptive afferents. Central sensitization is normally induced by a strong nociceptive input, 
e.g. after a severe injury, and is a hallmark of neuropathic pain and chronic inflammation. Like 
its peripheral counterpart, a number of mechanisms contribute to central sensitization. Firstly, 
wind-up (Dickenson, 1990; Suzuki and Dickenson, 2005) involves a progressive increase in 
the discharge rate of dorsal horn neurons in response to repeated low-frequency stimulation of 
nociceptive primary afferents. Windup arises from the summation of slow synaptic potentials that 
are evoked in dorsal horn neurons by nociceptive inputs. This will activate L-type calcium channels 
and remove the Mg2+ block from N-methyl-D-aspartate (NMDA) receptors, allowing Ca2+ ions 
to flow into the cell. This will increase the sensitivity of the neuron to synaptic inputs, including 
glutamate, the transmitter in nociceptive primary afferents. Windup, which lasts only during the 
period of stimulation, has been identified in volunteers that were subjected to repetitive painful 
electrical stimuli, and reported that the perceived intensity of the stimulus increased over time. 
More recently, a second form of central sensitization has been identified, which is the correlate of 
long-term potentiation (LTP) in the hippocampus (Ikeda et al., 2003; Willis, 2002). In contrast 
to wind-up, LTP may outlast the conditioning stimulus for many hours (Woolf, 1983; Woolf and 
Salter, 2000). Long-term changes in spinal pain transmission generally result from transcriptional 
changes, which may be induced by immediate early genes, e.g. c-Fos, see also Chapter 5 of this 
thesis. The behavioral correlate of central sensitization is mechanical allodynia, i.e. perceiving 
a non-noxious mechanical stimulus as painful. This phenomenon is especially pronounced in 
neuropathic pain conditions, when even the touch of clothing can be perceived as painful e.g. in 
patients with post-herpetic neuralgia.
So far only the afferent and ascending pain pathways were discussed. However the pain 
experience is also greatly influenced by descending controls, i.e. influences from brainstem centers 
that modulate spinal pain transmission (Ossipov and Porreca, 2005; Vanegas and Schaible, 
2004). The concept of descending pain modulation began to take root in the 1960s, when it 
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was found that microinjections of morphine in the midbrain periaqueductal grey (PAG) (Tsou and 
Jang, 1964) and electrical stimulation of that same region (Reynolds, 1969) produced powerful 
antinociception. This antinociceptive effect of PAG stimulation is for a large part due to inhibition 
of pain transmission in the spinal cord. This inhibition is achieved by PAG projections to the 
rostral ventromedial medulla (RVM), which includes the Raphe Magnus nucleus, and from there 
through the dorsolateral funiculus to the spinal dorsal horn. It is now well established that the 
descending brainstem projections to the dorsal horn are not only involved in pain inhibition, but 
also in the facilitation of pain transmission. While opioid analgesia makes use of the inhibitory 
effect of descending pain modulation, pain facilitation from the RVM is thought of as a major 
contributor to the persistence of neuropathic pain. Recently, it was suggested that persistent 
ascending nociceptive inputs may contribute to descending pain facilitation, through lamina I 
nociceptive specific NK-1 neurons (Suzuki et al., 2002; Suzuki et al., 2004). Thus, even though 
the presence of a descending pain modulatory system is firmly established, the exact mechanisms 
that are involved in the production of pain inhibition and facilitation are still unclear.
Taken together nociceptive signals are subject to extensive modulation at all levels of the pain 
system, i.e. the level of the nociceptor, the level of the spinal cord, in the brainstem and in various 
subcortical and cortical areas, where the nociceptive signal is finally perceived. The multitude 
neurotransmitters, neuromodulators and receptors involved in pain transmission underlines the 
complexity of the system. Our knowledge of the various mechanisms is constantly increasing, but 
a firmly established, comprehensive view on the organization of the pain system is still lacking.
THE INVOLVEMENT OF NEUROTROPHIC  
FACTORS IN SENSORY TRANSMISSION
Neurotrophic factors
In the 1930’s Viktor Hamburger at the University of Chicago discovered in a series of experiments 
that limb-bud removal and implantation in chick-embryos had a profound effect on the 
development of spinal cord and dorsal root ganglion (DRG) neurons (Fig. 5) (Cowan, 2001; 
Hamburger and Levi-Montalcini, 1949). In 1948, when it was observed that implantation of 
a sarcoma cell line in the body wall of chick embryos induced a striking hypertrophy of the 
hosts sympathetic and sensory ganglia (Bueker, 1948; Levi-Montalcini and Hamburger, 1951), 
it was concluded that this hypertrophic effect was probably due to a diffusible factor produced 
by the particular cell line. In the early 1950s the agent was named “a nerve growth-promoting 
factor” (Cohen et al., 1954; Levi-Montalcini and Hamburger, 1953), since at that time it was 
not yet clear whether it was a piece of DNA or a protein. Following isolation from snake venom 
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(Cohen and Levi-Montalcini, 1956) and mouse salivary gland (Cohen, 1960), the agent now 
termed nerve growth factor (NGF) appeared to be a protein with potent trophic and survival 
effects on cultured sympathetic and sensory ganglion cells (Campenot, 1981; Cohen, 1960). 
These findings have led Rita Levi-Montalcini, Stanley Cohen and Viktor Hamburger to postulate 
the “Neurotrophic Factor Hypothesis”. According to the neurotrophic factor hypothesis axonal 
connections are first established by a larger number of neurons than is appropriate for optimal 
functioning of the connection. To correct for this, the target, i.e. the innervated tissue, produces 
a limited amount of neurotrophic factors, as a consequence of which only a limited number of 
neurons will survive, while other neurons will atrophy and may eventually die (Levi-Montalcini, 
1987; Lewin and Barde, 1996). Although strictly speaking a neurotrophic effect only applies 
to an effect on neuronal survival, this term is generally interpreted to also encompass effects on 
neurite growth (Fig. 6) and neurotransmitter production. Neurotrophic factors are thus responsible 
for the correct establishment of neuronal connections in the peripheral and central nervous system 
and this in turn is essential for the proper function of the nervous system (Korsching, 1993; 
Zweifel et al., 2005). Numerous subsequent studies on the role of NGF by Levi-Montalcini and 
Cohen and the importance of the Neurotrophic Factor Hypothesis, which still holds true today, 
were awarded with the Nobel Prize in Physiology or Medicine in 1986.
Since NGF affects only a specific population of peripheral neurons, i.e. those neurons expressing 
TrkA, the receptor for NGF (see later), it was presumed that other neurotrophic factors must exist 
that would support growth and survival of other populations of neurons. However it was not until 
the 1980’s that another in vivo neurotrophic factor, Brain-Derived Neurotrophic Factor (BDNF) 
was discovered, by purification from pig brain (Barde et al., 1982; Hofer and Barde, 1988; 
Leibrock et al., 1989). Based on their structural homology, three other neurotrophic factors, i.e. 
neurotrophin-3 (NT-3) (Hohn et al., 1990), NT4/5 (Hallbook et al., 1991) and NT-6 (Gotz et al., 
1994) were then cloned, which together with NGF and BDNF make up the neurotrophin family.
Apart from the neurotrophins, various other proteins with trophic effects on neurons exist. 
Ciliary neurotrophic factor (CNTF), originally found to affect ciliary ganglion parasympathetic 
neurons (Barbin et al., 1984; Lin et al., 1989), also affects dorsal root ganglion neurons and 
central nervous system neurons (Hagg et al., 1992). Furthermore, although their effects are not 
restricted to neurons, Leukemia Inhibitory Factor (LIF) (Martinou et al., 1992; Murphy et al., 
1991) and Fibroblast Growth Factors (Eckenstein et al., 1990; Hatten et al., 1988) also affect 
neurons in both the peripheral and central nervous system.
In 1993, Glial cell line-Derived Neurotrophic Factor (GDNF) was discovered (Lin et al., 1993), 
as the first member of what later turned out to be a whole new group of neurotrophic factors 
called the GDNF family ligands (GFLs). GFLs are distant members of the Transforming Growth 
Factor-β super family. GDNF was isolated and cloned by virtue of its strong effect on survival, 
differentiation and dopamine uptake of embryonic midbrain dopaminergic neurons. The GFLs 
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also comprise Neurturin (NRTN) (Kotzbauer et al., 1996), Persephin (PSPN) (Milbrandt et al., 
1998) and Artemin (ARTN) (Baloh et al., 1998). Apart from effects on nerve cells, most notably 
dopaminergic cells, motoneurons, dorsal root ganglion (DRG) neurons and sympathetic neurons, 
the GFLs also have important functions outside the nervous system (Airaksinen and Saarma, 
2002; Meng et al., 2000; Schuchardt et al., 1994). As a result of its strong survival effects on 
cultured midbrain dopaminergic (Lin et al., 1993) cells and motoneurons (Henderson et al., 
1994), GDNF has been extensively tried and found successful in animal models of Parkinson’s 
disease (Behrstock et al., 2005) and amyotrophic lateral sclerosis (Bohn, 2004). However, 
phase I clinical trials with intrathecal GDNF in patients with Parkinson’s disease and ALS were 
discontinued because of a lack of efficacy.
Receptors for neurotrophic factors
Neurotrophins signal through the tropomyosin receptor kinase (Trk) family of protein kinases 
(Barbacid, 1995). Whereas NGF binds to TrkA, BDNF and NT-4/5 interact with TrkB. NT-3 
appears to be more promiscuous and binds to each of the Trk receptors, but its primary biological 
responses are mediated through TrkC (Fig. 7). In addition, neurotrophins interact with a second 
receptor, p75, a member of the tumor necrosis factor super family (Chao, 1994). Neurotrophins, 
which bind to Trk receptors with high-affinity, induce dimerization of Trk receptors and these 
activated receptor complexes consequently induce cell survival, neurite outgrowth and neuronal 
differentiation. In contrast to Trks, neurotrophins bind to p75 with much lower affinity, which has 
led to speculation that neurotrophins represent only partial ligands of p75 (Ibanez, 2002). More 
recently, pro-neurotrophins, the precursor molecules of the neurotrophins, have been discovered 
as the high affinity ligands for the p75 receptor (Ibanez, 2002; Lee et al., 2001; Teng et al., 
2005). Activation of p75 by pro-NGF (Lee et al., 2001) and pro-BDNF (Teng et al., 2005) 
results in apoptotic cell death (Frade et al., 1996), i.e. the opposite effect of Trk activation. In vivo 
however, since the affinity of Trk for neurotrophins is many times greater than that of p75, the 
trophic effects of the neurotrophins usually predominate (Chao et al., 1998).
The GFLs, on the other hand, signal through a completely different mechanism. In 1996 the 
proto-oncogene Rearranged during Transfection (RET) was discovered as the signaling receptor 
for GDNF (Durbec et al., 1996; Trupp et al., 1996). Later on it appeared that this tyrosine 
kinase receptor was the common signaling receptor for all GFLs. RET is activated only if the GFL 
is first bound to a GDNF-family receptor-α (GFRα). Four different GFRα receptors have been 
characterized (GFRα1-4), which determine the ligand specificity of the GFRα-RET complex. GDNF 
binds to GFRα1, then forms a complex with RET (Jing et al., 1996; Treanor et al., 1996). NRTN 
binds to GFRα2, ARTN to GFRα3 and PSPN activates RET by binding to GFRα4. NRTN and 
ARTN might crosstalk weakly with GFRα1, and GDNF with GFRα2 and GFRα3. In mammals at 
least PSPN can only bind to GFRα4 (Airaksinen and Saarma, 2002; Airaksinen et al., 1999) (Fig. 
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8). Although most in vivo biological effects of the GFLs can be attributed to GFL-RET signaling, 
in vitro experiments have shown RET-independent signaling through GFRα1 (Poteryaev et al., 
1999; Trupp et al., 1999) and effects through interactions of GDNF with neuron cell adhesion 
molecule (NCAM) (Paratcha et al., 2003; Sariola and Saarma, 2003). Additionally, it has recently 
been shown that RET can be activated by NGF, without interference of any of the GFRαs (Tsui-
Pierchala et al., 2002)
Trophic effects of neurotrophic factors on sensory neurons
During development of the nervous system, once proper synaptic connections are established, 
according to the Neurotrophic Factor Hypothesis, neurons remain dependent on the presence of 
their targets for continued survival and differentiation. In the adult nervous system, target-derived 
neurotrophic factors provide support to damaged neurons, addition of neurotrophic factors to 
damaged neurons may enhance their regeneration (Goldberg and Barres, 2000). However the 
Neurotrophic Factor Hypothesis needs to be updated in this respect that peripheral tissues (i.e. 
the targets) are not the only source of neurotrophic factors, since they have also been found to 
be released from supportive cells, other neurons and even the dependent neurons themselves, 
the latter via so-called autocrine signaling (Korsching, 1993). The above-described paradigm 
of neurotrophic factor functioning during development and in the adult holds true explicitly for 
sensory neurons.
NGF supports a subclass of small diameter nociceptive primary afferent sensory neurons 
during prenatal development (Fitzgerald, 2005). Depletion of NGF in knock-out animals results in 
a 70% reduction of DRG neurons (Crowley et al., 1994) and an increase in the number of these 
neurons occurs in NGF over-expressing mice (Albers et al., 1994; Jhaveri et al., 1996). DRG 
neurons are also dependent on other neurotrophins, like NT-3 (Albers et al., 1996; Ernfors et al., 
1994; Farinas et al., 1994) and BDNF (Jones et al., 1994). Strong evidence exists that some 
of these neurons require more than one neurotrophin to survive into adulthood (Mendell et al., 
1999). In most cases, neurotrophins appear to modulate cell numbers by regulating programmed 
cell death in the prenatal period (Farinas et al., 1996). Apart from an effect as a prenatal survival 
factor, NGF is also essential for normal postnatal development of the phenotype of nociceptors, 
as has been shown by reduced numbers of high-threshold mechanoreceptor afferents in animals 
that were treated postnatally with an antibody to NGF (Lewin et al., 1992; Mendell et al., 1999; 
Ritter et al., 1991), while total numbers of nociceptors remained unaltered. In early postnatal life 
about half of the neurons that are NGF dependent undergo a switch, changing from NGF to GDNF 
dependence (Molliver et al., 1997). The effects of absence of GDNF on nociceptor survival and 
development have not been studied, because animals lacking GDNF or RET have renal agenesis 
and die soon after birth (Schuchardt et al., 1994).
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In adulthood neurotrophic factors may contribute to regeneration following nerve damage. One 
striking peculiarity in higher vertebrates is the ability of peripheral nervous system (PNS) but not 
of central nervous system (CNS) neurons to regenerate their axons, which has already been noted 
by Ramón y Cajal in 1928 (Ramon y Cajal, 1928). Although much research has focused on 
inhibitory signals by CNS glia and more recently on the presence of growth-inhibitory molecules 
associated with myelin (Domeniconi and Filbin, 2005), loss of trophic stimuli needed to promote 
the survival and regeneration of axotomized neurons may also play an important role. As far as the 
sensory system is concerned, NGF, NT-3 and GDNF (but not BDNF) have all been shown (Ramer 
et al., 2002; Ramer et al., 2000) to promote growth of severed dorsal root axons across the Dorsal 
Root Entry Zone (DREZ), an area of the CNS which normally acts as a barrier to regenerating 
axons. In the peripheral nervous system NGF (Verge et al., 1995), BDNF (Acheson et al., 1995), 
GDNF (Bennett et al., 1998) and ARTN (Gardell et al., 2003) have all been shown to prevent 
axotomy-induced degenerative changes in DRG neurons bearing their respective receptors, and in 
the case of GDNF and ARTN to cause a reduction in neuropathic pain behavior in experimental 
animals. Although NGF has been tried in patients with diabetic neuropathy (Apfel, 2002; Apfel 
et al., 2000), no beneficial effects from NGF on the clinical condition of those patients has been 
described.
Involvement of neurotrophic factors in modulation of nociceptive 
information: NGF as an inducer of inflammatory hyperalgesia 
In contrast to the survival effects of neurotrophic factors on DRG neurons during development in 
utero and the effects on normal phenotypic development of DRG neurons in the early postnatal 
period, the physiological role of neurotrophic factors changes dramatically during adulthood. In 
1993 for the first time (Lewin et al., 1993), more than 40 years after the discovery of NGF as 
a trophic factor for sensory neurons, an acute effect of NGF as a contributor to inflammatory 
hyperalgesia has been described (Lewin and Barde, 1996; Lewin and Mendell, 1993) and 
subsequent papers (Koltzenburg et al., 1999; Lewin et al., 1994; McMahon et al., 1995; 
Woolf et al., 1994) have confirmed this. Inflammation induces both thermal and mechanical 
hyperalgesia. Thermal hyperalgesia is a form of primary hyperalgesia and arises from increased 
firing of high threshold C- and Aδ-nociceptor neurons. Primary hyperalgesia is usually confined 
to the area of tissue damage or inflammation, but may extend slightly beyond its borders, and 
is mediated by peripheral mechanisms, such as neurogenic inflammation caused by antidromic 
release of inflammatory mediators such as CGRP and SubP (Herbert and Holzer, 2002a; Herbert 
and Holzer, 2002b). The area of primary hyperalgesia is usually demarcated by a red flare. Pain 
evoked by stimulating tissue that is undamaged or unaffected by disease is termed secondary 
hyperalgesia and manifests itself as mechanical hyperalgesia. The extend of the area of secondary 
hyperalgesia is not determined by cutaneous processes such as the production of flare and involves 
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the activation of Aβ fibers that normally convey innocuous sensory information to the spinal cord. 
Following induction of inflammation in the skin of adult animals, endogenous NGF released by 
mast cells (Woolf et al., 1996) and other inflammatory cells, like activated macrophages and 
polymorphonuclear leucocytes (Sofroniew et al., 2001), induces both heat hyperalgesia and 
mechanical hyperalgesia (Lewin et al., 1994). It has been shown that NGF is both necessary 
(Koltzenburg et al., 1999) and sufficient (Lewin et al., 1993) for the induction of inflammatory 
hyperalgesia. NGF induced heat hyperalgesia is mediated by peripheral mechanisms, such as up 
regulation of the neuropeptides SubP (Woolf et al., 1994) and CGRP (McMahon et al., 1995) 
in DRG neurons and activation of p38 mitogen-activated protein kinase (MAPK), resulting in an 
upregulation of the capsaicin receptor transient receptor potential vanilloid type-1 (TRPV-1) (Ji et 
al., 2002). NGF induced mechanical hyperalgesia is mediated by central mechanisms, such as 
the upregulation of BDNF in DRG neurons (Apfel et al., 1996; Shu and Mendell, 1999) and the 
sensitization of NMDA receptors (Lewin et al., 1994).
Analogous to the role of endogenous NGF in modulation of inflammatory pain, a role for NGF 
as an inducer of hyperalgesia in cancer pain has more recently been described (Halvorson et al., 
2005; Jongen et al., 2002; Sevcik et al., 2005). Not surprisingly, one of the tumors used to 
induce bone cancer was a sarcoma cell-line (compare (Bueker, 1948), which secretes high levels 
of NGF (Jongen et al., 2002; Sevcik et al., 2005). In bone cancer, a NGF sequestering antibody 
was shown to reduce spontaneous pain behavior as well as heat (Halvorson et al., 2005) and 
mechanical hyperalgesia (Sevcik et al., 2005). The effect of anti-NGF on spontaneous cancer 
pain behavior was even stronger than high-dose systemic morphine (Halvorson et al., 2005). The 
mechanisms by which NGF may contribute to bone cancer pain have not been fully elucidated. 
A similar mode of action as in inflammatory pain may apply, since tumors generally contain a 
substantial number of tumor associated inflammatory cells (Jongen et al., 2002). In addition, 
NGF may modulate cancer specific pain mechanisms, since osteoclasts and many cancer cell 
types express the receptor components for NGF signaling (Descamps et al., 2001; Miknyoczki et 
al., 2002; Missale et al., 1998) and effects of NGF and antagonists on tumor growth have been 
described in many cancers in vitro (Benini et al., 1999; Missale et al., 1998; Oelmann et al., 
1995) and in vivo (George et al., 1999; Miknyoczki et al., 2002). As a result of the latter, it is 
remarkable that no differences in tumor growth or bone destruction were detected in bone cancer in 
anti-NGF treated animals as compared to controls (Halvorson et al., 2005; Sevcik et al., 2005).
In contrast to extensive data on the role of NGF in inflammatory and more recently cancer 
pain, relatively weak evidence for a role of NGF as a modulator in neuropathic pain exists. NGF 
has been shown to modulate neuropeptide (Verge et al., 1995) and BDNF (Fukuoka et al., 2001) 
expression in DRG neurons following nerve injury and an anti-NGF blocking antibody attenuated 
heat hyperalgesia (Ro et al., 1999) and mechanical hyperalgesia (Ren et al., 1995) following 
chronic constriction injury of the sciatic nerve.
20
Chapter 1
Involvement of neurotrophic factors in modulation of nociceptive 
information: BDNF as a modulator of centrally mediated hyperalgesia
While NGF is not produced in neurons, but derived from peripheral sources such as skin, Schwann 
cells and DRG satellite cells (Sofroniew et al., 2001), BDNF is produced in a subset of DRG neurons 
that also express TrkA and neuropeptides like SubP and CGRP (Michael et al., 1997; Wetmore 
and Olson, 1995; Zhou et al., 1999). Following inflammation (Apfel et al., 1996; Mannion et al., 
1999) and nerve injury (Fukuoka et al., 2001), BDNF is upregulated in DRG neurons in a NGF-
dependent fashion. This up regulation is mediated through TrkA, which is present in the same DRG 
neurons that also express BDNF. TrkA and BDNF expressing DRG neurons belong to the peptidergic 
primary afferents. Within this subgroup of DRG neurons, BDNF is anterogradely transported 
towards terminals in the superficial spinal dorsal horn (Holstege et al., 1997; Tonra et al., 1998; 
Zhou and Rush, 1996), where it is contained in dense-cored vesicles (Michael et al., 1997). 
Dense-cored vesicles contain catecholamines and peptide neurotransmitters, like CGRP and SubP, 
in contrast to synaptic vesicles, which contain small molecule neurotransmitters such as gamma-
amino butyric acid (GABA), glutamate and acetylcholine. Substances in dense-cored vesicles 
behave differently from those in synaptic vesicles, in the sense that they are only released following 
strong and prolonged stimulation. The presence of BDNF mRNA in DRG neurons, the anterograde 
transport within the dorsal root, the localization of BDNF in dense-cored vesicles in terminals and 
the presence of TrkB (Yan et al., 1997) on its postsynaptic target, i.e. local and projection neurons 
in the superficial dorsal horn, all point to a role for BDNF as a neurotransmitter in spinal pain 
transmission (Pezet et al., 2002b). Such a role has actually been demonstrated for BDNF in the 
spinal cord, where BDNF increases nociceptive spinal reflex excitability (Kerr et al., 1999) and is 
responsible for the mechanical hyperalgesia following injection of several inflammation inducing 
substances (Kerr et al., 1999; Mannion et al., 1999; Thompson et al., 1999). Although the exact 
mechanism of action of BDNF in spinal cord signaling is not known, it has been shown that BDNF 
induces activation of the signaling kinases Extracellular Signal-regulated Kinase (ERK) and Phospho 
Kinase C (PKC) via TrkB (Lever et al., 2003; Pezet et al., 2002a; Slack et al., 2004), resulting in 
subsequent phosphorylation of the N-methyl-d-aspartate (NMDA) receptor subunit 1 (NR1) (Slack 
et al., 2004) and transcription of the immediate early gene c-fos (Kerr et al., 1999). The effects 
of BDNF on ERK phosphorylation have been demonstrated more specifically in TrkB expressing 
spinothalamic tract projection neurons (Slack et al., 2005). Aside from the spinal cord, a role for 
BDNF as a neurotransmitter has also been described in other systems, like the hippocampus, 
where BDNF is involved in long-term potentiation (Figurov et al., 1996; Kang et al., 1997; Korte 
et al., 1995; Poo, 2001) and learning (Minichiello et al., 1999). Interestingly, proBDNF, acting 
through the p75 receptor, has exactly the opposite effect of BDNF, i.e. enhancement of long term 
depression (Woo et al., 2005), just like the opposite effects that have been described earlier for 
NGF and proNGF. At least in the brain it was shown that the Nav1.9 sodium channel underlies the 
fast BDNF-evoked excitation through TrkB (Blum et al., 2002; Rose et al., 2004).
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In addition to an effect from primary afferent BDNF on spinal pain neurons, recent evidence suggests 
that BDNF released from neurons originating in the periaqueductal gray acts on descending rostral 
ventromedial medulla neurons, thereby inducing facilitation of nociceptive transmission (Guo et 
al., 2006). In contrast to its role in modulating nociceptive, i.e. inflammatory, transmission, 
BDNF from DRG neurons does not seem to be involved in the modulation of neuropathic pain 
(Zhao et al., 2006). However, BDNF released from spinal microglia (Nakajima et al., 2002) has 
been shown to induce allodynia in a neuropathic pain model (Coull et al., 2005), in line with a 
growing notion that spinal microglia plays an important role in the generation and maintenance of 
neuropathic pain (Tsuda et al., 2005).
GDNF AS A POTENTIAL MODULATOR OF SPINAL PAIN 
TRANSMISSION-AIM OF THE THESIS
Although GDNF has traditionally been considered a trophic factor for a specific subpopulation 
of nociceptors (Bennett et al., 1998; Molliver et al., 1997), our finding that GDNF protein is 
strongly expressed in primary afferent terminals in the dorsal horn and the anterograde transport 
within dorsal root fibers was the first indication that GDNF might have other roles than a trophic 
role in the spinal dorsal horn (Holstege et al., 1998). Since at that time a role for BDNF as 
a neuromodulator of spinal nociceptive transmission had just been proposed, we hypothesized 
that GDNF may act in a similar way, based on the identical anatomical localizations of BDNF 
and GDNF in the spinal cord and their presence within dense-cored vesicles (Holstege et al., 
1999; Michael et al., 1997; Ohta et al., 2001). We therefore set out a series of anatomical and 
functional experiments, which are described in this thesis, to provide additional evidence for 
such a role of GDNF. Following the anatomical localization of GDNF protein in the spinal dorsal 
horn (Chapter 2), we subsequently studied its regulation following peripheral nerve transection 
(Chapter 3). We then studied the effects of intrathecally injected GDNF on immediate early gene 
expression in spinal dorsal horn neurons and compared the magnitude of the effect with that of 
BDNF and NMDA (Chapter 4). Immediate early gene expression in dorsal horn neurons was used 
as a marker for activation of these neurons by the intrathecally injected substances. Finally, the 
anatomical and functional expression of RET, the main signaling receptor for GDNF, was studied, 
both in the normal situation and following nerve injury (Chapter 5).
22
Chapter 1
REFERENCES
Acheson A, Conover JC, Fandl JP, DeChiara TM, Russell M, Thadani A, Squinto SP, Yancopoulos GD, Lindsay 
RM. 1995. A BDNF autocrine loop in adult sensory neurons prevents cell death. Nature 374(6521):450-
453.
Airaksinen MS, Saarma M. 2002. The GDNF family: signalling, biological functions and therapeutic value. 
Nat Rev Neurosci 3(5):383-394.
Airaksinen MS, Titievsky A, Saarma M. 1999. GDNF family neurotrophic factor signaling: four masters, one 
servant? Mol Cell Neurosci 13(5):313-325.
Albers KM, Perrone TN, Goodness TP, Jones ME, Green MA, Davis BM. 1996. Cutaneous overexpression 
of NT-3 increases sensory and sympathetic neuron number and enhances touch dome and hair follicle 
innervation. J Cell Biol 134(2):487-497.
Albers KM, Wright DE, Davis BM. 1994. Overexpression of nerve growth factor in epidermis of transgenic 
mice causes hypertrophy of the peripheral nervous system. J Neurosci 14(3 Pt 2):1422-1432.
Apfel SC. 2002. Is the therapeutic application of neurotrophic factors dead? Ann Neurol 51(1):8-11.
Apfel SC, Schwartz S, Adornato BT, Freeman R, Biton V, Rendell M, Vinik A, Giuliani M, Stevens JC, Barbano R, Dyck 
PJ. 2000. Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: 
A randomized controlled trial. rhNGF Clinical Investigator Group. Jama 284(17):2215-2221.
Apfel SC, Wright DE, Wiideman AM, Dormia C, Snider WD, Kessler JA. 1996. Nerve growth factor regulates 
the expression of brain-derived neurotrophic factor mRNA in the peripheral nervous system. MolCell Neurosci 
7:134-142.
Baloh RH, Tansey MG, Lampe PA, Fahrner TJ, Enomoto H, Simburger KS, Leitner ML, Araki T, Johnson EM, 
Jr., Milbrandt J. 1998. Artemin, a novel member of the GDNF ligand family, supports peripheral and central 
neurons and signals through the GFRalpha3-RET receptor complex. Neuron 21(6):1291-1302.
Barbacid M. 1995. Neurotrophic factors and their receptors. Curr Opin Cell Biol 7(2):148-155.
Barbin G, Manthorpe M, Varon S. 1984. Purification of the chick eye ciliary neuronotrophic factor. J Neurochem 
43(5):1468-1478.
Barde YA, Edgar D, Thoenen H. 1982. Purification of a new neurotrophic factor from mammalian brain. Embo 
J 1(5):549-553.
Behrstock S, Ebert A, McHugh J, Vosberg S, Moore J, Schneider B, Capowski E, Hei D, Kordower J, Aebischer 
P, Svendsen CN. 2005. Human neural progenitors deliver glial cell line-derived neurotrophic factor to 
parkinsonian rodents and aged primates. Gene Ther.
Benini S, Baldini N, Manara MC, Chano T, Serra M, Rizzi S, Lollini PL, Picci P, Scotlandi K. 1999. Redundancy 
of autocrine loops in human osteosarcoma cells. Int J Cancer 80(4):581-588.
Bennett DL, Michael GJ, Ramachandran N, Munson JB, Averill S, Yan Q, McMahon SB, Priestley JV. 1998. 
A distinct subgroup of small DRG cells express GDNF receptor components and GDNF is protective for these 
neurons after nerve injury. J Neurosci 18(8):3059-3072.
Blum R, Kafitz KW, Konnerth A. 2002. Neurotrophin-evoked depolarization requires the sodium channel 
Na(V)1.9. Nature 419(6908):687-693.
Bohn MC. 2004. Motoneurons crave glial cell line-derived neurotrophic factor. Exp Neurol 190(2):263-275.
23
Introduction
Braz JM, Nassar MA, Wood JN, Basbaum AI. 2005. Parallel "pain" pathways arise from subpopulations of 
primary afferent nociceptor. Neuron 47(6):787-793.
Bueker ED. 1948. Implantation of tumors in the hind limb field of the embryonic chick and the developmental 
response of the lumbosacral nervous system. Anat Rec 102:369-390.
Campenot RB. 1981. Regeneration of neurites on long-term cultures of sympathetic neurons deprived of nerve 
growth factor. Science 214(4520):579-581.
Caterina MJ, Leffler A, Malmberg AB, Martin WJ, Trafton J, Petersen-Zeitz KR, Koltzenburg M, Basbaum 
AI, Julius D. 2000. Impaired nociception and pain sensation in mice lacking the capsaicin receptor. Science 
288(5464):306-313.
Chao M, Casaccia-Bonnefil P, Carter B, Chittka A, Kong H, Yoon SO. 1998. Neurotrophin receptors: mediators 
of life and death. Brain Res Brain Res Rev 26(2-3):295-301.
Chao MV. 1994. The p75 neurotrophin receptor. J Neurobiol 25(11):1373-1385.
Cohen S. 1960. Purification of a nerve-growth promoting protein from the mouse salivary gland and its neuro-
cytotoxic antiserum. Proc Natl Acad Sci U S A 46(3):302-311.
Cohen S, Levi-Montalcini R. 1956. A nerve-growth factor stimulating factor isolated from snake venom. Proc 
Natl Acad Sci U S A 42(9):571-574.
Cohen S, Levi-Montalcini R, Hamburger V. 1954. A nerve growth factor-stimulating factor isolated from 
sarcomas 37 and 180. Proc Natl Acad Sci U S A 40(10):1014-1018.
Coull JA, Beggs S, Boudreau D, Boivin D, Tsuda M, Inoue K, Gravel C, Salter MW, De Koninck Y. 2005. 
BDNF from microglia causes the shift in neuronal anion gradient underlying neuropathic pain. Nature 
438(7070):1017-1021.
Coull JA, Boudreau D, Bachand K, Prescott SA, Nault F, Sik A, De Koninck P, De Koninck Y. 2003. Trans-
synaptic shift in anion gradient in spinal lamina I neurons as a mechanism of neuropathic pain. Nature 
424(6951):938-942.
Cowan WM. 2001. Viktor Hamburger and Rita Levi-Montalcini: the path to the discovery of nerve growth 
factor. Annu Rev Neurosci 24:551-600.
Craig AD. 2002. How do you feel? Interoception: the sense of the physiological condition of the body. Nat Rev 
Neurosci 3(8):655-666.
Craig AD. 2003. Pain mechanisms: labeled lines versus convergence in central processing. Annu Rev Neurosci 
26:1-30.
Crowley C, Spencer SD, Nishimura MC, Chen KS, Pitts-Meek S, Armanini MP, Ling LH, McMahon SB, 
Shelton DL, Levinson AD, et al. 1994. Mice lacking nerve growth factor display perinatal loss of sensory and 
sympathetic neurons yet develop basal forebrain cholinergic neurons. Cell 76(6):1001-1011.
Descamps S, Pawlowski V, Revillion F, Hornez L, Hebbar M, Boilly B, Hondermarck H, Peyrat JP. 2001. 
Expression of nerve growth factor receptors and their prognostic value in human breast cancer. Cancer Res 
61(11):4337-4340.
Dickenson AH. 1990. A cure for wind up: NMDA receptor antagonists as potential analgesics. Trends 
Pharmacol Sci 11(8):307-309.
Domeniconi M, Filbin MT. 2005. Overcoming inhibitors in myelin to promote axonal regeneration. J Neurol 
Sci 233(1-2):43-47.
24
Chapter 1
Durbec P, Marcos-Gutierrez CV, Kilkenny C, Grigoriou M, Wartiowaara K, Suvanto P, Smith D, Ponder B, 
Costantini F, Saarma M, et al. 1996. GDNF signalling through the Ret receptor tyrosine kinase. Nature 
381(6585):789-793.
Eckenstein FP, Esch F, Holbert T, Blacher RW, Nishi R. 1990. Purification and characterization of a trophic 
factor for embryonic peripheral neurons: comparison with fibroblast growth factors. Neuron 4(4):623-631.
Ernfors P, Lee KF, Kucera J, Jaenisch R. 1994. Lack of neurotrophin-3 leads to deficiencies in the peripheral 
nervous system and loss of limb proprioceptive afferents. Cell 77(4):503-512.
Farinas I, Jones KR, Backus C, Wang XY, Reichardt LF. 1994. Severe sensory and sympathetic deficits in mice 
lacking neurotrophin-3. Nature 369(6482):658-661.
Farinas I, Yoshida CK, Backus C, Reichardt LF. 1996. Lack of neurotrophin-3 results in death of spinal sensory 
neurons and premature differentiation of their precursors. Neuron 17(6):1065-1078.
Figurov A, Pozzo-Miller LD, Olafsson P, Wang T, Lu B. 1996. Regulation of synaptic responses to high-
frequency stimulation and LTP by neurotrophins in the hippocampus. Nature 381(6584):706-709.
Fitzgerald M. 2005. The development of nociceptive circuits. Nat Rev Neurosci 6(7):507-520.
Frade JM, Rodriguez-Tebar A, Barde YA. 1996. Induction of cell death by endogenous nerve growth factor 
through its p75 receptor. Nature 383(6596):166-168.
Fukuoka T, Kondo E, Dai Y, Hashimoto N, Noguchi K. 2001. Brain-derived neurotrophic factor increases in the 
uninjured dorsal root ganglion neurons in selective spinal nerve ligation model. J Neurosci 21(13):4891-4900.
Gardell LR, Wang R, Ehrenfels C, Ossipov MH, Rossomando AJ, Miller S, Buckley C, Cai AK, Tse A, Foley SF, 
Gong B, Walus L, Carmillo P, Worley D, Huang C, Engber T, Pepinsky B, Cate RL, Vanderah TW, Lai J, Sah 
DW, Porreca F. 2003. Multiple actions of systemic artemin in experimental neuropathy. Nat Med 9(11):1383-
1389.
George DJ, Dionne CA, Jani J, Angeles T, Murakata C, Lamb J, Isaacs JT. 1999. Sustained in vivo regression 
of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase 
inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555). Cancer Res 59(10):2395-2401.
Goldberg JL, Barres BA. 2000. The relationship between neuronal survival and regeneration. Annu Rev 
Neurosci 23:579-612.
Gotz R, Koster R, Winkler C, Raulf F, Lottspeich F, Schartl M, Thoenen H. 1994. Neurotrophin-6 is a new 
member of the nerve growth factor family. Nature 372(6503):266-269.
Guo W, Robbins MT, Wei F, Zou S, Dubner R, Ren K. 2006. Supraspinal brain-derived neurotrophic factor 
signaling: a novel mechanism for descending pain facilitation. J Neurosci 26(1):126-137.
Hagg T, Quon D, Higaki J, Varon S. 1992. Ciliary neurotrophic factor prevents neuronal degeneration and 
promotes low affinity NGF receptor expression in the adult rat CNS. Neuron 8(1):145-158.
Hallbook F, Ibanez CF, Persson H. 1991. Evolutionary studies of the nerve growth factor family reveal a novel 
member abundantly expressed in Xenopus ovary. Neuron 6(5):845-858.
Halvorson KG, Kubota K, Sevcik MA, Lindsay TH, Sotillo JE, Ghilardi JR, Rosol TJ, Boustany L, Shelton DL, 
Mantyh PW. 2005. A blocking antibody to nerve growth factor attenuates skeletal pain induced by prostate 
tumor cells growing in bone. Cancer Res 65(20):9426-9435.
Hamburger V, Levi-Montalcini R. 1949. Proliferation, differentiation and degeneration in the spinal ganglia of 
the chick embryo under normal and experimental conditions. J Exp Zool 111:457-459.
25
Introduction
Hatten ME, Lynch M, Rydel RE, Sanchez J, Joseph-Silverstein J, Moscatelli D, Rifkin DB. 1988. In vitro 
neurite extension by granule neurons is dependent upon astroglial-derived fibroblast growth factor. Dev Biol 
125(2):280-289.
Henderson CE, Phillips HS, Pollock RA, Davies AM, Lemeulle C, Armanini M, Simmons L, Moffet B, Vandlen 
RA, Simpson LCS. 1994. GDNF: a potent survival factor for motoneurons present in peripheral nerve and 
muscle. Science 266:1062-1064.
Herbert MK, Holzer P. 2002a. [Neurogenic inflammation. I. Basic mechanisms, physiology and pharmacology]. 
Anasthesiol Intensivmed Notfallmed Schmerzther 37(6):314-325.
Herbert MK, Holzer P. 2002b. [Neurogenic inflammation. II. pathophysiology and clinical implications]. 
Anasthesiol Intensivmed Notfallmed Schmerzther 37(7):386-394.
Hofer MM, Barde YA. 1988. Brain-derived neurotrophic factor prevents neuronal death in vivo. Nature 
331(6153):261-262.
Hohn A, Leibrock J, Bailey K, Barde YA. 1990. Identification and characterization of a novel member of the 
nerve growth factor/brain-derived neurotrophic factor family. Nature 344(6264):339-341.
Holstege JC, Jongen JL, Kennis JH, van Rooyen-Boot AA, Vecht CJ. 1998. Immunocytochemical localization 
of GDNF in primary afferents of the lumbar dorsal horn. Neuroreport 9(12):2893-2897.
Holstege JC, Kennis JHH, Van Rooyen-Boot A, Taal W, Yan Q, Vecht CJ. 1997. Light and electron microscopical 
identification of BDNF immunoreactivity in the rat spinal cord. Soc Neurosci Abstr 23:882.
Holstege JC, van Rooijen-Boot A, Jongen JLM, Haasdijk E, Neuteboom RF, Vecht CJ. 1999. Localization of 
BDNF and GDNF protein in rat spinal cord using light and electron microscopy immunocytochemistry. Soc 
Neurosci Abstr 25:1272.
Hunt SP, Mantyh PW. 2001. The molecular dynamics of pain control. Nat Rev Neurosci 2(2):83-91.
Ibanez CF. 2002. Jekyll-Hyde neurotrophins: the story of proNGF. Trends Neurosci 25(6):284-286.
Ikeda H, Heinke B, Ruscheweyh R, Sandkuhler J. 2003. Synaptic plasticity in spinal lamina I projection 
neurons that mediate hyperalgesia. Science 299(5610):1237-1240.
Jhaveri S, Erzurumlu RS, Laywell ED, Steindler DA, Albers KM, Davis BM. 1996. Excess nerve growth factor 
in the periphery does not obscure development of whisker-related patterns in the rodent brain. J Comp Neurol 
374(1):41-51.
Ji RR, Samad TA, Jin SX, Schmoll R, Woolf CJ. 2002. p38 MAPK activation by NGF in primary sensory 
neurons after inflammation increases TRPV1 levels and maintains heat hyperalgesia. Neuron 36(1):57-68.
Jing S, Wen D, Yu Y, Holst PL, Luo Y, Fang M, Tamir R, Antonio L, Hu Z, Cupples R, Louis JC, Hu S, Altrock 
BW, Fox GM. 1996. GDNF-induced activation of the ret protein tyrosine kinase is mediated by GDNFR-alpha, 
a novel receptor for GDNF. Cell 85(7):1113-1124.
Jones KR, Farinas I, Backus C, Reichardt LF. 1994. Targeted disruption of the BDNF gene perturbs brain and 
sensory neuron development but not motor neuron development. Cell 76(6):989-999.
Jongen JLM, Luger NM, Mach DB, Peters CM, Rogers SD, Sabino MA, Salak-Johnson JL, Mantyh PW. 
Neurotrophic factors and cancer pain: The expression of NGF, GDNF and BDNF by the murine osteolytic 
sarcoma cell line 2472 in vitro and in vivo and their potential involvement in bone cancer pain.; 2002. 
Washington DC: Society for Neuroscience. Program #52.20.
Julius D, Basbaum AI. 2001. Molecular mechanisms of nociception. Nature 413(6852):203-210.
26
Chapter 1
Kang H, Welcher AA, Shelton D, Schuman EM. 1997. Neurotrophins and time: different roles for TrkB 
signaling in hippocampal long-term potentiation. Neuron 19(3):653-664.
Kerr BJ, Bradbury EJ, Bennett DL, Trivedi PM, Dassan P, French J, Shelton DB, McMahon SB, Thompson SW. 
1999. Brain-derived neurotrophic factor modulates nociceptive sensory inputs and NMDA-evoked responses 
in the rat spinal cord. J Neurosci 19(12):5138-5148.
Koltzenburg M. 2004. The role of TRP channels in sensory neurons. Novartis Found Symp 260:206-213; 
discussion 213-220, 277-209.
Koltzenburg M, Bennett DL, Shelton DL, McMahon SB. 1999. Neutralization of endogenous NGF prevents the 
sensitization of nociceptors supplying inflamed skin. Eur J Neurosci 11(5):1698-1704.
Korsching S. 1993. The neurotrophic factor concept: a reexamination. J Neurosci 13(7):2739-2748.
Korte M, Carroll P, Wolf E, Brem G, Thoenen H, Bonhoeffer T. 1995. Hippocampal long-term potentiation is 
impaired in mice lacking brain-derived neurotrophic factor. Proc Natl Acad Sci U S A 92(19):8856-8860.
Kotzbauer PT, Lampe PA, Heuckeroth RO, Golden JP, Creedon DJ, Johnson EM, Jr., Milbrandt J. 1996. 
Neurturin, a relative of glial-cell-line-derived neurotrophic factor. Nature 384(6608):467-470.
Lee R, Kermani P, Teng KK, Hempstead BL. 2001. Regulation of cell survival by secreted proneurotrophins. 
Science 294(5548):1945-1948.
Leibrock J, Lottspeich F, Hohn A, Hofer M, Hengerer B, Masiakowski P, Thoenen H, Barde YA. 1989. Molecular 
cloning and expression of brain-derived neurotrophic factor. Nature 341(6238):149-152.
Leon A, Buriani A, Dal Toso R, Fabris M, Romanello S, Aloe L, Levi-Montalcini R. 1994. Mast cells synthesize, 
store, and release nerve growth factor. Proc Natl Acad Sci U S A 91(9):3739-3743.
Lever IJ, Pezet S, McMahon SB, Malcangio M. 2003. The signaling components of sensory fiber transmission 
involved in the activation of ERK MAP kinase in the mouse dorsal horn. Mol Cell Neurosci 24(2):259-270.
Levi-Montalcini R. 1987. The nerve growth factor 35 years later. Science 237(4819):1154-1162.
Levi-Montalcini R, Hamburger V. 1951. Selective growth-stimulating effects of mouse sarcoma on the sensory 
and sympathetic nervous system of the chick embryo. J Exptl Zool 116:321-362.
Levi-Montalcini R, Hamburger V. 1953. A diffusible agent of mouse sarcoma producing hyperplasia of 
sympathetic ganglia and hyperneurotization of the chick embryo. J Exptl Zool 123:233-388.
Lewin GR, Barde YA. 1996. Physiology of the neurotrophins. Annu Rev Neurosci 19:289-317.
Lewin GR, Mendell LM. 1993. Nerve growth factor and nociception. Trends Neurosci 16(9):353-359.
Lewin GR, Ritter AM, Mendell LM. 1992. On the role of nerve growth factor in the development of myelinated 
nociceptors. J Neurosci 12(5):1896-1905.
Lewin GR, Ritter AM, Mendell LM. 1993. Nerve growth factor-induced hyperalgesia in the neonatal and adult 
rat. J Neurosci 13(5):2136-2148.
Lewin GR, Rueff A, Mendell LM. 1994. Peripheral and central mechanisms of NGF-induced hyperalgesia. Eur 
J Neurosci 6(12):1903-1912.
Lin LF, Doherty DH, Lile JD, Bektesh S, Collins F. 1993. GDNF: a glial cell line-derived neurotrophic factor for 
midbrain dopaminergic neurons. Science 260:1130-1132.
Lin LF, Mismer D, Lile JD, Armes LG, Butler ET, 3rd, Vannice JL, Collins F. 1989. Purification, cloning, and 
expression of ciliary neurotrophic factor (CNTF). Science 246(4933):1023-1025.
27
Introduction
Malmberg AB, Chen C, Tonegawa S, Basbaum AI. 1997. Preserved acute pain and reduced neuropathic pain 
in mice lacking PKCgamma. Science 278(5336):279-283.
Mannion RJ, Costigan M, Decosterd I, Amaya F, Ma QP, Holstege JC, Ji RR, Acheson A, Lindsay RM, Wilkinson 
GA, Woolf CJ. 1999. Neurotrophins: peripherally and centrally acting modulators of tactile stimulus-induced 
inflammatory pain hypersensitivity. Proc Natl Acad Sci U S A 96(16):9385-9390.
Mantyh PW, Hunt SP. 2004. Setting the tone: superficial dorsal horn projection neurons regulate pain 
sensitivity. Trends Neurosci 27(10):582-584.
Mantyh PW, Rogers SD, Honore P, Allen BJ, Ghilardi JR, Li J, Daughters RS, Lappi DA, Wiley RG, Simone DA. 
1997. Inhibition of hyperalgesia by ablation of lamina I spinal neurons expressing the substance P receptor. 
Science 278:275-279.
Martinou JC, Martinou I, Kato AC. 1992. Cholinergic differentiation factor (CDF/LIF) promotes survival of 
isolated rat embryonic motoneurons in vitro. Neuron 8(4):737-744.
McMahon SB, Bennett DL, Priestley JV, Shelton DL. 1995. The biological effects of endogenous nerve growth 
factor on adult sensory neurons revealed by a trkA-IgG fusion molecule. Nat Med 1(8):774-780.
McMahon SB, Cafferty WB, Marchand F. 2005. Immune and glial cell factors as pain mediators and 
modulators. Exp Neurol 192(2):444-462.
McMahon SB, Koltzenburg M. 1992. Itching for an explanation. Trends Neurosci 15(12):497-501.
Melzack R, Wall PD. 1965. Pain mechanisms: a new theory. Science 150(699):971-979.
Mendell LM, Albers KM, Davis BM. 1999. Neurotrophins, nociceptors, and pain. Microsc Res Tech 45(4-
5):252-261.
Meng X, Lindahl M, Hyvonen ME, Parvinen M, de Rooij DG, Hess MW, Raatikainen-Ahokas A, Sainio K, 
Rauvala H, Lakso M, Pichel JG, Westphal H, Saarma M, Sariola H. 2000. Regulation of cell fate decision of 
undifferentiated spermatogonia by GDNF. Science 287(5457):1489-1493.
Michael GJ, Averill S, Nitkunan A, Rattray M, Bennett DL, Yan Q, Priestley JV. 1997. Nerve growth factor 
treatment increases brain-derived neurotrophic factor selectively in TrkA-expressing dorsal root ganglion cells 
and in their central terminations within the spinal cord. J Neurosci 17(21):8476-8490.
Miknyoczki SJ, Wan W, Chang H, Dobrzanski P, Ruggeri BA, Dionne CA, Buchkovich K. 2002. The 
neurotrophin-trk receptor axes are critical for the growth and progression of human prostatic carcinoma and 
pancreatic ductal adenocarcinoma xenografts in nude mice. Clin Cancer Res 8(6):1924-1931.
Milbrandt J, de Sauvage FJ, Fahrner TJ, Baloh RH, Leitner ML, Tansey MG, Lampe PA, Heuckeroth RO, 
Kotzbauer PT, Simburger KS, Golden JP, Davies JA, Vejsada R, Kato AC, Hynes M, Sherman D, Nishimura M, 
Wang LC, Vandlen R, Moffat B, Klein RD, Poulsen K, Gray C, Garces A, Johnson EM, Jr. 1998. Persephin, a 
novel neurotrophic factor related to GDNF and neurturin. Neuron 20:245-253.
Minichiello L, Korte M, Wolfer D, Kuhn R, Unsicker K, Cestari V, Rossi-Arnaud C, Lipp HP, Bonhoeffer T, Klein 
R. 1999. Essential role for TrkB receptors in hippocampus-mediated learning. Neuron 24(2):401-414.
Missale C, Codignola A, Sigala S, Finardi A, Paez-Pereda M, Sher E, Spano PF. 1998. Nerve growth factor abrogates 
the tumorigenicity of human small cell lung cancer cell lines. Proc Natl Acad Sci U S A 95(9):5366-5371.
Molliver DC, Wright DE, Leitner ML, Parsadanian AS, Doster K, Wen D, Yan Q, Snider WD. 1997. IB4-binding 
DRG neurons switch from NGF to GDNF dependence in early postnatal life. Neuron 19(4):849-861.
Murphy M, Reid K, Hilton DJ, Bartlett PF. 1991. Generation of sensory neurons is stimulated by leukemia 
inhibitory factor. Proc Natl Acad Sci U S A 88(8):3498-3501.
28
Chapter 1
Nakajima K, Tohyama Y, Kohsaka S, Kurihara T. 2002. Ceramide activates microglia to enhance the 
production/secretion of brain-derived neurotrophic factor (BDNF) without induction of deleterious factors in 
vitro. J Neurochem 80(4):697-705.
Oelmann E, Sreter L, Schuller I, Serve H, Koenigsmann M, Wiedenmann B, Oberberg D, Reufi B, Thiel 
E, Berdel WE. 1995. Nerve growth factor stimulates clonal growth of human lung cancer cell lines and 
a human glioblastoma cell line expressing high-affinity nerve growth factor binding sites involving tyrosine 
kinase signaling. Cancer Res 55(10):2212-2219.
Ohta K, Inokuchi T, Gen E, Chang J. 2001. Ultrastructural study of anterograde transport of glial cell line-
derived neurotrophic factor from dorsal root ganglion neurons of rats towards the nerve terminal. Cells Tissues 
Organs 169(4):410-421.
Olausson H, Lamarre Y, Backlund H, Morin C, Wallin BG, Starck G, Ekholm S, Strigo I, Worsley K, Vallbo AB, 
Bushnell MC. 2002. Unmyelinated tactile afferents signal touch and project to insular cortex. Nat Neurosci 
5(9):900-904.
Ossipov MH, Porreca F. 2005. Descending Modulation of Pain. In: Merskey H, Loeser JD, Dubner R, editors. 
The Paths of Pain 1975-2005. Seattle: IASP press. p 117-130.
Paratcha G, Ledda F, Ibanez CF. 2003. The neural cell adhesion molecule NCAM is an alternative signaling 
receptor for GDNF family ligands. Cell 113(7):867-879.
Pezet S, Malcangio M, Lever IJ, Perkinton MS, Thompson SW, Williams RJ, McMahon SB. 2002a. Noxious 
stimulation induces Trk receptor and downstream ERK phosphorylation in spinal dorsal horn. Mol Cell Neurosci 
21(4):684-695.
Pezet S, Malcangio M, McMahon SB. 2002b. BDNF: a neuromodulator in nociceptive pathways? Brain Res 
Brain Res Rev 40(1-3):240-249.
Poo MM. 2001. Neurotrophins as synaptic modulators. Nat Rev Neurosci 2(1):24-32.
Poteryaev D, Titievsky A, Sun YF, Thomas-Crusells J, Lindahl M, Billaud M, Arumae U, Saarma M. 1999. 
GDNF triggers a novel ret-independent Src kinase family-coupled signaling via a GPI-linked GDNF receptor 
alpha1. FEBS Lett 463(1-2):63-66.
Ramer MS, Bishop T, Dockery P, Mobarak MS, O'Leary D, Fraher JP, Priestley JV, McMahon SB. 2002. 
Neurotrophin-3-mediated regeneration and recovery of proprioception following dorsal rhizotomy. Mol Cell 
Neurosci 19(2):239-249.
Ramer MS, Priestley JV, McMahon SB. 2000. Functional regeneration of sensory axons into the adult spinal 
cord. Nature 403(6767):312-316.
Ramon y Cajal S. 1928. Degeneration and regeneration in the nervous system. New York: Hafner.
Ren K, Thomas DA, Dubner R. 1995. Nerve growth factor alleviates a painful peripheral neuropathy in rats. 
Brain Res 699(2):286-292.
Rexed B. 1952. The cytoarchitectonic organization of the spinal cord in the cat. J Comp Neurol 96(3):414-495.
Reynolds DV. 1969. Surgery in the rat during electrical analgesia induced by focal brain stimulation. Science 
164(878):444-445.
Ritter AM, Lewin GR, Kremer NE, Mendell LM. 1991. Requirement for nerve growth factor in the development 
of myelinated nociceptors in vivo. Nature 350(6318):500-502.
Ro LS, Chen ST, Tang LM, Jacobs JM. 1999. Effect of NGF and anti-NGF on neuropathic pain in rats following 
chronic constriction injury of the sciatic nerve. Pain 79(2-3):265-274.
29
Introduction
Rose CR, Blum R, Kafitz KW, Kovalchuk Y, Konnerth A. 2004. From modulator to mediator: rapid effects of 
BDNF on ion channels. Bioessays 26(11):1185-1194.
Sariola H, Saarma M. 2003. Novel functions and signalling pathways for GDNF. J Cell Sci 116(Pt 19):3855-3862.
Schuchardt A, D'Agati V, Larsson-Blomberg L, Costantini F, Pachnis V. 1994. Defects in the kidney and enteric 
nervous system of mice lacking the tyrosine kinase receptor Ret. Nature 367(6461):380-383.
Sevcik MA, Ghilardi JR, Peters CM, Lindsay TH, Halvorson KG, Jonas BM, Kubota K, Kuskowski MA, 
Boustany L, Shelton DL, Mantyh PW. 2005. Anti-NGF therapy profoundly reduces bone cancer pain and the 
accompanying increase in markers of peripheral and central sensitization. Pain 115(1-2):128-141.
Shu XQ, Mendell LM. 1999. Neurotrophins and hyperalgesia. Proc Natl Acad Sci U S A 96(14):7693-
7696.
Slack SE, Grist J, Mac Q, McMahon SB, Pezet S. 2005. TrkB expression and phospho-ERK activation by 
brain-derived neurotrophic factor in rat spinothalamic tract neurons. J Comp Neurol 489(1):59-68.
Slack SE, Pezet S, McMahon SB, Thompson SW, Malcangio M. 2004. Brain-derived neurotrophic factor 
induces NMDA receptor subunit one phosphorylation via ERK and PKC in the rat spinal cord. Eur J Neurosci 
20(7):1769-1778.
Snider WD, McMahon SB. 1998. Tackling pain at the source: new ideas about nociceptors. Neuron 20(4):629-632.
Sofroniew MV, Howe CL, Mobley WC. 2001. Nerve growth factor signaling, neuroprotection, and neural 
repair. Annu Rev Neurosci 24:1217-1281.
Suzuki R, Dickenson A. 2005. Spinal and supraspinal contributions to central sensitization in peripheral 
neuropathy. Neurosignals 14(4):175-181.
Suzuki R, Morcuende S, Webber M, Hunt SP, Dickenson AH. 2002. Superficial NK1-expressing neurons 
control spinal excitability through activation of descending pathways. Nat Neurosci 5(12):1319-1326.
Suzuki R, Rygh LJ, Dickenson AH. 2004. Bad news from the brain: descending 5-HT pathways that control 
spinal pain processing. Trends Pharmacol Sci 25(12):613-617.
Teng HK, Teng KK, Lee R, Wright S, Tevar S, Almeida RD, Kermani P, Torkin R, Chen ZY, Lee FS, Kraemer RT, 
Nykjaer A, Hempstead BL. 2005. ProBDNF induces neuronal apoptosis via activation of a receptor complex 
of p75NTR and sortilin. J Neurosci 25(22):5455-5463.
Thompson SW, Bennett DL, Kerr BJ, Bradbury EJ, McMahon SB. 1999. Brain-derived neurotrophic factor is 
an endogenous modulator of nociceptive responses in the spinal cord. Proc Natl Acad Sci U S A 96(14):7714-
7718.
Tonra JR, Curtis R, Wong V, Cliffer KD, Park JS, Timmes A, Nguyen T, Lindsay RM, Acheson A, DiStefano PS. 
1998. Axotomy upregulates the anterograde transport and expression of brain- derived neurotrophic factor by 
sensory neurons. J Neurosci 18:4374-4383.
Tracey I. 2005. Nociceptive processing in the human brain. Curr Opin Neurobiol 15(4):478-487.
Treanor JJ, Goodman L, de Sauvage F, Stone DM, Poulsen KT, Beck CD, Gray C, Armanini MP, Pollock 
RA, Hefti F, Phillips HS, Goddard A, Moore MW, Buj-Bello A, Davies AM, Asai N, Takahashi M, Vandlen 
R, Henderson CE, Rosenthal A. 1996. Characterization of a multicomponent receptor for GDNF. Nature 
382(6586):80-83.
Trupp M, Arenas E, Fainzilber M, Nilsson AS, Sieber BA, Grigoriou M, Kilkenny C, Salazar-Grueso E, Pachnis V, Arumae 
U. 1996. Functional receptor for GDNF encoded by the c-ret proto-oncogene. Nature 381(6585):785-789.
30
Chapter 1
Trupp M, Scott R, Whittemore SR, Ibanez CF. 1999. Ret-dependent and -independent mechanisms of glial cell 
line- derived neurotrophic factor signaling in neuronal cells. J BiolChem 274:20885-20894.
Tsou K, Jang CS. 1964. Studies on the Site of Analgesic Action of Morphine by Intracerebral Micro-Injection. 
Sci Sin 13:1099-1109.
Tsuda M, Inoue K, Salter MW. 2005. Neuropathic pain and spinal microglia: a big problem from molecules in 
"small" glia. Trends Neurosci 28(2):101-107.
Tsui-Pierchala BA, Milbrandt J, Johnson EM, Jr. 2002. NGF utilizes c-Ret via a novel GFL-independent, inter-RTK 
signaling mechanism to maintain the trophic status of mature sympathetic neurons. Neuron 33(2):261-273.
Vanegas H, Schaible HG. 2004. Descending control of persistent pain: inhibitory or facilitatory? Brain Res 
Brain Res Rev 46(3):295-309.
Verge VM, Richardson PM, Wiesenfeld-Hallin Z, Hokfelt T. 1995. Differential influence of nerve growth factor 
on neuropeptide expression in vivo: a novel role in peptide suppression in adult sensory neurons. J Neurosci 
15(3 Pt 1):2081-2096.
Wetmore C, Olson L. 1995. Neuronal and nonneuronal expression of neurotrophins and their receptors in sensory 
and sympathetic ganglia suggest new intercellular trophic interactions. J Comp Neurol 353(1):143-159.
Willis WD. 2002. Long-term potentiation in spinothalamic neurons. Brain Res Brain Res Rev 40(1-3):202-214.
Woo NH, Teng HK, Siao CJ, Chiaruttini C, Pang PT, Milner TA, Hempstead BL, Lu B. 2005. Activation of 
p75NTR by proBDNF facilitates hippocampal long-term depression. Nat Neurosci 8(8):1069-1077.
Woolf CJ. 1983. Evidence for a central component of post-injury pain hypersensitivity. Nature 306(5944):686-688.
Woolf CJ, Ma QP, Allchorne A, Poole S. 1996. Peripheral cell types contributing to the hyperalgesic action of 
nerve growth factor in inflammation. J Neurosci 16(8):2716-2723.
Woolf CJ, Safieh-Garabedian B, Ma QP, Crilly P, Winter J. 1994. Nerve growth factor contributes to the 
generation of inflammatory sensory hypersensitivity. Neuroscience 62(2):327-331.
Woolf CJ, Salter MW. 2000. Neuronal plasticity: increasing the gain in pain. Science 288(5472):1765-1769.
Yan Q, Radeke MJ, Matheson CR, Talvenheimo J, Welcher AA, Feinstein SC. 1997. Immunocytochemical 
localization of TrkB in the central nervous system of the adult rat. J CompNeurol 378:135-157.
Zhao J, Seereeram A, Nassar MA, Levato A, Pezet S, Hathaway G, Morenilla-Palao C, Stirling C, Fitzgerald M, 
McMahon SB, Rios M, Wood JN. 2006. Nociceptor-derived brain-derived neurotrophic factor regulates acute 
and inflammatory but not neuropathic pain. Mol Cell Neurosci.
Zhou XF, Deng YS, Chie E, Xue Q, Zhong JH, McLachlan EM, Rush RA, Xian CJ. 1999. Satellite-cell-derived 
nerve growth factor and neurotrophin-3 are involved in noradrenergic sprouting in the dorsal root ganglia 
following peripheral nerve injury in the rat. Eur J Neurosci 11(5):1711-1722.
Zhou XF, Rush RA. 1996. Endogenous brain-derived neurotrophic factor is anterogradely transported in 
primary sensory neurons. Neuroscience 74(4):945-953.
Zweifel LS, Kuruvilla R, Ginty DD. 2005. Functions and mechanisms of retrograde neurotrophin signalling. 
Nat Rev Neurosci 6(8):615-625.
Zylka MJ. 2005. Nonpeptidergic circuits feel your pain. Neuron 47(6):771-772.
Zylka MJ, Rice FL, Anderson DJ. 2005. Topographically distinct epidermal nociceptive circuits revealed by 
axonal tracers targeted to Mrgprd. Neuron 45(1):17-25.
31
Introduction
FIGURES
Fig. 1. The sensory component of pain. Major peripheral and central pathways for the discriminative 
aspects of pain and temperature sensation, which are perceived by the same systems. (A) The 
spinothalamic or anterolateral system, which carries information about these sensations from the 
body and extremities. (B) The trigeminal pain and temperature system, which carries information 
about these sensations from the face.
Fig. 2. The affective-motivational component of pain. Nociceptive information critical for signaling 
the unpleasant quality of pain is mediated by projections to the reticular formation (including 
the parabrachial nucleus) and to the intralaminar nuclei of the thalamus. From the latter tertiary 
neurons project to the cingulate cortex and insula. Parabrachial neurons on the other hand project 
to the amygdala and hypothalamus, but also to the periaqueductal gray, a structure that plays an 
important role in the descending control of activity in the pain pathway.
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Fig. 3. Diagram showing the two subclasses of C nociceptors, peptidergic nociceptors in red and 
non-peptidergic nociceptors in blue. The peptidergic nociceptors are dependent on NGF during 
development, express the receptor for NGF, TrkA, and neuropeptides, like CGRP and SubP, and 
terminate in lamina I and IIouter, the most superficial layers of the dorsal horn. An important central 
target of the peptidergic C nociceptors are nociceptive specific spinal projection neurons that express 
Neurokinin-1 (NK-1), the receptor for SubP. The non-peptidergic nociceptors are dependent on 
GDNF during development, express the receptor components for GDNF, RET and GFRα-1, and the 
plant lectin Isolectin B4 (IB4) and terminate in lamina IIinner. An important central target of the non-
peptidergic C nociceptors are interneurons that express the γ isoform of protein kinase C (PKCγ).
Fig. 4. The gate control theory
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Fig. 5. The history of NGF goes back to work by Samuel Detwiler, Viktor Hamburger and others 
in the 1920's and 1930's. They showed firstly that neuronal cell death occurred in the dorsal root 
ganglia of normally developing embryos, and that the number of sensory neurons which survived 
into adulthood depended on the size of the target which they innervated. In amphibians, the 
number of sensory neurons in the DRG could be reduced by removing the normal target, while it 
could be increased by transplanting an additional limb bud. This was found to be due to changes 
in the survival of postmitotic neurons and not in the division of neuronal precursor cells. 
Fig. 6. Experiment by (Campenot, 1981) showing that NGF can influence neurite outgrowth by 
local action. Three compartments of a culture disc (A, B, C) are separated from one another by 
a plastic divider sealed to the bottom of the disc by grease. Isolated rat sympathetic ganglion 
cells plated in compartment A can grow through the grease seal and into compartments B 
and C. (A magnified view looking down on the compartments is shown below.) Growth into a 
lateral chamber occurs as long as the compartment contains an adequate concentration of NGF. 
Subsequent removal of NGF from a compartment causes a local regression of neurites in the other 
compartments.
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Fig. 7. 
Fig. 8. 
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Fig. 7. (previous page) Neurotrophin receptors and their specificity for the neurotrophins. (A) The 
Trk family of  receptor tyrosine kinases for the neurotrophins. TrkA is primarily a receptor for NGF, 
TrkB a receptor for BDNF and NT-4/5, and TrkC a receptor for NT-3. Because of the high degree 
of structural homology among both the neurotrophins and the Trk receptors, there is some degree 
of cross-activation between factors and receptors. For example, NT-3 can bind to and activate 
TrkB, as indicated by the dashed arrow. These distinct receptors allow various neurons to respond 
selectively to the different neurotrophins. (B) The p75 low-affinity neurotrophin receptor binds all 
neurotrophins at low affinities (as its name implies). This receptor confers the ability to respond to 
a broad range of neurotrophins upon fairly broadly distributed classes of neurons in the peripheral 
and central nervous system.
Fig. 8. (previous page) GDNF-family ligands and receptor interactions. Homodimeric GDNF-
family ligands (GFLs), i.e. GDNF, NRTN, ARTN, PSPN, activate RET tyrosine kinase by first 
binding their cognate GDNF-family receptor-α (GFRα) receptors. Arrows indicate the preferred 
ligand-receptor interactions that are known to occur physiologically in vivo. GFRα proteins are 
attached to the plasma membrane by a glycosyl phosphatidylinositol (GPI) anchor. GFLs bind 
mainly to the second domain of GFRα receptors, which is also crucial for RET binding. Binding of 
Ca2+ ions to one of the four extracellular cadherin-like domains of RET is required for its activation 
by GFL-GFRα complexes. Phosphorylation of tyrosine residues (red balls) in the RET intracellular 
part induces several intracellular signaling cascades.
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ABSTRACT
Immunocytochemistry was used to identify glial cell line-derived neurotrophic factor (GDNF) in rat 
spinal cord. Strong GDNF labeling was found in fibers and terminals in laminae I and II (outer) and 
to a lesser extent in the remaining laminae. A few spinal ganglion cells also contained GDNF. After 
dorsal root transection GDNF disappeared from the dorsal horn and after dorsal root ligation there 
was accumulation of GDNF only on the ganglion side of the ligation. These findings demonstrate 
anterograde transport of GDNF within primary afferent fibers, which constitute the only source of 
GDNF labeling in the dorsal horn. The strong presence of GDNF in the superficial dorsal horn may 
indicate that GDNF has a role in pain transmission in the adult rat spinal cord.
Keywords: Dorsal horn, Glial cell line-derived neurotrophic factor, Immunocytochemistry,  Pain, 
Rat, Rhizotomy, Spinal cord, Spinal ganglion
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INTRODUCTION
Glial cell line-derived neurotrophic factor (GDNF) was originally purified and cloned as a survival 
factor for midbrain dopaminergic neurons.1 GDNF was shown to be able to protect adult 
dopaminergic neurons against various toxic substances or axotomy.2-6 In addition, similar to 
many other neurotrophic factors, GDNF rescues spinal motoneurons from dying after axotomy 
of a peripheral nerve in the neonatal period7,8 and may also play a role in the development and 
maintenance of sensory neurons.9,10 Injections of [125I]-GDNF showed retrograde transport of 
GDNF from the striatum to the nigra and from the periphery to the spinal ganglion,9,11 suggesting 
that in these systems GDNF acts as a retrogradely transported neurotrophic factor. Two other 
neurotrophic factors, neurturin and persephin, which are about 40% identical to GDNF, have 
recently been identified.12 Together with GDNF they constitute a separate family of neurotrophic 
factors, distantly related to the transforming growth factor-β superfamily, but also showing 
characteristics of the neurotrophin family.13 
A tyrosine kinase receptor, known as Ret, was identified recently as the receptor for GDNF. 
However, for signal transduction at the Ret receptor an additional extracellular GDNF-binding 
protein, named GFRα, is necessary, several of which have now been identified.14  Areas 
expressing mRNA encoding for GDNF and its various receptor components have been identified 
in the adult central nervous system. GDNF mRNA was found in specific areas of neocortex, 
thalamus, hippocampus, cerebellum, mesencephalon, pons medulla and spinal cord,15-17 while 
levels in dorsal root ganglia were low.18,19 The Ret and GFRα receptor mRNAs were also found 
in the majority of these areas, including dorsal root ganglia and the spinal dorsal horn.10,20,21
So far, the localization of the GDNF protein has not been studied in the central nervous 
system. We have used immunocytochemistry to localize GDNF protein in the rat spinal cord. 
Since GDNF immunoreactive fibers and terminals are abundantly present in the superficial dorsal 
horn, we have also used dorsal root transection or ligation for identifying the origin and the 
direction of transport of GDNF.
MATERIALS AND METHODS
For GDNF immunocytochemistry 12 male Wistar rats were deeply anesthetized with pentobarbital 
and perfused transcardially with 250 ml phosphate buffer (PB; 0.025M, pH 7.3), containing 
0.8% NaCl, 0.8% sucrose and 0.4% D-glucose followed by 400 ml of PB (0.05M) containing 
4% paraformaldehyde and 400 ml of the same fixative also containing 15% sucrose, both at 4°C. 
After perfusion, the spinal cord and the L4 and L5 spinal ganglia were removed and postfixed at 
4°C for 2 hours in fixative containing 15% sucrose. Frozen sections were cut at 40 µm, rinsed in 
Tris-buffered saline (TBS) and processed for immunocytochemistry (all steps at room temperature 
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except where indicated otherwise). The sections were preincubated in 10% normal goat serum 
(NGS) in TBS containing 0.4% Triton X-100 and then transferred to TBS containing 1% NGS, 
0.1% Triton X-100 and a GDNF antibody diluted 1:1500-3000 and incubated approximately 40 
hours at 4°C. Sections were then rinsed (4x) in TBS, incubated for 90 min in biotinylated goat-
anti-rabbit (1:200 in TBS also containing 0.1% Triton X-100 and 1% NGS), rinsed again (TBS; 
4x), processed with the ABC method (Vector Elite) and reacted with 0.025% diaminobenzidine 
(DAB), containing 0.005% hydrogen peroxide. The GDNF antibody (Santa Cruz sc-328) is a 
polyclonal antibody directed against amino-acids 186-205 of the precursor form of human GDNF. 
For controls, some sections were processed as above, except that the primary GDNF antibody was 
either omitted and substituted with TBS, or preincubated (2 h) with a 10-fold (by weight) excess 
of peptide antigen (Santa Cruz sc-328 P) in TBS.
Five rats were deeply anesthetized with 2% halothane in a mixture of O2 and N2O. A 
laminectomy was performed at L3, after which the L3-S1 dorsal roots, which pass at this level, 
were transected. After closing the wound the animals survived for 10 days. They were then 
deeply anesthetized with pentobarbital and perfused as above. The spinal cord was removed and 
processed for GDNF immunocytochemistry as above. For dorsal root ligation a similar procedure 
was used for exposing the L3-S1 dorsal roots. One or two of these roots were tightly ligated 
using a 6.0 nylon thread. Two of these animals survived for 1 day and 4 animals survived for 9 
days. After perfusion, the dorsal roots were removed and embedded in gelatin, after which frozen 
sections were cut and treated for GDNF immunocytochemistry as above.
RESULTS
Light microscopical examination of the lumbo-sacral spinal cord sections processed for GDNF 
immunocytochemistry showed very dense reaction product in fibers and presumed terminals of 
the superficial dorsal horn (laminae I and outer lamina II). A few labeled varicose fibers were also 
seen in laminae II (inner), III, IV and in the central and lateral parts of lamina V. Occasionally 
these fibers appeared to form a sort of cluster, centrally in laminae IV and V (Fig. 1). In the 
medial part of the dorsal horn, at the border between the gray and white matter, a narrow band 
of strongly labeled fibers was seen, which seemed to terminate in the area dorsal to the central 
canal. This was especially clear at low lumbar and sacral levels, where the area dorsal to the 
central canal becomes larger. Labeled fibers were also present in the lateral spinal nucleus and 
in the sacral parasympathetic nucleus. The remaining laminae showed only a few lightly labeled 
fibers. Labeled neurons were not observed.
In the spinal ganglia several ganglion cells showed a variable amount of faint granular 
labeling, but only very few cells were unambiguously labeled and quantification was therefore not 
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attempted. Labeled ganglion cells were small or medium sized and occasionally were observed 
to give rise to an immunoreactive fiber that could be followed over some distance (Fig. 2). 
Immunoreactive fibers, often showing fine immunoreactive granules, were seen throughout the 
ganglion.
In order to determine whether GDNF immunoreactive fibers in the dorsal horn were dorsal root 
fibers, a rhizotomy was performed by cutting the lumbo-sacral dorsal roots, leading to primary 
afferent degeneration in the spinal cord. In these cases, the strongly GDNF-immunoreactive fibers 
in the superficial dorsal horn and in laminae III-V as well as those dorsal to the central canal 
nearly all disappeared in the corresponding segments on the rhizotomized side. A few weakly 
labeled fibers usually remained, mainly in the superficial dorsal horn. In contrast, the same area 
on the non-rhizotomized contralateral (control) side was still strongly labeled (Fig. 3). The labeled 
fibers in the sacral parasympathetic nucleus also disappeared after a lumbosacral rhizotomy, 
while the limited number of lightly stained fibers in the ventral horn remained on the rhizotomized 
side as on the contralateral side.  
The dorsal roots that were processed for GDNF immunocytochemistry showed several-GDNF 
immunoreactive fibers at the ganglion side of the ligation (Fig. 4), both at 1 and 9 days survival 
after the ligation. The spinal side of a ligation never showed a significant amount of GDNF 
immunoreactivity. 
Control sections, incubated with TBS or with GDNF antibody pre-incubated with peptide 
antigen did not show immunoreactivity, strongly suggesting that the antibody only recognized the 
GDNF-specific peptide sequence. 
DISCUSSION
In this study we have used immunocytochemistry with a highly specific antibody against GDNF 
to identify the distribution of GDNF protein in the lumbo-sacral spinal cord and corresponding 
ganglia. The GDNF-immunoreactive fibers and presumed terminals were especially strong in the 
superficial dorsal horn, with some varicose fibers in the deeper laminae and the area around the 
central canal. This characteristic pattern of labeling is also observed with various neuropeptides 
like calcitonin gene-related peptide (CGRP), somatostatin, substance P and galanin.22 However, 
some of these neuropeptides are also present in neurons of the dorsal horn, while we never 
observed neuronal labeling with GDNF in the spinal cord. Studies using in situ hybridization 
or the more sensitive reverse transcription-polymerase chain reaction have shown that neurons 
expressing GDNF mRNA in the adult spinal cord15-17, 19 are motoneurons and interneurons of 
the ventral horn, rather than the dorsal horn.16, 23 The lack of neuronal labeling that we observed 
in the spinal cord, may indicate that the GDNF protein level in neuronal somata is too low for 
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detection with immunocytochemistry, either because only low amounts of GDNF are produced 
or because GDNF is transported away from the soma immediately after production. The latter 
situation may also apply for the spinal ganglion cells, which were only weakly immunoreactive, 
while their (presumed) terminals in the dorsal horn were strongly immunoreactive, probably due to 
the accumulation of GDNF in these terminals. A similar phenomenon occurs with the localization 
of various peptides, in which cases colchicine an be used to increase neuronal labeling.22 We 
are currently exploring the possibility to enhance neuronal labeling for GDNF after colchicine 
treatment.
In order to investigate the origin of the GDNF fibers, dorsal rhizotomies were performed, 
which resulted in a dramatic decrease of GDNF immunolabeling in the dorsal horn. This strongly 
suggests that GDNF in the dorsal horn is present exclusively in primary afferent fibers and their 
terminals and is not derived from spinal or supraspinal sources. The few fibers that remained in 
the dorsal horn after a rhizotomy were probably derived from distant intact dorsal roots, which 
are known to travel long distances in the spinal cord. However, another origin of these fibers, 
e.g. from local interneurons, cannot be excluded on the basis of our data. The experiments using 
ligation of a dorsal root showed that GDNF accumulated at the ganglion side of a ligation. This 
finding suggests that GDNF is anterogradely transported in primary afferent fibers towards their 
terminals in the dorsal horn. It seems most likely that the transported GDNF is produced in the 
ganglion cells, although in our material only few weakly labeled ganglion cells were observed. 
Immunocytochemical studies on human post mortem tissue, however, showed small to medium 
sized ganglion cells that were strongly immunoreactive for GDNF.24 This would be in agreement 
with in situ hybridization data showing that spinal ganglion cells produce GDNF mRNA in relatively 
low amounts in the adult,19 in contrast to the early neonatal period when GDNF mRNA levels 
were higher.15 Taken together, our data indicate that GDNF, produced in dorsal root ganglia, is 
transported anterogradely to the terminals of primary afferent fibers in the dorsal horn. However, 
it cannot be excluded that GDNF, produced in the periphery, is transported transganglionically to 
primary afferent terminals in the dorsal horn.
Our findings on the spinal distribution and transport of GDNF very much resemble those of 
brain derived neurotrophic factor (BDNF), a member of the neurotrophin family. Both substances 
show the strongest labeling in the superficial dorsal horn, disappear after dorsal rhizotomy and 
accumulate at the ganglion side of a ligation.25, 26 Furthermore, BDNF was found within dense 
cored vesicles,26, 27 suggesting activity dependent release of BDNF. The localization in dense 
cored vesicles explains the accumulation after a ligation and the relative weak labeling of ganglion 
cells, since dense cored vesicles are produced in the cell soma and subsequently transported to 
the terminal. The granular appearance of the labeled fibers observed in the ganglion may also 
indicate localization in dense cored vesicles. Obviously, electron microscopy is needed to resolve 
this issue.
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So far there are no conclusive data with respect to the function of GDNF in the dorsal horn. 
Since both BDNF and GDNF containing fibers are concentrated in the superficial layers of the 
dorsal horn, which receive fibers that are primarily involved in nociceptive transmission, it seems 
likely that both substances are involved in nociception. If GDNF, as BDNF, would be localized 
in dense cored vesicles, this would imply the activity-dependent release of GDNF from primary 
afferent fibers and bring GDNF into the realm of neurotransmission. On the other hand, a recent 
study10 showed that changes in the dorsal horn, that normally occur after a peripheral after 
nerve lesion, were partially reversed by intrathecal GDNF application, suggesting a trophic rather 
than a neuromodulator-like role for GDNF. The finding in the same study10 that Ret is present in 
presumed terminals in the inner part of lamina II combined with our finding that GDNF is present 
in fibers terminating in lamina I and outer lamina II suggests that the subset of ganglion cells 
expressing GDNF does not express the Ret receptor. Again, similar observations have been made 
previously with respect to BDNF, which is expressed in a subset of ganglion cells, while another 
subset expressed Trk B, the BDNF receptor.26 
CONCLUSION
The present study shows that GDNF is present in spinal ganglion cells and is transported 
anterogradely within primary afferent fibers, which terminate predominantly in the superficial 
dorsal horn. Since the superficial dorsal horn mainly receives nociceptive fibers, it seems likely 
that GDNF is involved in the processing of nociceptive input at the spinal level. Whether GDNF 
acts as an anterograde trophic messenger, maintaining normal neuronal functioning, or whether it 
has a more direct effect as a neuromodulator in pain transmission, remains to be elucidated. 
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FIGURES
Fig. 1. Light micrograph of a section from the rat L5 segment showing dense GDNF immunoreactive 
fibers and presumed terminals in lamina I and outer lamina II. Several strongly immunoreactive 
fibers are also present in the central parts of laminae IV and V (arrowheads). The other laminae 
also contain a few varicose fibers.
Fig. 2. Light micrograph of a section from the L5 ganglion. A strongly GDNF-immunoreactive 
ganglion cell is present on the right. From this cell a curling fiber originates (arrowheads), that 
contains granular GDNF labeling. On the left, another, weakly labeled, ganglion cell is present. 
Both cells may contain a few immunoreactive granules.
Fig. 3. Light micrograph of a section from the L5 segment after a L3-S1 dorsal rhizotomy on the 
right side. Note the nearly complete disappearance of GDNF immunoreactivity on the rhizotomized 
side, while GDNF labeling on the non-rhizotomized control side is still present.
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Fig. 4. (a-c) Light micrographs of a section through a gelatin embedded L5 dorsal root, 9 days 
after ligation. The section was treated for GDNF immunocytochemistry.
(a) Overview showing the area of ligation in the center (large arrowhead) with the spinal side 
on the left and the ganglion side on the right of the ligation. The boxes indicate the areas of 
magnification shown in (b) and (c).
(b) Magnification of the area indicated in (a) showing that GDNF immunoreactivity is absent on 
the spinal side of the ligation.
(c) Magnification of the area indicated in (a) showing GDNF immunoreactive fibers (small 
arrowheads) on the ganglion side of the ligation.
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ABSTRACT
Glial cell line-derived neurotrophic factor (GDNF) is produced in a subset of adult rat spinal 
ganglion neurons and anterogradely transported to the superficial dorsal horn. In this study 
the effect of sciatic nerve axotomy on the expression of GDNF protein in the dorsal horn was 
investigated, using immunocytochemistry. Image analysis showed a 44% decrease relative to 
the non-transected side after 5 days survival, progressing to more than 80% decrease after 10 
days and remaining so for at least 100 days. This rapid and strong decrease suggests active 
downregulation of the expression of GDNF protein after peripheral axotomy. The observed down-
regulation of GDNF is compared with changes observed for other substances in primary afferents 
after peripheral axotomy and is discussed in light of its presumed trophic or transmitter role in 
nociception.
Key words: Axotomy; Dorsal horn; Glial cell line-derived neurotrophic factor; Image analysis; 
Immunocytochemistry; Neuropeptide; Rat; Spinal cord
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INTRODUCTION
Glial cell line-derived neurotrophic factor (GDNF) is a highly potent trophic factor for midbrain 
dopaminergic neurons, motoneurons and sensory neurons.1-4 While distantly related to the 
transforming growth factor-β superfamily, GDNF is now considered as a member of  a separate 
class of neurotrophic factors, together with neurturin and persephin.5 GDNF mRNA is found in the 
adult neocortex, thalamus, hippocampus, cerebellum, mesencephalon, pons, medulla and spinal 
cord.6 Using immunocytochemistry, we recently identified GDNF protein in dorsal root ganglion 
(DRG) neurons in the adult rat and demonstrated anterograde transport of GDNF within their 
central projections.7 GDNF immunoreactivity (GDNF-IR) in the dorsal horn is derived exclusively 
from primary afferent fibres and is especially strong in laminae I and II-outer, suggesting that 
GDNF is preferentially localized in nociceptive fibres. A similar termination pattern was shown for a 
variety of other substances including brain derived neurotrophic factor (BDNF)8 and neuropeptides 
like substance P (SubP), calcitonin gene-related peptide (CGRP), galanin (GAL) and vasoactive 
intestinal peptide (VIP).9 While neuropeptides are known to be involved in the modulation of 
nociceptive transmission,10 the role of BDNF and GDNF in the nociceptive system is still unclear.
Following peripheral axotomy a number of changes in the expression of neuropeptides in the 
dorsal horn has been observed, including downregulation of SubP and CGRP and up-regulation of 
GAL and VIP.9 In addition, sciatic nerve axotomy may lead to up-regulation or de novo synthesis 
of BDNF immunoreactivity in presumed myelinated fibres in the ipsilateral gracile nucleus and 
lamina III and IV of the dorsal horn.11 Thus, the expression of neuropeptides and BDNF is actively 
regulated in response to peripheral axotomy.
In this study, we investigated the effect of sciatic nerve axotomy on GDNF-IR in the superficial 
dorsal horn, in order to determine whether GDNF expression in primary afferents is also actively 
regulated in response to peripheral axotomy.
MATERIALS AND METHODS
Adult male Wistar rats were anesthetized with 2% halothane in O2 /N2O (30/70%). The left sciatic 
nerve was exposed, dissected free and locally anesthetized with lidocaine. Subsequently, the 
nerve was transected and 5 mm was removed at the midthigh level to prevent regeneration of the 
proximal stump into the distal stump. The rats were allowed to survive for 5, 10, 25, 40 or 100 
days (n=3 for each survival time), after which they received an overdose of sodium pentobarbital 
and were perfused as described previously.7 Three normal rats were used as controls. After 
perfusion the lumbar spinal cord was dissected and from three experimental animals (10, 40 and 
100 days survival) and one control animal, the medulla oblongata was also dissected. The right 
side was marked. Sections (34 µm) were cut on a freezing microtome and every fourth section 
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was collected. Then they were routinely processed for GDNF immunocytochemistry, using the 
ABC method and a specific antibody (Santacruz), as described previously.7 Subsequently, the 
sections were randomly mounted on slides. For controls some sections were treated as above, 
except that the GDNF antibody was either substituted by saline or preincubated (2 h) with a 10-
fold (by weight) excess of peptide antigen (Santacruz) in TBS.
For quantification of GDNF-IR, the first four L5 sections encountered on the slide were 
selected. These sections were photographed with a Kodak 64 ASA daylight film (diapositive) in 
a light microscope (Leica DMR) equipped with a photoautomat, using a 5x/0.12 objective and 
a CB 12 (blue) filter. After processing the diapositives were scanned at 337 dpi using a Polaroid 
SprintScan slide scanner connected to a Power Macintosh computer. The resulting images (n=72) 
were further analysed using the public domain NIH Image (v 1.61) program. A square selection of 
128x128 pixels was made such that it contained the entire medial superficial dorsal horn on each 
side. Processing and image analysis of this selection was performed as described previously,12 
using a threshold of 75. This method created an image that appeared in black against a white 
background. This binary image was an accurate representation of the GDNF-IR area in the section 
and was expressed in number of pixels. 
The mean pixel number of three animals was calculated for each side and for each survival 
time, using the mean of four sections per rat as one observation. The mean pixel number of the 
control sides of the experimental animals was compared with the right and left side of control 
animals, using the unpaired t-test. For each of the images from the experimental animals the 
difference between the pixel number of the control (right) side and the axotomized (left) side was 
expressed as a percentage of the control side. For the control animals the difference between the 
right and the left side was calculated in a similar way. The unpaired t-test was used to compare 
these percentages.
RESULTS
Light microscopic examination of the dorsal horn of sections from control rats showed strong 
GDNF-IR in the superficial dorsal horn of the L5 segment (lamina I and II-outer) and a few labeled 
fibres in the deeper layers (lamina II-inner, III, IV, V and X) on both sides (Fig. 1a, b), as described 
previously.7 Control L5 sections incubated with saline or with GDNF antibody preincubated with 
peptide antigen did not show immunoreactive structures.
After axotomy, GDNF-IR on the axotomized side was strongly decreased, especially after 
longer survival times. The decrease occurred only in the medial dorsal horn, corresponding to the 
territory of the sciatic afferents, while immunoreactivity in the lateral part and on the contralateral 
side appeared as normal (Fig. 1c-g). Comparisons of the mean pixel numbers, representing the 
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area in the medial superficial dorsal horn occupied by GDNF-IR fibres, on the control side of 
experimental animals and either side of control animals, showed that they were not significantly 
different (p>0.15; Table 1). This allowed for a comparison between the control side and the 
axotomized side. The mean pixel number of the axotomized side showed a 44% decrease relative 
to the control side at 5 days after axotomy and between 82% and 91% at 10,  25, 40 or 100 days 
(Table 1). At all survival times the relative decrease in the experimental animals was significantly 
different from the relative difference between right and left in control animals (Table 1).
At 100 days after axotomy some GDNF-IR fibres reappeared in the medial superficial dorsal 
horn (Fig. 1g-h). Although these fibres were sparse, they were consistently present in all three 
animals that survived 100 days after axotomy.
GDNF-IR fibres were never observed in the dorsal column nuclei of the caudal medulla 
oblongata in the control animal nor in the three animals that survived 10, 40 or 100 days after 
axotomy.
DISCUSSION
Sciatic nerve axotomy resulted in a dramatic decrease in GDNF-IR in the medial superficial 
dorsal horn of the L5 segment on the axotomized side. Quantification of the immunoreactive 
area showed a rapid decrease of  > 80% relative to the control side at 10 days, after which the 
decrease remained stable at this low level for at least 100 days.
The image analysis method employed in the present study represents an objective means 
for  quantification of immunoreactive areas.12 However, since the GDNF-IR area is susceptible to 
variations in the immunocytochemical procedure we used the control or right side as an internal 
control. This was justified, because there was no statistically significant difference in the analysed 
GDNF-IR area between the control side of the experimental animals and either side of the control 
animals. We therefore conclude that the reduction in the GDNF-IR area represents a decrease 
in GDNF protein, although the exact amount of this decrease cannot be determined with this 
technique.
Following peripheral axotomy, there is a rapid change in the expression of a number of 
substances within primary afferents that have a similar distribution as GDNF in the superficial 
dorsal horn. These changes include down-regulation of SubP and CGRP and up-regulation of GAL 
and VIP.9,10 In contrast, BDNF immunoreactivity, which is also present in primary afferents of the 
superficial dorsal horn, is not clearly affected following peripheral axotomy (Holstege & Kennis, 
unpublished observations) and may even be upregulated or de novo expressed in myelinated 
primary afferents.11 Thus, the rapid downregulation of GDNF after axotomy may represent a 
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similar phenomenon as observed for SubP and CGRP but is unlike that of GAL, VIP and BDNF, 
the only other neurotrophic factor now known to be present in primary afferent fibers.
We cannot rule out that the decrease of GDNF is secondary to a degenerative process rather 
than the result of down-regulation. Two recent studies13,14 have shown selective degeneration 
of unmyelinated fibers, 4-8 months after sciatic nerve lesion. The rapid decline in GDNF-IR (> 
80% at 10 days after axotomy), makes it unlikely that this decrease is secondary to degeneration 
of unmyelinated fibers. Peripheral axotomy also results in a series of progressing morphological 
changes of primary afferent terminals in the superficial dorsal horn, known as transganglionic 
degenerative atrophy (TDA).15 Signs of TDA occur as soon as six days following peripheral 
axotomy16 and therefore the decrease in GDNF-IR can also be explained as secondary to TDA. 
However, in that case all other substances within primary afferent fibers of the superficial dorsal 
horn would also be expected to decrease rapidly. In contrast, VIP, GAL and BDNF are upregulated 
or unaffected in the superficial dorsal horn after peripheral axotomy. We therefore conclude that 
the down-regulation of GDNF is an active process, induced by peripheral axotomy and is not 
secondary to primary afferent degeneration.
The GDNF-IR fibers that reappeared in the axotomized superficial dorsal horn at 100 days after 
axotomy may represent myelinated fibers expressing GDNF. This would fit with observations that 
peripheral nerve injury causes sprouting of myelinated afferents into the superficial dorsal horn,17 
some of which were reported to express BDNF.11 However, the GDNF-IR processes could never 
be traced into laminae III and IV of the dorsal horn. Moreover, the gracile nuclei, which receive 
direct myelinated fibre input from lumbar dorsal ganglia, never showed any GDNF-IR neither in 
control nor in axotomized rats, including the one rat that survived 100 days after axotomy. It is 
therefore unlikely that the GDNF-IR fibers observed after 100 days survival represent myelinated 
fibers showing de novo expression of GDNF.
Studies on the functional role of GDNF in the sensory system (see Snider and McMahon18 
for a review) suggest that peripherally produced and retrogradely transported GDNF supports a 
subpopulation of nociceptors that are characterized by expressing GDNF receptor components 
and by their central projection to lamina II-inner.19 Evidence for this trophic role of GDNF has been 
obtained from experiments19 showing that intrathecal application of GDNF reversed the down-
regulation of several substances in these GDNF-dependent nociceptors and prevented sprouting of 
myelinated fibers into the superficial dorsal horn. Our previous findings7 have shown that a source 
of GDNF is actually present within primary afferents in lamina I and II-outer, which may provide 
the trophic supply for GDNF-dependent primary afferent nociceptors terminating in lamina II-inner. 
If this spinal source of GDNF is depleted after axotomy, as shown here, the lack of GDNF might 
induce the changes described above. It would also explain that intrathecally applied GDNF is able 
to counteract these changes, namely by substituting for the axotomy induced depletion of GDNF 
from lamina I and II-outer. If this hypothesis holds true, it would imply that GDNF, produced in 
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GDNF-independent DRG neurons, is anterogradely transported to the superficial dorsal horn to act 
as a trophic factor for GDNF-dependent DRG neurons.
Apart from its potential neurotrophic effects, GDNF may exert rapid effects on nociceptive 
transmission in the spinal cord, thus acting as a neuromodulator, as has been suggested for 
BDNF.20 Support for this hypothesis is provided by preliminary data, 21 indicating that GDNF 
is at least partly present in dense cored vesicles in primary afferent terminals of the superficial 
dorsal horn, suggesting activity dependent release and that intrathecally applied GDNF rapidly 
increases c-Fos expression in the superficial dorsal horn, suggesting a rapid excitatory effect on 
spinal neurons. This is in line with the finding22 that RET and GFRα-1, the receptor components 
necessary for GDNF signalling, are present in dorsal horn neurons, although this was not confirmed 
in another report.23
CONCLUSION
The dramatic decrease of GDNF-IR in the superficial dorsal horn after sciatic nerve section is 
most likely the result of active down-regulation of GDNF within primary afferents in response to 
peripheral axotomy. This behaviour resembles that of CGRP and SubP, which are both involved in 
nociceptive transmission, but is in contrast to that of GAL, VIP and BDNF, which are up-regulated 
or remain unchanged after axotomy. In order to clarify the functional meaning of the down-
regulation of GDNF after axotomy, further study of its role in nociception, as a trophic factor and 
as a neuromodulator, is needed.
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FIGURES
Fig. 1. Light micrographs of sections from the rat L5 segment, after processing for GDNF 
immunocytochemistry.
(a) Sections from a control animal, showing strong GDNF-IR in the superficial dorsal horn (lamina 
I and II-outer) and a few labeled fibers in the deeper layers (lamina II-inner, III, IV, V and X) on 
both sides. The box indicates the area of magnification shown in (b).
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(b) Magnification of (a), showing that GDNF-IR is mainly present in the superficial dorsal horn. I 
is lamina I, IIo is the outer part of lamina II, IIi is the inner part of lamina II.
(c-g) Progressing decrease of GDNF-IR in the medial dorsal horn on the left (axotomized) side, 
while immunoreactivity on the lateral part and on the contralateral side remains intact. The box 
in (g) indicates the area of magnification shown in (h).
(h)  Magnification of the axotomized dorsal horn 100 days after axotomy, showing three labeled 
fibers in the medial superficial dorsal horn
Table
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ABSTRACT
Glial cell line-derived neurotrophic factor (GDNF) and brain-derived neurotrophic factor (BDNF) 
are potent trophic factors for dorsal root ganglion cells. In addition, these factors are produced 
in subsets of dorsal root ganglion cells and transported anterogradely to their terminals in the 
superficial dorsal horn of the spinal cord, where they constitute the only source of GDNF and 
BDNF. We investigated the effect of 10 µg GDNF and BDNF injected by lumbar puncture, on the 
expression of the immediate early gene (IEG) products c-Fos, c-Jun and Krox-24 in the adult rat 
dorsal horn. In the dorsal horn of S1 spinal segments, GDNF and BDNF induced a strong increase 
in IEG expression, which was most pronounced in laminae I and II (2.9-4.5 fold). More distal from 
the injection site, in the dorsal horn of L1/L2 spinal segments, the increase in IEG expression was 
less pronounced, suggesting a concentration-dependent effect. In order to explain the effects of 
intrathecally injected GDNF, we investigated whether lumbo-sacral dorsal horn neurons expressed 
RET protein, the signal-transducing element of the receptor complex for GDNF. It was found that 
several of these neurons contained RET immunoreactivity and that some of the RET-labeled 
neurons had the appearance of nociceptive specific cells, confirming their presumed role in pain 
transmission. Additionally, using double-labeling immunofluorescence combined with confocal 
microscopy, it was found that after intrathecal GDNF injection 35% of c-Fos-labeled cells were 
also labeled for RET. These results demonstrate that intrathecally administered GDNF and BDNF 
induce IEG expression in dorsal horn neurons in the adult rat, supposedly by way of their cognate 
receptors, which are present on these neurons. We further suggest that the endogenous release of 
GDNF and BDNF, triggered by nociceptive stimuli, is involved in the induction of changes in spinal 
nociceptive transmission as in various pain states.
Key words: brain-derived neurotrophic factor, c-Fos, c-Jun, GDNF family receptor α1, glial cell 
line-derived neurotrophic factor, Krox-24, pain, neurturin, RET, tyrosine kinaseB
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INTRODUCTION
Neurotrophic factors are traditionally considered to play a critical role in neuronal survival and 
differentiation during development and, during adulthood, in the maintenance of neuronal 
connections and regeneration of damaged neurons (Barde, 1989; Lewin and Barde, 1996). For 
these purposes, neurotrophic factors are taken up by neurons in their target area through high-
affinity receptors and retrogradely transported to their cell bodies. However, more recent findings 
showed that brain-derived neurotrophic factor (BDNF) and neurotrophin-3 (NT-3), which are 
both members of the neurotrophin family, are produced within neurons and transported in an 
anterograde rather than in a retrograde direction (for reviews see Altar and DiStefano, 1998; 
Conner et al., 1998; von Bartheld et al., 2001). Evidence for anterograde transport of BDNF was 
first obtained in central and peripheral projections of dorsal root ganglion (DRG) neurons (Zhou 
and Rush, 1996) and subsequently in the central nervous system (Altar et al., 1997). Glial cell 
line-derived neurotrophic factor (GDNF), a member of the GDNF family of proteins and unrelated 
to the neurotrophins (Lin et al., 1993; Airaksinen and Saarma, 2002), is also transported in an 
anterograde direction within primary afferent fibers (Holstege et al., 1998; Ohta et al., 2001; Rind 
and von Bartheld, 2002). Ultrastructural data suggest that anterogradely transported BDNF and 
GDNF are stored in dense-cored vesicles in primary afferent terminals in lamina I and II-outer of 
the dorsal horn (Michael et al., 1997; Holstege et al., 1999; Ohta et al., 2001). Since this region 
of the dorsal horn receives mainly nociceptive afferent input, it seems likely that both BDNF and 
GDNF are involved in the processing of nociceptive information in the spinal dorsal horn. Indeed, 
BDNF has been shown to modulate pain transmission in the spinal cord, especially by inducing 
hypersensitivity in pathological pain states (Kerr et al., 1999; Mannion et al., 1999). This effect 
is likely mediated by the receptor for BDNF, tyrosine kinase B (TrkB), which is expressed on spinal 
dorsal horn neurons (Yan et al., 1997a; Mannion et al., 1999; Garraway et al., 2003). These 
findings, together with data that BDNF can directly excite cells through TrkB receptors (Kafitz 
et al., 1999), strongly suggest that BDNF acts as a neuromodulator in spinal pain transmission 
(Pezet et al., 2002). 
With regard to GDNF, previous studies (Bennett et al., 1998; Boucher et al., 2000; Ramer et 
al., 2000; Paveliev et al., 2004) have shown that it exerts various trophic and regenerative effects 
on adult primary afferent neurons. GDNF acts on neurons that express the receptor components 
for GDNF signaling: the signal transducing element RET and a ligand binding domain, known as 
GDNF family receptor α1 (GFRα1) (Airaksinen and Saarma, 2002; Tsui-Pierchala et al., 2002). 
Recently it was shown that the neural cell adhesion molecule NCAM can also function as a 
signaling receptor for GDNF (Paratcha et al., 2003). In addition to the long-term effects described 
in the peripheral nervous system and spinal cord, there are reports showing acute effects of GDNF 
on synaptic transmission in other parts of the central nervous system (Ribchester et al., 1998; 
Yang et al., 2001; Wang et al., 2003). Evidence for acute effects of GDNF combined with the 
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anterograde transport of GDNF to the superficial dorsal horn and its localization in dense-cored 
vesicles suggests that GDNF, like BDNF, acts as a neuromodulator in spinal pain transmission.
The main goal of the present paper was to determine whether intrathecal injection of GDNF 
and BDNF induces a rapid activation of dorsal horn neurons, as indicated by increased expression 
of the immediate early gene (IEG) products c-Fos, c-Jun and Krox-24 (Hunt et al., 1987). We also 
studied IEG expression after intrathecal injection of neurturin (NRTN), another neurotrophic factor 
of the GDNF family, although the evidence that NRTN is involved in pain transmission is limited 
(Vellani et al., 2004). In order to explain increased IEG expression after intrathecal injection of a 
neurotrophic factor, the presence of its cognate receptor is critically important. Since the presence 
of RET mRNA has not been unequivocally demonstrated in adult rat dorsal horn neurons, we 
additionally studied RET protein expression in the rat spinal cord using immunohistochemistry 
(IHC). Finally, we studied c-Fos and RET double-labeling after intrathecal GDNF injections, using 
immunofluorescence (IF) combined with confocal microscopy. Increased expression of IEGs after 
intrathecal GDNF and BDNF injection, combined with our previous observation that these trophic 
factors are present in dense-cored vesicles in primary afferent terminals in the dorsal horn, would 
strengthen the idea that GDNF and BDNF act as modulators of spinal pain transmission.
MATERIALS AND METHODS
Intrathecal injections and perfusion
24 Adult male Wistar rats were successfully injected and processed in five separate sessions. 
The first two sessions each consisted of one animal injected with vehicle, one with GDNF, one 
with BDNF and one with N-methyl-d-aspartate (NMDA). Session three and four each consisted 
of 5 animals, by including one animal with neurturin (NRTN). The last session consisted of two 
animals injected with vehicle, two with NRTN and two with GDNF. The injection procedure was as 
follows: rats were anaesthetized with 2% halothane in O2/N2O (30/70%) and shaved at the lower 
back. A lumbar puncture was performed (Sandkühler et al., 1996) between the L4-L5 or L5-L6 
vertebrae, using a 30-gauge needle through which 40 µl of vehicle  alone (1% bovine serum 
albumin in 0.025M phosphate buffer), mixed with 3 µl 10% Alcian Blue (an inert dye), or vehicle 
and Alcian Blue also containing 10 µg human recombinant NRTN (PeproTech Inc., Rocky Hill, 
NJ), 10 µg rat recombinant GDNF (R&D systems, Minneapolis, MN), 10 µg human recombinant 
BDNF (kindly donated by Regeneron, Tarrytown, NY) or 25 nmol NMDA (Sigma, St. Louis, MO). 
Alcian Blue was added to the injection fluid, in order to determine after dissection whether the 
injection fluid had actually been delivered intrathecally. Immediately after injection the animals 
were replaced in their cages. After 90 minutes they received an overdose of sodium pentobarbital 
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and were perfused transcardially with 250 ml of 0.025 M phosphate buffered saline (PBS) 
containing 0.8% sucrose and 0.4% D-glucose, followed by 750 ml of 4% paraformaldehyde in 
0.05 M phosphate buffer (PB) (200C), the last 375 ml of fixation fluid containing 15% sucrose 
for cryoprotection. The spinal cord was exposed and inspected for spread of the injection fluid 
(i.e. the Alcian Blue). Animals with extradural injection, lesioned spinal roots or a lesioned conus 
medullaris were discarded. Then, the lumbo-sacral spinal cords of the successfully injected 
animals were dissected. All experiments had been approved by the Rotterdam Animal Ethics 
Committee.
Immunohistochemistry
For IEG immunohistochemistry, all spinal cords from one session were processed simultaneously 
as follows: they were postfixed for two hours at 200C in the fixation fluid containing 15% sucrose, 
transferred to 30% sucrose in 0.05M PB and left overnight at 40C. Sections (40 µm) were cut 
on a freezing microtome and collected for IHC. They were preincubated (1h at 200C) with 10% 
normal goat serum (NGS) and 0.3% Triton X-100 in 0.05M PBS, followed by incubation (60 
h at 40C) with the primary antibodies, 1% NGS and 0.1% Triton in PBS. Primary antibodies 
were rabbit anti-c-Fos (1:40,000; Oncogene Research Products, La Jolla, CA), rabbit anti-c-Jun/
AP-1 (1:20,000; Oncogene) and rabbit anti-Egr-1/Krox-24 (1:10,000; SantaCruz Biotechnology, 
SantaCruz, CA). Subsequently, sections were rinsed and incubated (1.5h at 200C) with biotinylated 
goat-anti-rabbit (1:200; Vector Laboratories Inc., Burlingame, CA), 1% NGS and 0.1% Triton 
in PBS. Finally, they were rinsed and placed in ABC reagent (avidin/biotin/peroxidase, Vector) 
containing 0.3% Triton (1.5h at 200C), rinsed again with 0.05M PB and reacted with 0.05% 
3'-3 diaminobenzidine tetrahydrochloride and 0.005% H2O2 dissolved in PB. Sections from each 
animal and each antibody were randomly mounted on a slide and coverslipped, using Permount 
(Fisher, Hampton, NH) as mounting medium.
BDNF immunohistochemistry was performed on 2 rats that had undergone intrathecal injection 
with 4 and 0.7 µg BDNF respectively. The BDNF antibody used here is a polyclonal antibody 
produced in rabbits and raised against E. coli-derived recombinant human BDNF (1:1500; kindly 
donated by Dr. Q. Yan, Amgen Inc., Thousand Oaks, CA). For specificity of the antibody see (Yan 
et al., 1997b). Perfusion and IHC were performed according to (Holstege et al., 1997), but 
without tyramide signal amplification. 
RET immunohistochemistry was performed on 6 naive rats. The RET antibody used here is 
a biotinylated polyclonal antibody produced in goats and raised against recombinant mouse RET 
extracellular domain (1:100; R&D systems, Minneapolis, MN). The antibody was tested with 
the two isoforms that exist and was found to identify both isoforms, in line with the fact that the 
antibody is directed against the common extracellular domain of RET (de Graaff et al., 2001). The 
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same perfusion protocol as for IEG IHC was used, except that 0.25% glutaraldehyde was added 
to the fixation fluid and sections were postfixed for 2 hours at 200C and overnight at 40C. The 
same immunohistochemical protocol as for IEG IHC was used except that sections were heated in 
25mM sodium citrate for 30 minutes at 800C (Jiao et al., 1999) prior to incubation with normal 
serum, and 0.1M Tris buffered saline was used instead of PBS. Controls included omitting the 
primary RET antibody and preabsorbing with the synthetic protein the antibody was raised against 
(R&D systems).
For c-Fos and RET double-labeling immunofluorescence, the same perfusion and 
immunohistochemical protocol as for IEG IHC was used, c-Fos and RET antibody were diluted 
1:5000 and 1:40 respectively. Cy3-conjugated donkey anti-goat and FITC-conjugated donkey 
anti-rabbit were used as secondary antibodies (1:200, 1.5h at 200C; Jackson ImmunoResearch, 
West Grove, PA). Vectashield (Vector) was used as mounting medium.
Sections processed for BDNF, IEG and RET IHC were photographed using a Leica DC 300 
digital camera on a Leica DMRB light microscope. Sections processed for c-Fos and RET double-
labeling IF were photographed using a Zeiss LSM 510 confocal laser scanning microscope. Figures 
were composed using Adobe Photoshop 7 (Adobe Systems Inc., San Jose, CA). Adjustments were 
made only to brightness/contrast and sharpness.
Collection and analysis of data from the intrathecal injection experiment
For cell counts and analysis of IEG immunohistochemistry, the slides were blinded and analyzed 
with a camera lucida microscope (Neurolucida, MicroBrightfield Inc., Williston, VT). For each 
animal and each antibody (anti-c-Fos, -c-Jun, -Krox-24), the first four S1-sections encountered on 
a slide were selected. For animals injected in session one to four, also the first four L1/L2-sections 
encountered on a slide were selected. The S1-segment was defined primarily by the size and 
shape of the dorsal horn and dorsal columns and on this basis distinguished from the S2-segment. 
Sections containing the dorsomedial or dorsolateral motor nuclei (Holstege et al., 1996) were 
considered belonging to the L6-segment and discarded from analysis. The L1/L2-segment was 
defined by the size and shape of the ventral horn and on this basis distinguished from T13 and 
L3-segments (Molander et al., 1984). The outline of the dorsal horns and boundaries between 
laminae were identified bilaterally (Molander et al., 1984) and lines were drawn accordingly, using 
a camera lucida microscope. IEG-immunoreactive (-ir) nuclei were plotted in these drawings. 
Cells were counted separately in laminae I and II, in laminae III and IV and in lamina V. After all 
sections had been counted, the slides were deblinded and results were quantitatively assessed. 
Mean cell counts of four sections per animal were considered as one observation. Data were 
presented as means ± SEM of relative increase of IEG-ir cells, using the following formula: relative 
increase of cells = xi / xv, where xi is the absolute number of cells after injection of vehicle, NRTN, 
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GDNF, BDNF or NMDA and xv is the mean number of cells after vehicle injection. The results 
of vehicle (n=6 at S1, n=4 at L1/L2), NRTN (n=4 at S1, not determined at L1/L2), GDNF 
(n=6 at S1, n=4 at L1/L2), BDNF (n=4 at S1 and L1/L2) and NMDA (n=4 at S1 and L1/L2) 
treated animals were compared using the unpaired t-test in laminae I and II (where cell counts 
were normally distributed) or Mann-Whitney’s rank-sum test in laminae III and IV and lamina V 
(where cell counts were non-normally distributed), for each antibody separately (Stata 7.0; Stata 
Corporation, College Station, TX).
To analyze the degree of c-Fos and RET double-labeling, we used double-labeling IF combined 
with confocal microscopy on S1 sections adjacent to the sections used for immunoperoxidase 
labeling of IEGs, from three animals that had received intrathecal injections of 10 µg GDNF. The 
lateral half of lamina I and II from those sections, where the large majority of c-Fos-labeled cells 
was present, was systematically scanned for c-Fos-ir cells, RET-ir neurons and double-labeled 
neurons, using a Zeiss LSM 510 confocal laser scanning microscope and a 20x objective. The 
percentages of double-labeled neurons as a proportion of total number of c-Fos-ir cells and RET-ir 
neurons were expressed as means ± SEM, using Stata 8.0.
RESULTS
Expression and quantification of IEGs in the spinal dorsal horn after 
intrathecal injections of neurotrophic factors
After perfusion of the intrathecally-injected rats, the successful injections were identified by 
the staining due to the Alcian Blue in the injection fluid. Blue staining was present around the 
lumbo-sacral roots and the caudal part of the spinal cord. More rostrally, the blue staining slowly 
faded but always reached low thoracic segments, indicating that the injected fluid had diffused 
intrathecally alongside at least the entire lumbo-sacral cord (see also Sandkühler et al., 1996 
and Kusmirek et al., 1997). In a separate experiment we used BDNF IHC to study diffusion 
of intrathecally injected BDNF. Exogenous BDNF was detectable from S2 up to T10 as a rim 
of immunoreactive product around the entire spinal cord including the dorsal horn, where also 
endogenous BDNF immunoreactivity was present in the superficial layers (see also Zhou and Rush, 
1996). Density and thickness of exogenous BDNF immunoreactivity gradually decreased in a 
caudo-rostral direction and was dependent on the amount of intrathecally injected BDNF (Fig.1).
Light microscopical examination of the sections processed for c-Fos, c-Jun or Krox-24 IHC 
showed almost exclusively nuclear staining, which could be easily identified (Fig. 2). After 
intrathecal injection of vehicle, a few c-Fos-ir and c-Jun-ir cells were scattered throughout the 
dorsal horn, both in S1-sections and in L1/L2-sections. Krox-24-ir cells after vehicle injection 
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were observed mainly in lamina III and IV (see also Herdegen et al., 1991). After NRTN injection, 
the distribution of c-Fos, c-Jun and Krox-24-ir cells at the S1 spinal level was similar as observed 
after vehicle injection and the number of IEG-ir cells after NRTN injection was not significantly 
different from that after vehicle injection (p>0.05; Fig. 3, Table).
After intrathecal GDNF injection, c-Fos, c-Jun and Krox-24 expression in laminae I and II at the 
S1 spinal level was significantly increased compared to both vehicle and NRTN (p≤0.01). At the 
L1/L2 spinal level, c-Fos and c-Jun expression (p≤0.05), but not Krox-24 expression (p=0.07), 
was significantly increased compared to vehicle in laminae I and II. The relative increase at S1 
(2.9-4.5 fold) was greater than at L1/L2 (2.3-2.4 fold). In laminae III and IV and in lamina V c-
Jun expression was never increased, while c-Fos expression was significantly increased in laminae 
III and IV at S1 and at L1/L2 and Krox-24 expression was significantly increased in laminae III 
and IV and in lamina V at S1 (p≤0.05, all compared to vehicle). 
After intrathecal BDNF injection, IEG expression was significantly increased in laminae I and II 
at S1 (p≤0.05 compared to vehicle and NRTN), while at L1/L2 the increase was not statistically 
significant. In laminae III and IV and in lamina V, there was no statistically significant increase.
IEG expression in laminae I and II after GDNF and BDNF injection was not statistically different 
from IEG expression after injection of NMDA, both at S1 and at L1/L2 (p>0.05).
Description of immunohistochemical expression of RET in the dorsal horn of 
naïve rats
Light microscopical examination of S1 sections from naïve rats processed for RET IHC showed 
a dense band of presumed terminal labeling in lamina II-inner. In the ventral horn labeling of 
motoneurons was observed. In addition, several strongly RET-ir neurons (Fig. 4) and a significant 
number of weakly labeled neurons were observed scattered in lamina I and II, as well as in the 
deeper layers of the dorsal horn. In neuronal somata RET labeling was prominent in the cytoplasm 
and sometimes extended into the primary dendrites. Typically most sections showed a few RET-ir 
cells in lamina I, which appeared as fusiform neurons, possibly representing nociceptive specific 
neurons (Lima and Coimbra, 1983; Han et al., 1998). Immunoreactivity was absent in sections 
in which the primary antibody was omitted or preincubated with the synthetic protein the antibody 
was raised against.
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Expression and quantification of c-Fos and RET double-labeling
The general labeling pattern of c-Fos and RET obtained with IF and confocal microscopical imaging, 
was the same as described for light microscopy. Double-labeled neurons were characterized by 
nuclear labeling for c-Fos with sparing of the nucleolus, surrounded by cytoplasmatic labeling 
for RET which sometimes extended into the primary dendrites (Fig. 5). A total number of 251 
immunoreactive cells were counted in the lateral superficial dorsal horn of S1 sections from three 
GDNF injected animals. It was found that 35 ± 2% (mean ± SEM) of c-Fos-labeled cells were 
also labeled for RET and 40 ± 4% (mean ± SEM) of RET-labeled neurons were also labeled for 
c-Fos.
DISCUSSION
IEG induction by intrathecal administration of GDNF and BDNF
We have shown here that intrathecal injection of GDNF or BDNF through lumbar puncture induces 
a strong increase in the number of neurons expressing c-Fos, c-Jun and Krox-24 in the dorsal 
horn of the adult rat S1 spinal segment. The increase in IEG expression is most pronounced in 
the superficial dorsal horn, i.e. lamina I and II, and of the same magnitude as the increase after 
intrathecal NMDA injection. Intrathecal injection through lumbar puncture is a minimally invasive 
technique, which has no confounding effects on spinal nociception and does not induce c-Fos 
expression in the spinal dorsal horn (Sandkühler et al., 1996). Accordingly, we found that only a 
few cells express IEGs after vehicle injection, as in untreated rats. Furthermore, after injection of 
NRTN, a member of the GDNF family (Kotzbauer et al., 1996; Airaksinen and Saarma, 2002), 
the number of cells expressing IEGs remained low as in vehicle treated rats. Based on the above it 
is concluded that the increase in IEG expression that we observed after GDNF and BDNF injection 
is the direct result of the presence of these substances in the injection fluid.
The finding that NRTN, in contrast to GDNF and BDNF, did not induce IEG expression, may 
be regarded as somewhat surprising, given that the receptor components for NRTN, i.e. GFRα2 
(Widenfalk et al., 2001) and RET, are present in the adult rat dorsal horn. To our knowledge 
there is only one other paper studying the in vivo effects of NRTN on nociceptive transmission 
(Hoane et al., 1999). In this paper an allodynic effect of intraventricularly administered GDNF is 
described, while no such effect was detectable for NRTN. Since the recombinant NRTN protein 
that we used has been shown to be biologically active (e.g. Coulpier et al., 2002 and Holm et al., 
2002), one may speculate that NRTN does not penetrate as deeply as GDNF into nervous tissue, 
as also suggested by others (Hoane et al., 1999; Rosenblad et al., 1999). Alternatively, the effect 
of NRTN on dorsal horn neurons may not include activation of intracellular pathways that lead to 
increased expression of the IEGs that we have investigated.
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We found that the IEG changes in the L1/L2 segments are less pronounced than in the S1 
segment. This is likely a concentration-dependent effect, since the spread of intrathecally injected 
substances is generally limited (Sandkühler et al., 1996; Kusmirek et al., 1997), leading to a 
rapid decrease in concentration at relatively limited distances from the injection site. Accordingly, 
the intensity of Alcian Blue staining of the spinal cord was weaker at high lumbar levels, i.e. further 
away from the injection site, than at high sacral levels. In line with these findings immunoreactivity 
of intrathecally administered BDNF decreased from S2 to T10. Furthermore a lower dose of BDNF 
caused an overall weaker immunohistochemical staining. It seems likely that the same effects 
hold true for the other substances that we administered. Thus, the lower level of IEG expression 
at high lumbar as compared to high sacral levels probably reflects a lower concentration of the 
injected substances at these high lumbar levels.
Expression of RET in spinal dorsal horn neurons
 The distribution of RET-immunoreactivity in the spinal cord is in agreement with previous reports 
showing localization in primary afferent terminals in lamina II-inner and in motoneurons in the 
spinal cord (Bennett et al., 1998; Duberley et al., 1998). We also observed several strongly RET-
ir neurons in both the superficial and deep layers of the dorsal horn. Additionally, a substantial 
number of weakly RET-ir neurons was observed. This may be due to low expression levels of RET 
in these neurons, which makes it difficult to detect them by IHC and which may also explain why 
RET mRNA has so far not been unequivocally demonstrated in the adult rat dorsal horn (Glazner 
et al., 1998; Widenfalk et al., 2001). The presence of RET protein in dorsal horn neurons, shown 
here for the first time, is a prerequisite to explain the induction of the IEGs after intrathecal 
administration of GDNF. At the subcellular level it was observed that RET immunoreactivity in 
dorsal horn neurons was preferentially localized in the cytoplasm, which is in line with descriptions 
of neuronal RET-immunoreactivity elsewhere in the nervous system (Arce et al., 1998; Bennett 
et al., 1998; Walker et al., 1998). 
How do GDNF and BDNF act on dorsal horn neurons?
Several studies have shown direct facilitatory effects of locally administered BDNF on spinal 
pain transmission (Kerr et al., 1999; Mannion et al., 1999). These effects are considered to 
be mediated by TrkB receptors, which are expressed on spinal dorsal horn neurons (Yan et al., 
1997a; Mannion et al., 1999). In a recent study using spinal cord slices, a direct action of BDNF 
on substantia gelatinosa cells was identified leading to prolonged facilitation of dorsal horn neurons 
(Garraway et al., 2003). Although some primary afferents that terminate in the spinal dorsal horn 
express TrkB, it is unlikely that these presynaptic receptors are involved in the effects of BDNF on 
nociception, since these fibers are non-nociceptive in nature and terminate preferentially in the 
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deep dorsal horn (Michael et al., 1997; Carroll et al., 1998). Therefore the effect of BDNF on 
spinal pain transmission is likely mediated by postsynaptic TrkB receptors on dorsal horn neurons, 
as observed elsewhere in the brain (Kovalchuk et al., 2002; Manabe, 2002). 
GDNF preferentially acts through GFRα1 receptors, using RET as the signal-transducing 
element. Both GFRα1 and RET are expressed in primary afferent neurons (Bennett et al., 1998) 
and we now show that RET, in addition to GFRα1 (Glazner et al., 1998; Matsuo et al., 2000; 
Widenfalk et al., 2001), is also expressed in adult rat dorsal horn neurons. It seems unlikely 
that GDNF induces IEG expression by acting presynaptically on primary afferent fibers, since the 
distribution of IEG-ir neurons after GDNF injection does not match the known distribution of RET-
ir primary afferent terminals, which are present primarily in lamina II-inner of the dorsal horn. 
Since several strongly RET-ir neurons and a significant number of weakly labeled neurons were 
identified in both the superficial and deep dorsal horn and since 35% of c-Fos-labeled cells were 
also labeled for RET in the superficial dorsal horn, we suggest that intrathecally injected GDNF 
induces IEG expression in the dorsal horn at least partly through RET receptors on dorsal horn 
neurons. The observation that not all c-Fos-labeled cells were also RET-labeled may be due to 
limitations of immunohistochemical detection of RET, or may indicate that other receptors, like 
NCAM, are involved in GDNF signaling in the spinal dorsal horn. NCAM is diffusely expressed in 
both the adult chick and mouse spinal gray matter (Daniloff et al., 1986; Brook et al., 2000) and 
its polysialylated form (PSA-NCAM) is expressed mainly in fibers but also occasionally in neurons 
of the adult rat superficial dorsal horn (Bonfanti et al., 1992; Seki and Arai, 1993; Bonfanti et 
al., 1996). Although the possibility that GDNF participates in the regulation of synaptic plasticity 
through activation of NCAM has been suggested to occur in the brain (Paratcha et al., 2003), 
there is presently no evidence for such interactions in the spinal cord.
Taken together, the above findings suggest that both GDNF and BDNF induce IEG expression 
in dorsal horn neurons at least partly through direct activation of their postsynaptic tyrosine kinase 
receptors.
GDNF and BDNF as modulators of spinal pain transmission
c-Fos, c-Jun and Krox-24 expression in dorsal horn neurons increases after noxious, but not 
after non-noxious stimulation (Hunt et al., 1987; Herdegen et al., 1991). Especially after GDNF 
administration, we found increased expression of c-Fos and Krox-24 in the superficial and deep 
dorsal horn, while the increase in c-Jun expression was restricted to the superficial dorsal horn, 
a similar distribution as seen after electrical stimulation of nociceptive fibers (Herdegen et al., 
1991). These findings suggest that IEG upregulation after intrathecal injection of GDNF and BDNF 
preferentially occurs in neurons that receive input from nociceptive primary afferents. Accordingly, 
some of the RET-ir neurons in the superficial dorsal horn had the typical appearance of fusiform 
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neurons which, based on their morphology, are known to be nociceptive specific (Han et al., 
1998), indicating that RET expressing cells in the superficial dorsal horn are indeed involved in 
nociceptive transmission. 
The region where the strongest IEG upregulation was observed after intrathecal injection of 
GDNF and BDNF, i.e. the superficial dorsal horn, coincides with the area in which GDNF-ir and 
BDNF-ir primary afferent terminals are present. This leads to the hypothesis that a similar IEG 
upregulation as described here, may also occur following release of endogenous GDNF and BDNF 
from nociceptive primary afferent terminals, which constitute the only source of endogenous 
GDNF and BDNF in the dorsal horn (Zhou and Rush, 1996; Holstege et al., 1998). Unlike BDNF, 
GDNF mRNA has so far not been detected in DRG neurons, possibly because mRNA levels are 
too low to be detected by in situ hybridization (compare Stöver et al., 2001). GDNF protein 
levels in the somata of DRG neurons are also low (Bar et al., 1998; Holstege et al., 1998; Ohta 
et al., 2001). This may be due to low production or may indicate that GDNF protein is directly 
transported to the terminals in the dorsal horn, where it accumulates and is detected more easily. 
Alternatively, GDNF protein may be taken up in the periphery and transported transganglionically 
(Ohta et al., 2001; Rind and von Bartheld, 2002; von Bartheld, 2004).
Release of BDNF in the spinal cord from primary afferent fibers in response to nociceptive 
stimuli leads to increased postsynaptic excitability and behavioral effects suggesting that BDNF 
is involved in the induction of central sensitization (Pezet et al., 2002). C-Fos, and possibly 
other IEGs, are involved in downstream events following activation of TrkB by BDNF and their 
increase may thus reflect the central changes in nociception that develop after intrathecal BDNF 
injection (Herdegen and Leah, 1998; Kerr et al., 1999; Pezet et al., 2002). The present finding 
that intrathecal GDNF, like BDNF, induces an increase in IEG expression, may indicate that also 
GDNF released from nociceptive fibers in the spinal cord is directly involved in spinal nociceptive 
processing. Although this idea is supported by increasing evidence obtained in other neuronal 
systems that GDNF has acute effects on excitability (Ribchester et al., 1998; Yang et al., 2001; 
Wang et al., 2003), there are conflicting data about its role in nociceptive transmission. One 
report describes allodynia following intraventricular administration of 1.25 µg/h GDNF (Hoane 
et al., 1999), which findings are supported by data showing an anti-hyperalgesic effect of an 
intrathecally administered GDNF function-blocking antibody in complete Freund’s adjuvans induced 
inflammation (Fang et al., 2003). However, Boucher et al., 2000, who showed that intrathecal 
administration of 0.5 µg/h GDNF had potent analgesic effects in rat models of neuropathic pain, 
also described that the same dosage did not affect mechanical and thermal thresholds in normal 
animals. Although differences in GDNF concentration and type of administration could account 
for these seemingly contradictory observations, it remains difficult to relate the increase in IEG 
expression that we found to a specific change in pain behavior. Obviously detailed behavioral tests 
need to be carried out in conjunction with IEG IHC to learn more about the exact role of GDNF 
and IEGs in pain transmission.
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In this study we have shown that intrathecal injection of GDNF and BDNF induces a strong 
increase of three different IEGs in dorsal horn neurons, supposedly through their cognate receptors 
which are present on these neurons. Similarly, release of endogenous GDNF and BDNF, triggered by 
nociceptive input, may lead to increased IEG expression in dorsal horn neurons and subsequently 
to changes in spinal nociceptive transmission, like central sensitization, in the adult rat. Thus, 
in addition to their trophic effects on developing and regenerating neurons, we suggest that both 
GDNF and BDNF act as neuromodulators in the adult spinal dorsal horn. As a consequence GDNF 
and BDNF may be considered as multifunctional signaling proteins that are especially important 
in the nociceptive system. Modulation of the synthesis and release of these factors in various 
painful conditions may eventually prove an effective tool for alleviating pain.
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FIGURES
Fig.1. Light micrographs, showing rat spinal cord sections after intrathecal injection of BDNF, 
followed by processing for BDNF IHC. In S2 (A) and L5 (B) sections, exogenous BDNF- 
immunoreactivity can be seen overlapping with endogenous BDNF-immunoreactivity in the 
superficial dorsal horn. More rostral from the injection site, exogenous BDNF-immunoreactivity is 
decreased, but could still be immunohistochemically detected in T10 (C) sections. Injection of 0.7 
µg of BDNF resulted in weaker BDNF labeling in L5 sections (D) as compared to 4 µg of BDNF.
Fig. 2. (next page) Light micrographs, showing sections from the rat S1 segment after intrathecal 
injection with vehicle, NRTN, GDNF, BDNF or NMDA, followed by processing for c-Fos (A), 
c-Jun (B) or Krox-24 (C) IHC. Staining is almost exclusively nuclear, except for weak staining 
of fibers in the Krox-24 sections, giving these sections a darker appearance. After injection of 
vehicle and NRTN, a few scattered c-Fos-ir and c-Jun-ir cells are visible throughout the dorsal 
horn, while Krox-24 is mainly expressed in lamina III and IV (C1). After injection of GDNF, BDNF 
and NMDA, the increase in IEG expression compared to vehicle and NRTN is most pronounced 
in the superficial dorsal horn, while a smaller increase in c-Fos and Krox-24 can be observed in 
the deeper layers of the dorsal horn. C-Jun expression in the deep dorsal horn was not clearly 
increased after GDNF and BDNF injection. Lamina II-inner was almost devoid of IEG-ir cells after 
injection of GDNF and BDNF (A3, B3, C3).
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Fig. 3. (previous page) Quantification of IEG expression in the superficial dorsal horn at S1 and 
at L1/L2 after intrathecal injections. Values are means ± SEM of relative increase of c-Fos-ir 
(A), c-Jun-ir (B) and Krox-24 (C)-ir cells in the superficial dorsal horn, i.e. lamina I and II, after 
NRTN, GDNF, BDNF and NMDA injection. The values between brackets represent the means of 
the absolute numbers of cells after vehicle injection. Significance levels: *p≤0.05; **p≤0.01; 
***p≤0.001, versus vehicle, unpaired t-test.
Table. Quantification of IEG expression in the deep dorsal horn at S1 and at L1/L2 after intrathecal 
injections.
Values are means ± SEM of relative increase of c-Fos-ir, c-Jun-ir and Krox-24-ir cells in the 
deep dorsal horn, i.e. lamina III and IV and lamina V after NRTN, GDNF, BDNF and NMDA 
injection. The values between brackets represent the means of the absolute numbers of cells after 
vehicle injection. Significance levels: *p≤0.05; **p≤0.01; ***p≤0.001, versus vehicle, Mann-
Whitney’s rank-sum test.
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Fig. 4. Light micrographs, showing the dorsal horn of S1 sections from naïve rats processed for 
RET IHC. RET-immunoreactivity is localized in motoneurons (D1) and presumed terminals in 
lamina II-inner (A1, B1, C1, D1), but also in the cytoplasm and primary dendrites of neurons 
in the superficial (A1-3, B1-2, C1-2) and deep (C1, C3-5) dorsal horn. Some cells in lamina I 
appeared as fusiform neurons, possibly represening nociceptive specific neurons (B2, C2). Control 
sections in which the primary antibody was omitted (D2) or preincubted with the synthetic protein 
the antibody was raised aganst (D3) showed virtually no immunohistochemical staining.
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Fig. 5. Confocal IF images of the superficial dorsal horn of S1-sections from rats injected 
intrathecally with 10 µg GDNF (A, B). c-Fos is labeled with FITC (green; E, H) and RET is 
labeled with Cy3 (red; F, I). Superimposed images (C, G, and J) showing double-labeled neurons 
(arrowheads). The percentage of double-labeled neurons as a proportion of total number of c-
Fos-ir cells and RET-ir neurons in the lateral half of lamina I and II, where the large majority of 
c-Fos-labeled cells was present, is shown in D. Thickness of optical sections: 4.6 µm (A-G) and 
1 µm (H-J).
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ABSTRACT
RET (REarranged during Transfection) is a transmembrane tyrosine kinase signaling receptor for 
members of the glial cell line-derived neurotrophic factor (GDNF) family of ligands. We used RET 
immunohistochemistry (IHC), double labeling immunofluorescence (IF) and in situ hybridization 
(ISH) in adult naïve and nerve injured rats to study the distribution of RET in the spinal cord.
In the dorsal horn, strong RET-immunoreactive (-ir) fibers were abundant in lamina II-inner 
(IIi) and clusters of varicose fibers were found in the deeper layers, although this labeling was 
preferentially observed after an antigen unmasking procedure. Following dorsal rhizotomy, the 
fibers in lamina IIi and the varicose fibers completely disappeared from the dorsal horn, indicating 
that they were all primary afferents. Following peripheral axotomy, RET-ir in primary afferents 
decreased in lamina IIi and appeared to slightly increase in lamina III and IV. RET-ir was also 
observed in neurons and dendrites throughout the dorsal horn. Some RET-ir neurons in lamina I 
had the morphological appearance of nociceptive projection neurons, which was confirmed by the 
finding that 54% of RET-ir neurons in lamina I colocalized with neurokinin-1.
In the ventral horn, RET-immunoreactivity (-ir) was strongly expressed by motoneurons, with 
the strongest staining in small, presumably gamma-motoneurons, since they did not express 
cholinergic boutons and m2 muscarinic acetylcholine receptor-ir on their plasma membrane, in 
contrast to alpha-motoneurons. Increased RET expression following peripheral axotomy was most 
pronounced in alpha-motoneurons.
The expression and regulation pattern of RET in the spinal cord is in line with its involvement 
in regenerative processes following nerve injury. The presence of RET in dorsal horn neurons, 
including nociceptive projection neurons, suggests that RET also has a role in signal transduction 
at the spinal level. This role may include mediating the effects of GDNF released from nociceptive 
afferent fibers.
Indexing Terms: axotomy; dorsal horn; Glial cell-line derived neurotrophic factor; 
immunohistochemistry; in situ hybridization histochemistry; motoneurons; neurokinin-1; pain; 
rhizotomy; rat
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RET (REarranged during Transfection) is a proto-oncogene, originally identified by DNA 
rearrangement (Takahashi et al., 1985), encoding a tyrosine kinase receptor protein. After 
its initial discovery RET was found to play many, often diverse, roles. Mutations leading to a 
constitutively active form of RET are involved in producing human papillary thyroid carcinoma 
(Grieco et al., 1990) and multiple endocrine neoplasia (Hofstra et al., 1994; Mulligan et al., 
1993), while inactive RET leads to various developmental disturbances, including Hirschsprung's 
disease and renal dysgenesis (Schuchardt et al., 1994). In 1996 it was found that Glial cell 
line-Derived Neurotrophic Factor (GDNF) was the endogenous ligand for the RET tyrosine kinase 
receptor (Durbec et al., 1996; Trupp et al., 1996), and that a Glycosyl PhosphatidylInositol 
(GPI)-linked ligand binding subunit, now known as GDNF Family Receptor-α1 (GFRα1), was 
needed for activating RET tyrosine kinase by GDNF (Jing et al., 1996; Treanor et al., 1996). More 
recent findings have shown that other members of the GDNF family of neurotrophic factors, also 
known as GDNF-family ligands (GFLs), i.e. Neurturin (NRTN) (Kotzbauer et al., 1996), Artemin 
(ARTN) (Milbrandt et al., 1998) and Persephin (PSPN) (Baloh et al., 1998), also use RET as their 
signal transducing element, with GFRα2, GFRα3 and GFRα4 respectively as their preferential 
co-receptor (Airaksinen and Saarma, 2002).
Lipid rafts and localization of RET 
The last decade has shown accumulating evidence that parts of the neuronal cell surface are 
organized into lipid based microdomains, also known as lipid rafts: islands of highly ordered 
sphingolipids and cholesterol on the outer leaflet of the plasma membrane (Munro, 2003; Simons 
and Toomre, 2000; Tsui-Pierchala et al., 2002). RET in neurons can be localized inside or outside 
lipid rafts. When a GFL binds to its cognate GFRα, which is preferentially localized inside rafts, 
the complex will recruit RET to the raft, where the GFL-GFRα-RET complex is stabilized. These 
events, also known as in cis signaling, preferentially occur when RET and GFRα are produced by 
the same cell (Paratcha and Ibanez, 2002; Tansey et al., 2000; Yu et al., 1998). When GFRα 
originates from a source outside the cell arriving through the intracellular space, it will initially 
form a GFL-GFRα complex and bind RET in the membrane outside rafts (in trans signaling) and 
the complex may subsequently translocate to a raft (Paratcha and Ibanez, 2002; Paratcha et 
al., 2001). The distinction between in cis and in trans signaling is important, since signaling 
properties of RET in the lipid raft environment differ from those when RET is located outside lipid 
rafts (Paratcha and Ibanez, 2002).
The GFLs, their GFRα co-receptors and RET, have all been identified in the developing and 
adult peripheral and central nervous system, mostly by using ISH (Glazner et al., 1998; Golden 
et al., 1998; Golden et al., 1999; Nosrat et al., 1997). RET expressing structures include the 
sympathetic and parasympathetic ganglia (Enomoto et al., 2000; Nishino et al., 1999; Rossi 
et al., 2000), midbrain dopaminergic neurons (Trupp et al., 1997), dorsal root ganglion (DRG) 
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and trigeminal ganglion neurons (Bennett et al., 2000; Bennett et al., 1998; Golden et al., 
1999; Holstege et al., 1998; Molliver et al., 1997; Naveilhan et al., 1998; Orozco et al., 2001; 
Widenfalk et al., 1998) and the spinal cord, most notably motoneurons (see later). RET is generally 
expressed in two isoforms, RET9 and RET51 (Coulpier et al., 2002; de Graaff et al., 2001; Wong 
et al., 2005). In the present study, as in most studies, probes were used that did not distinguish 
between the two isoforms, and recognized both.
RET in DRG and spinal cord
In the DRG RET is expressed by both large and small diameter DRG neurons (Bennett et al., 
1998; Molliver et al., 1997). Small diameter DRG neurons only start to express RET postnatally, 
when these ganglion cells switch from expressing the Nerve Growth Factor (NGF) receptor TrkA to 
expressing RET (Molliver et al., 1997). These small size DRG neurons are further characterized by 
co localization of the plant lectin IB4 and one or more of the GFRαs (Bennett et al., 1998; Orozco 
et al., 2001). Although the exact functional role of the various RET expressing DRG neurons is not 
clear, large diameter RET-expressing DRG neurons have been associated with mechanosensitivity 
in the skin (Molliver et al., 1997; Snider and McMahon, 1998), while small diameter RET- and 
IB4-expressing DRG neurons have unmyelinated fibers and are involved in nociception (Boucher 
et al., 2000; Gardell et al., 2003; Stucky et al., 2002).
Several studies have identified RET protein or mRNA in the adult spinal cord in two specific 
neuronal structures: in motoneurons (Glazner et al., 1998; Golden et al., 1998; Golden et al., 
1999; Josephson et al., 2001; Leitner et al., 1999; Nosrat et al., 1997; Widenfalk et al., 
2001) and in fibers terminating in the inner part of lamina II (Bennett et al., 1998; Molliver et 
al., 1997), originating from DRG neurons as described above. In motoneurons, RET serves as 
part of the receptor complex involved in retrograde signaling as part of the survival, maintenance 
and regeneration machinery of the neuron (Boyd and Gordon, 2003; Henderson et al., 1994; 
Leitner et al., 1999; Li et al., 1995; Oppenheim et al., 1995; Vejsada et al., 1998; Yan et al., 
1995; Yuan et al., 2000; Zhao et al., 2004), which becomes activated by GFLs originating from 
muscle and Schwann cells. Early studies, which did not mention gamma motoneurons, suggested 
that RET is specifically expressed in alpha motoneurons, (Glazner et al., 1998; Nosrat et al., 
1997), although this has never been confirmed. Damage of motor axons leads to increased RET 
expression in motoneurons (Burazin and Gundlach, 1998; Hammarberg et al., 2000; Homma 
et al., 2003; Naveilhan et al., 1997; Tsujino et al., 1999), following a short-lived increase in 
GDNF expression in damaged nerve Schwann cells (Hoke et al., 2002; Naveilhan et al., 1997) 
and a delayed increase in skeletal muscle (Naveilhan et al., 1997). In these circumstances, GDNF 
appears to be involved in promoting terminal axon branching and synapse formation. During 
aging there is also increased RET expression (Bergman et al., 1999), possibly compensatory to 
decreased release of trophic factors from muscle. 
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Aim of the study
In most studies cited so far, the role of RET is interpreted as signaling the effects of GFLs, acting 
as retrograde neurotrophic factors. However, we have found evidence that suggests that in the 
spinal cord GDNF may act as a neuromodulator, which is released from primary afferent fibers and 
is involved in sensory processing in the dorsal horn (Holstege et al., 1998; Jongen et al., 2005; 
Jongen et al., 1999). 
GDNF is present in dense cored vesicles in primary afferent fibers terminating in laminae 
I and II-outer of the spinal dorsal horn and in the spinal trigeminal nucleus (Del Fiacco et al., 
2002; Holstege et al., 1998; Ohta et al., 2001; Quartu et al., 1999). Furthermore, exogenously 
applicated GDNF can rapidly induce c-Fos in dorsal horn neurons (Jongen et al., 2005). If GDNF, 
released from primary afferent fibers, is to activate spinal neurons, it would be expected that RET 
is expressed in the postsynaptic targets of the GDNF containing primary afferent fibers. However, 
so far the presence of RET protein in dorsal horn neurons has not been described in detail and 
data on the presence of RET-mRNA in dorsal neurons are conflicting (Glazner et al., 1998; Golden 
et al., 1998). Therefore, we have initiated the present study to examine in detail the anatomical 
and functional expression of RET protein in the adult rat spinal cord, with a focus on the dorsal 
horn, using immunohistochemistry with an antibody recognizing both isoforms of RET and in situ 
hybridization (ISH). In addition we analyzed the expression of RET in other areas of the spinal 
cord, including motoneurons.  Finally, we studied changes in the expression of RET protein in the 
spinal cord following peripheral axotomy and dorsal rhizotomy. 
MATERIALS AND METHODS
Animals and surgery
Experiments were performed on a total number of 22 adult male Wistar rats (Harlan Netherlands 
B.V., Horst, NL), weighing 250-300 g. Additionally, mice with a targeted mutation in the RET 
gene (RETk-; see (Schuchardt et al., 1994)) were used along with their wild type littermates 
(MRC, London, UK). Experiments were performed in accordance with the ‘Principles of Laboratory 
Animal Care’ (NIH publication no. 86-23). Local Animal Ethics Committees had approved all 
experiments.
Peripheral axotomies were performed on six rats under general anesthesia with 2% 
halothane in O2/N2O (30/70%). The left sciatic nerve was exposed, dissected free and locally 
anaesthetized with xylocaine 1%/adrenaline 1:100,000 (Astra Pharmaceutica BV, Zoetermeer, 
NL). Subsequently, the nerve was transected and 5 mm was removed at the midthigh level to 
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prevent regeneration of the proximal stump into the distal stump. After 9 days survival the rats 
were euthanized, dissected and immunohistochemistry was performed as described below.
Dorsal root transections were performed on four rats under general anesthesia. At the L2-L3 
vertebrae a laminectomy was performed and the L2-S2 dorsal roots, which pass at this level, were 
anesthetized with xylocaine/adrenaline and then transected by removing 1-2 mm of nerve. After 
6 days survival the rats were euthanized, dissected and immunohistochemistry was performed 
as described below.
Immunohistochemistry and immunofluorescence
For immunohistochemistry (IHC) and immunofluorescence (IF), rats were deeply anesthetized with 
intraperitoneal (i.p.) sodium pentobarbital and perfused transcardially with 250 ml phosphate 
buffer (PB; 0.05M, pH 7.3), containing 0.8% NaCl, 0.8% sucrose and 0.4% D-glucose, followed 
by 600 ml of 0.05M PB containing 4% paraformaldehyde (PFA) and 4% of the same fixative 
also containing 15% sucrose. The lumbosacral spinal cord was removed and post fixed in 4% 
PFA/15% sucrose for 2 hours (h) at room temperature. Some sections were post fixed in the same 
fixative for an additional 2 hours at 40C the same day. 40µm Frozen sections were cut on a sliding 
microtome, collected in 0.1 M PB and processed as free floating sections. Sections from animals 
with the longer post fixation period were heated at 800C in a 0.025M sodium citrate buffer 
solution (pH 8.75), in order to unmask immunoreactivity (see also (Jiao et al., 1999).
A RETk-/+ pregnant female bearing RETk- mice and their wild type littermates, was transcardially 
perfused at day 17.5 of pregnancy, in the same way as described for adult rats. Embryos were 
dissected, genotyped and spines were removed and post fixed in 4% paraformaldehyde for two 
hours at room temperature. Whole spines from a homozygous RETk- mouse embryo and from a 
wild type littermate were embedded in gelatin blocks and 40 µm frozen sections were cut on a 
sliding microtome. All sections were pretreated by heating them in sodium citrate buffer.
For single-labeling RET immunohistochemistry on rats and mice, all sections were preincubated 
with 10% normal horse serum (NHS) in 0.05M tris-buffered saline (TBS) containing 0.5% Triton 
X-100, followed by incubation (40 hours at 40C) in TBS (pH 7.6) containing 1% NGS, 0.1% 
Triton X-100 and goat anti-mouse RET (R&Dsystems, Minneapolis, MN; see also (Jongen et al., 
2005), diluted 1:100 (heated sections) or 1:50 (unheated sections). Sections were then rinsed 
(4x) in TBS, incubated for 90 minutes in biotinylated donkey anti-goat (Vector, Burlingame, CA) 
diluted 1:200 in TBS also containing 2% NHS and 0.4% Triton X-100, rinsed again in TBS 
(4x), processed with the ABC method (Vector Elite) and reacted with 0.025% diaminobenzidine, 
containing 0.005% hydrogen peroxide. To control for the specificity of the primary antibody and 
the immunohistochemical procedure the following control experiments were performed: omission 
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of the primary antibody, preincubation with a 10x (by weight) excess of the synthetic protein the 
antibody was raised against (R&D systems) and staining of spinal cord/DRG sections of a RETk- 
mouse embryo (see also (Jongen et al., 2005).
For double- and triple-labeling experiments, the same protocol as for RET single-labeling 
immunohistochemistry was used, without heating. Other primary antibodies included: Anti-
microtubule-associated protein 2 (MAP2) polyclonal antibody raised in rabbit (Chemicon, 
Temecula, CA; see also (Niu et al., 2004) used at a dilution of 1:100, anti-neurokinin-1 (NK-1) 
polyclonal antibody raised in rabbit (kindly provided by Dr. P.W. Mantyh, Neurosystems Center, 
University of Minnesota, Minneapolis, MN; see also (Mantyh et al., 1995; Vigna et al., 1994) 
used at 1:5000, rat m2 muscarinic acetylcholine receptor monoclonal antibody (Chemicon; 
see also (Levey et al., 1995) at 1:100 and mouse choline acetyltransferase (ChAT) monoclonal 
antibody (mAb 5, kindly provided by Dr. C. Cozzari, Institute for Cell Biology, CNR, Rome, Italy; 
see also (Jaarsma et al., 1996) at 1:100. Secondary antibodies included Cy3-conjugated donkey 
anti-goat, FITC-conjugated donkey anti-rabbit, Cy3-conjugated donkey anti-rat, FITC-conjugated 
donkey anti-mouse and Cy5-conjugated donkey anti-goat (Jackson ImmunoResearch, West Grove, 
PA), all used at a dilution of 1:200, for 1.5 h at 200C. Vectashield (Vector Laboratories Inc., 
Burlingame, CA) was used as a mounting medium.
In situ hybridization
For RET-ISH four adult Wistar rats received an overdose of sodium pentobarbital and were 
transcardially perfused with 250 ml sterile saline, followed by 750 ml 4% PFA in 0.12 M PB 
(pH 7.4). The lumbar segment was removed and post-fixed overnight at 40C in RNAse-free 
fixative, i.e. 4% PFA/30% sucrose in diethylpyrocarbonate (DEPC)-treated PB. 40µm Frozen 
sections were cut on a sliding microtome, collected in RNAse free PB and processed as free 
floating sections. Sections went through the following steps before prehybridization: 5 minutes 
in 0.2% glycine (Sigma-Aldrich, St. Louis, MO); 10 minutes in 0.1 M triethanolamine (pH 8) 
(Merck, Whitehouse Station, NJ) and 0.0025% acetic anhydride (Sigma), all in DEPC-treated 
and autoclaved phosphate buffered saline (PBS). After washes in 4x standard saline citrate (SSC), 
sections were transferred to an aqueous hybridization solution containing 50% formamide, 5x 
SSC, 2% blocking reagent (Roche Diagnostics GmbH, Mannheim, Germany), 0.05% 3-[(3-Chola
midopropyl)dimethylammonio]-1-propanesulfonate (CHAPS; Sigma), 1 µg/ml yeast tRNA, 5 mM 
ethylenediaminetetraacetic acid (EDTA), 50 µg/ml heparin and 1x Denhardt’s solution (Sigma), 
for 1 hour at 65 0C. The riboprobe for RET mRNA was directed against the extracellular domain 
of mouse RET and encompassed the first 1.8 kb SacII-SalI fragment (kindly provided by Dr. V. 
Pachnis, Division of Molecular Neurobiology, MRC, London, UK). The RET plasmid was linearized 
with BamHI and transcribed with T3 RNA polymerase in the presence of digoxigenin-11-UTP 
(Roche). Sections were incubated in hybridization solution for 16 hours at 650C. Subsequently 
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sections were rinsed in 2x SSC, treated three times with a solution of 50% formamide and SSC, at 
65 0C and rinsed in PBS. Sections were then processed for detection of digoxigenin-incorporated 
RET riboprobes with a sheep polyclonal antibody conjugated to alkaline phosphatase (1:4000; 
Roche) in a 2% BSA, 0.5% Triton, 0.05 M PBS solution for 48 h at 40C. Alkaline phosphatase 
was reacted with nitroblue tetrazolium and 5-bromo-4-chloro-3-indonyl-phosphate (Roche) for 9 
hours in the dark at room temperature. After rinsing, sections were mounted, air-dried overnight, 
dehydrated with absolute ethanol (VWR, West Chester, PA) and coverslipped with Permount as a 
mounting medium (Fisher, Hampton, NH). Control sections, hybridized with sense probes, were 
also analyzed but did not show any specific labeling.
Image analysis and quantification of immunohistochemical data
To analyze the degree of RET and NK-1 co localization, we used double labeling immunofluorescence 
combined with confocal microscopy on L5 sections that were 200 µm apart, from 5 rats. Lamina 
I was systematically scanned for RET-ir neurons, NK-1-ir neurons and double labeled neurons, 
using a Zeiss LSM 510 confocal laser scanning microscope and a 20x objective. Thickness of 
optical sections was 4.6 µm. A total number of 201 immunoreactive cells were counted. The 
percentages of double labeled neurons as a proportion of total number of RET-ir and NK-1-ir 
neurons were expressed as means ± SEM.
For quantification of regulation of RET-ir in lamina IIi and III following peripheral axotomy, 
the first four L5 sections (each 200 µm apart) encountered on slides from 5 axotomized animals 
were photographed with a Leica DC 300 digital camera on a Leica DMRB light microscope. The 
resulting images (n=20) were further analyzed using the public domain ImageJ (v1.33) software, 
a Java application based on NIH image (http://rsb.info.nih.gov/nih-image/about.html). A square 
selection of 64x64 pixels containing part of the medial half of lamina IIi and a similar selection 
ventral to the former, containing a part of lamina III, was selected on both sides. Processing and 
image analysis was performed as described previously (Wu et al., 1997), with the exception of 
transition to and from the frequency domain. This method creates an image that appears black 
against a white background, which is an accurate representation of RET-ir in the selected area. 
The labeled area was expressed as the number of black pixels. Mean values of 5 animals were 
calculated for control and axotomy sides and were compared using a paired t-test.
Quantification of RET-ir in motoneurons was performed on the first L5 section encountered 
on the slide (each 200 µm apart) from the same 5 axotomized animals as above. The resulting 
images (n=5) were also preprocessed according to (Wu et al., 1997) and immunoreactive profiles 
in the ventrolateral spinal gray matter containing a nucleus, i.e. motoneurons, were selected using 
the freehand selection tool. Feret diameter of motoneuronal somata (in µm) and mean gray value 
of the cytoplasm of motoneuronal somata (ranging form 0-255) were measured with ImageJ. 
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Mean values of 5 animals were calculated for control and axotomy sides. Additionally, mean 
values from three naïve rats were determined. Thus, a total number of 318 RET-ir motoneurons 
were analyzed. For quantification motoneurons were grouped in 5 µm Feret diameter intervals and 
proportions of RET-ir neurons with intensities < 110 (i.e. darkly stained) were calculated for each 
group. Motoneurons with diameters of < 25 and ≥ 60 µm were discarded from analysis, since 
too few data were available to make estimates of proportions reliable. t-Test statistics were used 
to compare density of RET staining in control sides of axotomized rats with that in naïve rats, to 
compare proportions of darkly stained RET neurons in small size motoneurons with a diameter 
of <40µm with that in medium-large size (≥40 µm diameter) motoneurons and to compare the 
axotomy side with the control side of axotomized animals. 
Statistical analysis was performed with Stata v8.0 software (www.stata.com). Figures were 
composed with Adobe Photoshop v7.0 software. Adjustments were made only to brightness 
and contrast, unless otherwise indicated in the figure legends. Evenness of illumination of light 
microscopical sections was provided by background subtraction using the TWAIN software that 
came with the Leica DC 300 digital camera.
RESULTS
RET general labeling pattern and epitope unmasking
Light microscopical examination of the sections processed for RET-IHC showed that at low-
magnification, RET-ir was most prominent in lamina IIi and in mooneurons (Fig. 1A). Many other 
neurons were also RET-ir, but with a much lower intensity than motoneurons. These weakly RET-
ir neurons were found in all laminae, except for lamina II, which contained only a few labeled 
neurons. The many fiber-like structures that were labeled throughout the spinal cord were mainly 
dendrites, since virtually all of these structures also expressed the dendritic marker MAP2 (see 
later). However, the fibers in lamina IIi were primary afferent fibers terminating in this area, since 
these fibers disappeared after dorsal rhizotomy (see later). This general labeling pattern was seen 
along the entire length of the spinal cord. The prominent RET labeling in primary afferent fibers 
in lamina IIi was preferentially observed after pretreatment of the sections at 80
0C in sodium 
citrate buffer, the so-called unmasking procedure. When this treatment was omitted, only labeling 
of neuronal somata and dendrites was observed (Fig. 1B), demonstrating that the unmasking 
procedure only affects RET protein associated with axonal and terminal structures.
In the spinal cord of an E 17.5 wild type mouse strong RET-ir was observed in DRG neurons, 
motoneurons and primary afferent terminals (Fig. 1D), especially after the unmasking procedure. 
Without this treatment, labeling of primary afferent terminals was nearly absent (Fig. 1E), exactly 
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as observed in the adult rat, while labeling of motoneurons and DRG neurons was also somewhat 
weaker. RET-ir primary afferent fibers at this age, when the dorsal horn and its connections 
are still in development, were present throughout lamina I-IV of the dorsal horn, as described 
previously (Molliver et al., 1997). A limited number of RET-ir neurons were also identified in the 
dorsal horn, although the multitude of afferent fibers made it difficult to ascertain their presence. 
In a mouse with a targeted mutation in the gene encoding the RET protein (Schuchardt et al., 
1994), which lack normal RET mRNA, no labeling in any of the aforementioned structures was 
observed after pretreatment for epitope unmasking (Fig. 1C), confirming the specificity of the 
antibody. However, there was some labeling of structures resembling radial glia in the embryonic 
mice lacking RET protein. Although this labeling was relatively weak, it prompted us to consider 
labeling in glial structures as non specific.
We also used non-radioactive ISH on free floating sections (Key et al., 2001) to study the 
presence of RET mRNA in the spinal cord (Fig. 2). In the ventral horn, strong RET-mRNA labeling 
was present in motoneurons (Fig. 2C), while in the dorsal horn, several weakly, but still distinct, 
RET mRNA expressing neurons were present in the superficial (Fig. 2A and 2B) and deep (not 
shown) layers. Generally, the distribution of labeled neurons corresponded very well with the 
general neuronal distribution, obtained with RET-IHC (compare Figs. 1, 2 and 4).
The general distribution and relative intensity of RET-ir in the spinal cord is summarized in the 
table. Specific spinal nuclei showing RET-ir neurons (Fig. 3) were the lateral spinal nucleus, the 
dorsal nucleus (nucleus dorsalis of Clarke; thoraco-lumbar spinal cord), the intermediolateral nucleus 
(thoraco-lumbar spinal cord), the sacral parasympathetic nucleus and the nucleus dorsomedialis and 
dorsolateralis (homologues to Onuf’s nucleus in man; L6 segment) (see also (Holstege et al., 1996). 
Tanycytes (see also (Honda et al., 1999) around the central canal also showed RET-ir.
RET expression in dorsal horn neurons
Several strongly RET-ir neurons and a significant number of more weakly labeled neurons were 
observed scattered throughout the entire dorsal horn (Fig. 4A). Typically, each section contained 
several RET-ir neurons in lamina I, some of which had the characteristic appearance of nociceptive 
projection neurons (Fig. 4B) (see also (Grudt and Perl, 2002; Han et al., 1998). RET-ir neurons 
were relatively abundant in lamina V and sparse in lamina II. Lamina III, IV and V contained, 
in addition to somatic RET labeling, many RET-ir fiber-like structures that were not affected by 
dorsal rhizotomy. These structures represented dendrites, as double-labeling IF combined with 
confocal microscopy showed that virtually all of them were immunoreactive for RET as well as for 
the dendritic marker MAP2 (Fig. 5). Since MAP2 is selectively expressed in neuronal somata and 
dendrites and not in glia, the extensive co localization of RET and MAP2 immunoreactivity further 
demonstrates that labeled structures in the dorsal horn are neuronal rather than glial.
95
Distribution of RET Immunoreactivity in the Rodent Spinal Cord and Changes after Nerve Injury
Using double-labeling confocal IF, it was determined whether RET-ir neurons in lamina I were also 
NK-1-ir. A quantitative analysis of these neurons showed that 54 ± 4% (mean ± SEM) of the 
RET labeled neurons were also labeled for NK-1 and that 65 ± 4% (mean ± SEM) of the NK-1 
labeled neurons were also labeled for RET (Fig. 6).
RET expression in primary afferent fibers
A dense band of RET-ir fibers was observed in lamina IIi and clusters of varicose fibers were 
observed in the medial part of lamina IV and V, especially in sections that were pretreated using 
antigen unmasking. These RET-ir fibers represented primary afferent terminals, since a L2-S2 
dorsal rhizotomy resulted in a nearly complete disappearance of RET-ir fibers in lamina IIi of the 
L4-L6 segments (Fig. 7).
In the dorsal horn of rats that were subjected to an axotomy of the sciatic nerve at thigh 
level 10 days previously, a 45% decrease (P≤0.05) of RET labeling density was observed in 
the medial half of lamina IIi on the axotomized side (Fig. 8A, C), which is the projection area of 
RET-ir sciatic nerve afferents. A simultaneous increase of RET-ir was observed in the adjacent 
medial half of lamina III and IV on the axotomized side. However, a density measurement of 
this increase in RET-ir in the medial half of lamina III just failed to reach statistical significance 
(P=0.08). The apparent increase was not observed when sciatic nerve axotomy was followed 
by dorsal rhizotomy of L2-S2, suggesting that the apparent increase in lamina III and IV labeling 
after peripheral axotomy occurred in primary afferent fibers rather than in neuronal somata and 
dendrites (Fig. 8B, C).
RET expression in motoneurons.
RET-ir was strongly expressed in motoneurons throughout the rat spinal cord (Fig. 1, 9). This 
was confirmed by RET and ChAT double-labeling IF, since virtually all motoneurons, as identified 
by their ChAT labeling, were also labeled for RET (Fig. 10A). RET labeling was prominent in the 
cytoplasm with sparing of the nucleus and extended into the dendrites. Generally, RET-ir was 
much stronger in small (diameter < 40 µm) than in large-sized (diameter ≥ 40 µm) motoneurons 
(Fig. 9). The proportion of motoneurons with intensities lower than 110 on a 256 gray level scale 
(i.e. darkly stained motoneurons) was almost twice as high in the group of small motoneurons, 
than in the group of large motoneurons  (1.9 times; P≤0.01, group 25-40 µm versus 40-60 
µm diameter, paired t-test; see also Fig. 11C). Small, strongly RET-ir neurons co expressed m2 
receptor-ir weakly or not at all and did not show cholinergic boutons on their plasma membrane 
(Fig. 10B).
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In the ventral horn, 10 days following sciatic nerve axotomy, an almost twofold increase in the 
proportion of darkly RET-labeled motoneurons was observed on the axotomized side as compared 
to the control side (Fig. 11; 1.8 fold; P≤0.01). The increase was almost entirely due to increased 
labeling in large motoneurons (Fig. 11 A, C). RET labeling intensities of motoneurons on the control 
sides of axotomized rats did not differ from those in naïve rats nor did motoneuron diameters 
(P=0.88, P=0.14 respectively; data not shown).
DISCUSSION
In this study we have used immunohistochemistry to identify the distribution of RET protein in 
the adult rat spinal cord. The strongest expression was found in small diameter motoneurons, 
presumably gamma motoneurons, while slightly weaker RET expression was observed in alpha 
motoneurons. RET-ir in motoneurons was confirmed by ISH. Strong labeling was also observed 
in primary afferent fibers after an unmasking procedure. Weaker but distinct RET labeling 
was observed in neurons of nearly all laminae, especially in the dorsal horn. The cellular 
immunohistochemical expression pattern in the dorsal horn was confirmed by weak, yet distinct, 
RET mRNA expression.
A potential concern regarding any immunohistochemical study is the specificity of the 
antibody that is used. In the present study our main data were obtained with a polyclonal antibody 
produced in goats and raised against the extracellular domain of recombinant mouse RET protein. 
The antibody has been previously tested (de Graaff et al., 2001) and was found to identify both 
RET isoforms, in line with the fact that the antibody is directed against the common extracellular 
domain of RET. RET-ir was absent in present and previous (Jongen et al., 2005) standard negative 
controls for the antibody and corresponded well with previous findings regarding RET expression 
in the spinal cord, i.e. localization in fibers in lamina IIi (Molliver et al., 1997) and in motoneurons 
(Leitner et al., 1999). We also tested the antibody on prenatal mice lacking RET expression. 
Various neuronal structures, like DRG neurons, motoneurons and primary afferent fibers, that 
were strongly labeled in wild type mice, were completely devoid of labeling in mice lacking RET 
expression, thus confirming the specificity of the antibody. Finally, the distribution pattern of RET 
mRNA expression corresponded well with the immunohistochemical findings. We thus conclude 
that the immunohistochemical expression pattern that we observed reflects the actual presence 
of RET protein in the spinal cord.
We demonstrated, both in adult and embryonic tissue, that primary afferent fibers are best 
visualized following an antigen retrieval technique, which basically consists of pretreating the 
sections by heating them in sodium citrate at 80 0C for 30 minutes (Jiao et al., 1999; Montero, 
2003). While the labeling of primary afferent terminals in lamina IIi became much more intense 
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by this procedure, somatic and dendritic labeling was only slightly affected. It seems likely that 
this differential effect of pretreatment on the antigenicity of RET protein towards the antibody that 
we used in this study, is related to the different types of cellular compartments containing RET 
protein: preterminal axonal and terminal membrane localization on the one hand and somatic 
and dendritic localization on the other. One explanation for the observed effects may be that 
RET protein in somata and dendrites is always recognized by the antibody when it is localized 
in the cytoplasm, while RET protein in the cytoplasmatic membrane is either sparsely present or 
cannot be recognized by the antibody whether the tissue is pretreated or not. In primary afferent 
terminals RET protein is preferentially visualized after pretreatment, suggesting that in this case 
pretreatment was effective in unmasking the relevant epitopes of RET protein, in line with a 
similar finding obtained elsewhere for NMDA and GABAA-receptor epitopes (Fritschy et al., 1998). 
Whether this means that RET protein in the cytoplasmatic membrane of dorsal horn neurons is 
differentially localized with respect to lipid rafts than RET in primary afferent terminals cannot be 
ascertained. However it is tempting to speculate that the different effects of pretreatment on RET 
protein expression reflect differences between the role of RET in terminals, i.e. retrograde trophic 
signaling, and RET in dorsal horn neurons, i.e. local modulation of neurotransmission (see later). 
These different roles of RET are also compatible with observed differences in RET signaling when 
localized inside or outside lipid rafts.
RET expression in dorsal horn neurons
Although relatively weak, RET protein and RET mRNA are clearly expressed in neurons of the 
dorsal horn, especially in laminae I and V. Virtually complete colocalization of RET with the neuron 
specific marker MAP2 confirms that cellular RET is almost exclusively localized in neurons. In 
this study, as in a previous study (Jongen et al., 2005) we observed RET-ir in fusiform neurons in 
lamina I, which by morphology and location likely represent nociceptive specific projection neurons 
(Han et al., 1998). In order to confirm this idea, we applied double labeling IF for RET and NK-1, 
the receptor for Substance P. NK-1 was used as a marker, since the large majority of the NK-1-ir 
neurons in lamina I are known to be nociceptive specific projection neurons, which targets include 
the thalamus, the lateral parabrachial area, the periaqueductal gray the and caudal ventrolateral 
medulla (Klop et al., 2005; Littlewood et al., 1995; Spike et al., 2003; Yu et al., 1999). The 
high degree (i.e. over 50%) of RET and NK-1 co localization that we observed thus demonstrates 
that the majority of RET-ir neurons in lamina I are involved in nociceptive signaling and are able to 
respond to activation by GFLs like GDNF, since they contain the RET protein necessary for signal 
transduction. Although we did not perform co localization experiments to characterize neurons in 
dorsal horn laminae other than lamina I, the relative abundance of RET-ir neurons in lamina V 
may suggest its presence in wide dynamic range neurons (Craig, 2003; Craig, 2004; Price et al., 
2003), which are also involved in processing nociceptive information.
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RET expression in primary afferent terminals
This is the first study to provide direct proof that the strong RET-ir fibers in the dorsal horn, most 
abundantly in lamina IIi, are primary afferents, since an almost complete disappearance of this 
labeling was observed following dorsal rhizotomy.
Following peripheral axotomy a different reaction was observed. In this case a strong 
downregulation of RET-ir in fibers in lamina IIi is accompanied by an apparent upregulation of 
RET-ir fibers in lamina III and IV. The finding that this upregulation was not present when axotomy 
is followed by a rhizotomy, strongly suggests that the upregulation occurs in a subgroup of primary 
afferent fibers. We propose that this subgroup are myelinated Aβ fibers, which preferentially 
terminate in this laminae and belong to large diameter ganglion cells, possibly involved in 
mechanosensitivity in the skin. Our findings are in agreement with those of (Bennett et al., 2000), 
who described an increase of RET mRNA expression in large diameter DRG neurons after peripheral 
axotomy. The downregulation in one and simultaneous upregulation in another subpopulation of 
primary afferents may also explain why previous studies (Bennett et al., 2000; Hoke et al., 
2002; Kashiba et al., 1998) have reported that the overall RET expression in primary afferents 
is unaffected by peripheral axotomy. A similar situation has been described for neuropeptides 
and BDNF (Hokfelt et al., 1994; Michael et al., 1999; Neumann et al., 1996; Noguchi et al., 
1995). Taken together, our findings show that primary afferents are the only RET expressing fibers 
terminating in the spinal cord and that this expression is downregulated after peripheral axotomy 
in small diameter fibers, while an upregulation appeared to occur in large diameter fibers.
RET in motoneurons
Motoneurons show the most intense RET-ir in the spinal cord. However, within the group of 
motoneurons, small motoneurons were labeled even stronger than large motoneurons. We propose 
that these small, intensely labeled motoneurons represent gamma motoneurons, in contrast to 
previous suggestions that alpha motoneurons show the strongest RET expression (Glazner et al., 
1998; Nosrat et al., 1997). Early studies have demonstrated a bimodal size-frequency distribution 
of motoneurons, with gamma motoneurons representing those with a mean diameter smaller than 
35-40 µm (Bryan et al., 1972; Limwongse and DeSantis, 1980; Peyronnard et al., 1986; Strick 
et al., 1976). We did not observe  such a bimodal size-frequency distribution of RET-ir neurons in 
the ventrolateral gray matter, in agreement with other studies using various immunohistochemical 
markers (Ramer et al., 2003; Welton et al., 1999). Nevertheless, we did find a clear distinction, 
based on RET labeling intensity, between neurons with Feret diameters <40 µm, presumably 
gamma motoneurons, and those with diameters ≥ 40 µm. A similar observation has also been 
made with respect to ChAT labeling of motoneurons (Barber et al., 1984). Additionally, small 
strongly RET-ir neurons rarely expressed cholinergic boutons and m2 receptor-ir on their plasma 
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membrane, also supporting a gamma motoneuronal phenotype (Limwongse and DeSantis, 1980; 
Welton et al., 1999). These findings may indicate that gamma motoneurons produce larger 
amounts of RET protein than alpha motoneurons, although the functional significance of this 
phenomenon remains obscure. 
The upregulation of RET-ir in motoneurons that we observed following sciatic nerve transection 
confirms the finding in numerous other studies, which show an increase in RET mRNA after 
axotomy, e.g. (Burazin and Gundlach, 1998; Hammarberg et al., 2000; Naveilhan et al., 1997). 
Upregulation of RET in axotomized motoneurons is generally considered to reflect a compensation 
for the limited availability of GFLs as a result of the axotomy.
Functional implications: The role of RET in the spinal cord
Based on our previous studies (see introduction) we have argued that GDNF is present in the spinal 
cord in primary afferent nociceptive fibers from which is it released as a neuromodulator to act on 
dorsal horn neurons in lamina I and II. This hypothesis is now substantiated by our finding that 
RET is expressed in NK-1 expressing nociceptive specific projection neurons, which is in line with 
our previous finding that intrathecal GDNF injection induced c-Fos in neurons that coexpressed 
RET (Jongen et al., 2005). The expression of GFRα1 in dorsal horn neurons (Glazner et al., 1998; 
Matsuo et al., 2000; Widenfalk et al., 2001) completes the idea of GDNF as a neuromodulator in 
spinal nociceptive transmission. The presence of GFRα2 in dorsal horn neurons (Widenfalk et al., 
2001) would suggest that NRTN, the preferred ligand for GFRĐ2, may also play a role in signaling 
through RET in the spinal cord. However, so far NRTN has not been identified in the dorsal horn 
or in dorsal root ganglion cells and, after intrathecal injection, does not induce immediate early 
gene expression, in contrast to GDNF (Jongen et al., 2005). GFRĐ3 (Widenfalk et al., 1998) and 
GFRα4 have not been described in the spinal dorsal horn, nor have their ligands ARTN and PSPN. 
Thus, NRTN, ARTN and PSPN are unlikely to play a role in spinal nociceptive transmission.
Although the nature of an effect of GDNF on dorsal horn neurons is still unclear, spinal intrathecal 
application of a GDNF-function blocking antibody attenuated the hyperalgesia induced by complete 
Freund’s adjuvans injection in rats (Fang et al., 2003) and a more recent observation has shown 
acute effects of intrathecally injected GDNF on thermal nociceptive thresholds in mice (Beidas et 
al., 2005). In the brain GDNF has been shown to directly modulate ion channels (Wang et al., 
2003; Yang et al., 2001), although the role of RET or any other receptor in this process is still 
unclear. Modulation of ion channels may explain the direct behavioral effects of GDNF described 
above. Similar effects, on NMDA receptors (Kerr et al., 1999) in the spinal cord and on sodium 
channels in the brain (Blum et al., 2002), have also been described for BDNF. In summary, we 
suggest that GDNF, like BDNF, may exert a neuromodulatory role in spinal nociceptive transmission, 
through a direct effect on RET expressing dorsal horn neurons.
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In contrast to the possible effect of GDNF released from primary afferent fibers on spinal dorsal horn 
neurons discussed above, it has been suggested that GDNF acts on RET and GFRα1 expressing 
primary afferents. However the expression areas of GDNF-ir and RET-ir primary afferents in the 
spinal cord are hardly overlapping (Bennett et al., 1998; Holstege et al., 1998; Molliver et al., 
1997). In pathological situations on the other hand, like inflammation or nerve injury, GDNF and 
other GFLs might be up regulated in spinal cord glia, as has been shown for BDNF (Coull et al., 
2005), exerting trophic effects on DRG afferents. Exogenous application of GDNF (Bennett et al., 
1998; Boucher et al., 2000) and ARTN (Gardell et al., 2003) have actually been shown to exert 
such effects on DRG neurons.
In the ventral horn, RET is involved in the survival of motoneurons during development and 
in regeneration following damage in the adult. GDNF and NRTN act as trophic factors released 
by target tissue, i.e. muscle (Trupp et al., 1997; Trupp et al., 1995; Widenfalk et al., 1997) and 
supporting cells, i.e. Schwann cells (Hoke et al., 2002) and possibly glial cells in the ventral 
horn (Zhao et al., 2004). These effects are mediated by RET and GFRα1 or GFRα2, which 
are all present in motoneurons (see introduction), although the exact role of these receptors in 
this trophic process is largely unknown. Nevertheless, GDNF has been extensively used as a 
therapeutic in animals models of motoneuron disease (Bohn, 2004) and in a phase I clinical 
trial with intraventricular application of GDNF in patients with ALS, although this study was 
discontinued because of a lack of efficacy.
In conclusion we have shown widespread RET protein expression in the adult rat spinal cord, 
including changes in RET expression following nerve injury. The expression and regulation pattern 
of RET in primary afferent terminals and motoneurons confirms previous findings and is in line 
with a neurotrophic role of GFLs. The expression of RET in neurons in the dorsal horn that we now 
show for the first time in detail, supports a role of RET as a mediator of activity-dependent effects 
of GDNF. We therefore suggest that modulation of GDNF-RET interactions on spinal nociceptive 
projection neurons may have acute effects on spinal nociceptive transmission. As such, GDNF 
and RET may be promising targets for the development of pharmaceuticals to alleviate pain and 
hyperalgesia.
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FIGURES
Fig. 1. Light micrograph showing L5 sections from a naïve rat (A, B) and sections from the upper 
cervical spinal cord with DRGs from a E 17.5 RETk- mouse (C) and its wild-type littermate (D, 
E), all processed for RET-IHC. (A, B) Strong labeling of motoneurons is obvious, but the dense 
band of immunoreactive fibers in lamina IIi was observed only after pretreatement for epitope 
unmasking (A). (D, E) Similarly, in embryonic mouse sections RET-ir primary afferent fibers were 
nearly absent without pretreatment (E), while labeling of motoneurons and DRG neurons was only 
slightly affected. (C) No neuronal labeling was observed in sections from a RETk- mouse.
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Fig. 2. Light micrograph showing a L4 section from a naïve rat processed for non-radioactive RET-
ISH. Strong RET-ir is expressed inmotoneurons (C) and weaker but still distinct labeling is shown 
in the superficial dorsal horn, as indicated by arrowheads (A,B).
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Table. Distribution and labeling intensity of RET-ir in the dorsal horn of the adult rat.
Laminae are according to (Molander et al., 1984). Abbreviations: lateral spinal nucleus (LSN), 
the dorsal nucleus (DN), the intermediolateral nucleus (IML), the sacral parasympathetic nucleus 
(SPN) and the dorsomedial and dorsolateral nucleus (DM and DL).
Fig. 3. (next page) Light micrographs (A, C, D) and confocal IF images (B) showing sections from 
naïve rats processed for RET-IHC/IF at different spinal levels. In the confocal images, RET was 
labeled with Cy3 (red), MAP2 with FITC (green). (A, A1) S2 section showing a RET-ir neuron 
in the lateral spinal nucleus (arrow) and several neurons in the sacral parasympathetic nucleus 
(dashed oval). (B) Three RET/MAP2 double labeled neurons and dendrites in the lateral spinal 
nucleus and one in lamina I (arrows) of a L3 section. Thickness of optical sections: 4.6 µm (B), 
1 µm (B1). (C) Several weakly labeled neurons, some of which are indicated by arrows, in the 
dorsal nucleus (C1) and intermediolateral nucleus (C2) in a L2 section. (D) L6 section showing 
RET-ir in the dorsomedial and dorsolateral nucleus (D1; dashed ovals). Note: bundles of dendrites 
characteristically radiating away from the motoneurons in the DM nucleus. All sections but the 
ones in (B) were treated using the unmasking procedure.
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Fig. 4. Light micrographs showing the dorsal horn of a L5 (A) and a L3 (B) section from a naïve rat 
processed for RET-IHC. RET-ir neurons (arrows) are shown in lamina III (A1), the medial part of 
lamina V (A2) and in lamina I (B1). RET-ir is preferentially localized in the cytoplasm and primary 
dendrites of these neurons. These sections were processed without the unmasking procedure, 
hence labeling of primary afferent fibers is very weak, greatly facilitating the identification of 
neuronal somata. Figure A1 is an overlay of two optical sections.
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Fig. 5. Confocal IF images of the dorsal horn of an L4 section from a naïve rat processed for RET 
and MAP2-IF. RET was labeled with Cy3 (red), MAP2 with FITC (green). Overlapping signals are 
present in cell somata in lamina I and IV (A, B), and in fibers in lamina IV (A). Insets indicate 
where images were taken. (A) Colocalization of RET and MAP2 confirms the presence of RET in 
neuronal somata and dendrites. (B) Neuronal somata in lamina I are indicated by arrows. The 
elongated single labeled structure, indicated by arrowheads, represents an axon. The section was 
processed without the unmasking procedure. Thickness of optical sections: 1 µm.
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Fig. 6. Confocal IF images of the dorsal horn of an L4 section from a naïve rat processed for RET 
and NK-1-IF. RET is labeled with Cy3 (red), NK-1 with FITC (green). (A1) A large neuron and 
dendrite in lamina I are double labeled for RET and NK-1 (arrow). Note preferential localization 
of RET-ir in the cytoplasm and NK-1-ir alongside the limiting membrane of the soma and the 
dendrite. The small RET-ir neuron is not double labeled with NK-1 (arrowhead). (B) Large double 
labeled neuron (arrow) and two single labeled neurons (arrowheads), one RET-ir and one NK-1-ir. 
The sections were processed without the unmasking procedure. Thickness of optical sections: 4.6 
µm (A), 1 µm (A1, C). (C) Histogram, showing percentage of colocalization of RET and NK-1 in 
lamina I.
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Fig. 7. Light micrographs showing the dorsal horn of a L4 section from a rhizotomized rat, 
processed for RET-IHC. On the control side strong RET-ir is present in lamina IIi (A1) and RET-
ir is expressed in clusters of varicose fibers in the central part of lamina IV and V (B1). On the 
rhizotomized side RET-ir almost completely disappeared from both superficial (A2) and deep 
dorsal horn (B2). This section was treated using the unmasking procedure.
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Fig. 8. Light micrographs of L5 sections 
processed for RET-IHC from a rat after 
sciatic nerve transection (A) and from a 
rat in which sciatic nerve transection was 
followed by dorsal rhizotomy (B). RET-ir 
is decreased in lamina IIi and apparently 
increased in lamina III and IV (A2). The 
apparent increase of RET-ir in lamina III 
and IV is of primary afferent origin since 
it disappeared following dorsal rhizotomy 
(B2). (C) Histogram showing means ± 
SEM of the area occupied by RET-ir fibers, 
relative to the control side, which was set 
at 100%. Significance levels: *P≤0.05, 
versus control side, paired t-test.
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Fig. 9. Light micrograph showing a composition of 20 high power images of a part of the 
ventrolateral gray matter (see inset) from the same L5 section as in Fig 1. Labeling is present in 
the cytoplasm and dendrites with sparing of the nucleus. Note that the intensity of RET-ir varies 
with the size of the motoneurons.
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Fig.10. Confocal IF images of the ventral horn of a L4 (A) and a L3 (B) section from a naïve rat 
processed for RET, ChAT and m2 receptor-IF. Insets indicate where images were taken. (A) RET 
is labeled with Cy5 (blue), ChAT with FITC (green) and m2 receptor with Cy3 (red). Virtually all 
ChAT-ir motoneurons also expressed RET. Generally, RET-ir and ChAT-ir is strongest in small size 
motoneurons. Many medium to large size motoneurons with relatively weak RET-ir expressed 
m2-receptor on their plasma membrane, the latter indicated by a thin red line that directly 
surrounds the motoneurons (asterixes). Small motoneurons with strong RET labeling did not or 
very weakly express m2-receptor. (B) RET is labeled with Cy3 (red), ChAT with FITC (green). 
A large motoneuron with weak RET labeling receives multiple ChAT-ir boutons on its plasma 
membrane, two of which are indicated with arrowheads in the merged high-power image. Two 
small, strongly RET-ir neurons do not receive cholinergic boutons. Thickness of optical sections: 
4.6 µm for low-power images, 1µm for high power images. The high-power images in figure B are 
overlays of a stack of 4 optical sections.
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Fig. 11. (A) Light micrograph 
of a L5 section from a rat 
after sciatic nerve transection, 
processed for RET-IHC. Sciatic 
nerve transection induced a 
strong increase in the proportion 
of darkly stained motoneurons. 
This increase was almost entirely 
due to increased staining of large 
diameter motoneurons. Note that 
the increase only occurred in the 
motoneuron pool contributing to 
the sciatic nerve. (B) Scatterplot 
relating neuronal size to RET 
staining intensity on the control 
(open circles) and axotomized 
side (closed circles) of rats 
after sciatic nerve transection. 
Generally neurons on the 
axotomized side were darker 
than those on the control side. 
(C) Size-proportion histogram 
showing means ± SEM of the 
proportion of motoneurons with 
staining intensities lower than 
110 on 256 level gray scale, 
i.e. darkly stained motoneurons. 
The increase in proportions of 
darkly stained motoneurons 
on the axotomized side (gray 
bars) versus the control side 
(white bars) was statistically 
highly significant: P≤0.01, 
axotomized versus control side, 
paired t-test.
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In this thesis, a series of experiments were described and in each chapter the results were 
discussed in detail. All these experiments suggest that Glial cell line-Derived Neurotrophic Factor 
(GDNF) plays a role as a neuromodulator in spinal pain transmission and pieces of evidence for 
this suggestion were brought forward in each of the chapters. Here, in the general discussion, 
all the evidence that now exists on the issue whether or not GDNF plays a neuromodulatory role 
in the spinal dorsal horn, will be reviewed. Finally, the potential relevance of the findings in this 
thesis for clinical practice will be discussed.
MAY GDNF BE CONSIDERED A NEUROMODULATOR IN SPINAL 
PAIN TRANSMISSION?
In order to answer this question, it must first be determined what is meant by the term 
neuromodulator. This question is difficult to answer, since no clear definition exists. Originally the 
term neuromodulator took root when it was discovered that next to the classical neurotransmitters, 
like the amino acids and monoamines, neuropeptides could be present in the same terminal, 
"modulating" the postsynaptic effect of classical neurotransmitters (Hokfelt et al., 1980; Hokfelt et 
al., 1975). Nowadays, the term neuromodulator is generally used to indicate substances that are 
co-released with the classical neurotransmitters, although they may have different postsynaptic 
effects, which are usually mediated through activation of G-protein coupled receptors or tyrosine 
kinase receptors. Since no definite criteria for the term neuromodulator exist, the criteria that 
define a neurotransmitter will be used for evaluating GDNF, also because there are no compelling 
arguments to suggest that these criteria should not be applied.
Criteria for neurotransmitters
The criteria for considering a particular substance as a neurotransmitter have evolved slowly in 
the past century. In 1921, acetylcholine, then termed “Vagusstoff”, i.e. a substance originating 
from the vagus nerve, was the first substance to be identified as a chemical transmitter, by Otto 
Loewi (Fig. 1). Since then numerous other transmitter-like substances were identified, which 
according to some should be considered as neurotransmitters, while others argued that there was 
not enough evidence to make such a claim. From this discussion a set of criteria emerged that had 
to be fulfilled if a substance was to be considered a neurotransmitter. The criteria for a putative 
neurotransmitter may be summarized as follows (Pezet et al., 2002; Purves, 2004): 
1. A putative neurotransmitter should be synthesized within a neuron and the substance should 
be found within a nerve terminal.
2. It should be released following stimulation.
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3. After release it should act on a post-synaptic receptor and cause a biological effect.
4. When the putative neurotransmitter is applied on the post-synaptic membrane, it should 
have the same effect as when it is released by a neuron. Known antagonists of the putative 
neurotransmitter should block its effect in a dose-dependent manner.
5. After a putative neurotransmitter is released from a neuron, it should be inactivated, e.g. 
through a reuptake mechanism or by an enzyme that stops the action of the transmitter.
We will now consider to what extent GDNF also meets the above criteria in the context of 
nociceptive transmission in the dorsal horn of the spinal cord.
The first criterion states that a putative transmitter should be synthesized within a neuron and that 
it should be found within a nerve terminal. To comply with this criterion in the context of spinal 
nociception, GDNF should be synthesized in dorsal root ganglion (DRG) cells and it should be 
found within primary afferent terminals in the spinal dorsal horn. Several authors have described 
GDNF protein, identified by immunohistochemistry, in the somata of DRG neurons (Chapter 2 
and Bar et al., 1998; Dong et al., 2005a; Dong et al., 2005b; Fang et al., 2003; Honda et al., 
1999; Ohta et al., 2001) and those of the trigeminal ganglion (Del Fiacco et al., 2002; Quartu et 
al., 1999). Specificity of the antibody was confirmed by standard immunohistochemical controls 
(Chapter 2) and also by clearly enhanced Western blot levels in mice overexpressing GDNF (Meng 
et al., 2000). However, labeling of cell somata is relatively weak in comparison to fiber and 
terminal labeling in the superficial dorsal horn (Chapter 2 and Ohta et al., 2001). The presence 
of GDNF protein suggests that GDNF is synthesized in the DRG neuron, but clearly identification 
of GDNF mRNA is necessary to prove unambiguously that GDNF is actually synthesized in these 
neurons. Sofar GDNF mRNA has not been detected in studies that included DRG neurons in their 
general description of GDNF mRNA in the nervous system (Golden et al., 1998; Hammarberg 
et al., 1996; Josephson et al., 2001; Widenfalk et al., 1999). Therefore some authors (Rind 
and von Bartheld, 2002; von Bartheld et al., 2001) have suggested that GDNF protein in DRG 
neurons originates from sources outside the DRG, i.e. Schwann cells or target tissues. If this 
holds true, the presence of GDNF protein would be explained by uptake and retrograde transport 
of GDNF protein synthesized by Schwann cells or peripheral tissues. Since GDNF protein is 
abundant in the terminals of primary afferent fibers in the dorsal horn, this would imply that, after 
retrograde transport from the periphery, GDNF protein is transported anterogradely towards the 
terminals in the spinal cord for release through a process called neuronal transcytosis (Rind and 
von Bartheld, 2002; von Bartheld et al., 2001). An alternative and more plausible possibility 
is that the GDNF mRNA levels are too low to be detected by standard in situ hybridization 
procedures. This is supported by the fact that GDNF immunoreactivity is clearly enhanced by 
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pretreatment of animals with colchicine, which blocks axonal transport (Ohta et al., 2001). If 
GDNF protein would originate in the periphery, an axonal transport block would also block the 
flow of GDNF protein from the periphery towards the DRG somata, leading to unchanged levels 
of GDNF in the DRG (or a decrease due to breakdown of GDNF protein) rather than an increase 
in GDNF. In contrast, the observed increase in GDNF immunoreactivity favors an accumulation 
of GDNF that is synthesized in DRG somata. Furthermore, ligation of the sciatic nerve in rats led 
to an accumulation of GDNF at the ganglion side of the ligation (Neuteboom, R.F. and Holstege, 
J.C., unpublished observation and Honda et al., 1999), indicating that GDNF is transported 
anterogradely (i.e. away from the DRG soma) rather than retrogradely. Finally, it may be argued 
that the weak GDNF immunohistochemical signal in the DRG somata indicates that GDNF, after 
synthesis, is directly transported peripherally to the terminals in peripheral tissues and centrally to 
terminals in the spinal dorsal horn, where it accumulates. This would also explain weak somatic 
and strong terminal labeling.
GDNF is present in fibers that terminate in lamina I and the outer layer of lamina II of the 
spinal dorsal horn (Chapter 2) and (Ohta et al., 2001). These primary afferent fibers are the 
only source of GDNF in the dorsal horn, since a transection of these fibers (a dorsal rhizotomy) 
leads to a complete disappearance of GDNF from the dorsal horn (Chapter 2). Based on the 
immunohistochemical distribution of GDNF in the spinal cord, which is almost identical to the 
distribution of the peptidergic primary afferent fibers, in many of which substance P, CGRP and 
galanin are colocalized, we suggest that GDNF is also localized in neurons belonging to the subgroup 
of peptidergic primary afferents. This idea is substantiated by the finding that GDNF colocalizes 
with SubP in the spinal cord (Fang et al., 2003). Furthermore, it was demonstrated that GDNF 
protein is mainly present in small to medium sized DRG neurons and that only a small number 
of GDNF-ir DRG cells belonged to the group of non-peptidergic neurons (Honda et al., 1999). All 
these findings are in accordance with a localization of GDNF in fibers from peptidergic neurons. 
Ultrastructural studies of the localization of GDNF in the superficial dorsal horn showed that 
GDNF was localized in dense-cored vesicles (Holstege et al., 1999; Ohta et al., 2001) (Fig. 2). 
This type of vesicle also contains neuropeptides like Substance P (SubP), calcitonin gene-related 
peptide (CGRP) and the neurotrophin Brain-Derived Neurotrophic Factor (BDNF). Dense-cored 
vesicles are filled with neuropeptides in the Golgi complex in the DRG soma and subsequently 
transported towards the axon terminals where they are released in an activity dependent 
manner, but only when calcium levels in the terminal are relatively high, i.e. after strong and 
prolonged stimulation. This suggests that GDNF is released in a similar, activity dependent, way. 
In conclusion, the presence of GDNF protein in DRG somata, the anterograde transport within 
primary afferent fibers and its localization in dense-cored vesicles in terminals of primary afferents 
in the superficial dorsal horn, are all in agreement with synthesis of GDNF within DRG neurons 
and its presence in primary afferent terminals.
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The second criterion states that a putative neurotransmitter should be released following 
stimulation. With respect to GDNF, there is presently no direct evidence suggesting that GDNF is 
released in an activity dependent manner. The main argument here is that GDNF is localized within 
dense-cored vesicles, which implies that GDNF is released the same way as dense-cored vesicles 
release their content. In contrast to the release from small clear vesicles, release from dense-cored 
vesicles occurs not only at the active zones in nerve terminals, but also at extrasynaptic sites 
(Purves, 2004). Furthermore, release from dense-cored vesicles only takes place when there is 
a significant rise in the calcium level throughout the terminal, which is achieved solely by high 
frequency stimulation, i.e. by strong nociceptive stimulation. So far GDNF release from neurons 
has never been shown in vivo or in an ex-vivo dorsal root-spinal cord preparation, like has been 
shown for BDNF (Lever et al., 2001). Actual release has only been shown in vitro from neural 
progenitor cells that were genetically modified to secrete GDNF (Behrstock et al., 2005; Klein et 
al., 2005), which were intended for the treatment of amyotrophic lateral sclerosis and Parkinson’s 
disease. In conclusion, only the above discussed indirect evidence suggests that GDNF is released 
following stimulation.
The third criterion states that, following release, a putative neurotransmitter should act on a 
post-synaptic receptor and cause a biological effect. GDNF signaling is mediated by a receptor 
complex consisting of RET, the signal transducing element, and GFRα-1, the GDNF binding co-
receptor. The presence of GFRα-1 has been demonstrated in the spinal dorsal horn using in 
situ hybridization (Glazner et al., 1998; Widenfalk et al., 2001) and immunohistochemistry 
(Matsuo et al., 2000). In Chapter 4 and 5 of this thesis it was shown that RET is expressed 
in dorsal horn neurons, that were identified by their simultaneous expression of the neuron 
specific marker MAP2 (Chapter 5). RET expressing neurons in lamina I at least partly represent 
nociceptive specific projection neurons, both by morphology (chapter 3) and by a high degree of 
colocalization with the SubP receptor NK-1 (chapter 4). In conclusion, in the termination area of 
GDNF containing primary afferent fibers, many (nociceptive specific) RET and GFRα-1 neurons 
are present, showing that there is a good match between the putative neurotransmitter (i.e. 
GDNF) and its postsynaptic receptor (i.e. RET and GFRα-1). This provides the basic requirements 
for GDNF to act as a neuromodulator in spinal pain transmission.
The fourth criterion states that when a putative transmitter is applied on the post-synaptic 
membrane, it should have the same effect as when it is released by a neuron, and known 
antagonists of the putative transmitter should block its effect in a dose-dependent manner. In 
2001 it was shown for the first time that GDNF induced acute effects, namely the activation 
of potassium channels on dopaminergic cells in vitro, via a mechanism that involves activation 
of MAP kinase (Yang et al., 2001). Later it was shown that this effect was not restricted to 
potassium channels but also involved acute potentiation of calcium channels (Wang et al., 2003). 
Chapter 3 describes that intrathecal GDNF injection in rats rapidly induces an upregulation of the 
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immediate early gene (IEG) products c-Fos, c-Jun and Krox-24 in spinal dorsal horn neurons, 
which effect was concentration dependent and, in case of c-Fos, occurred in about 40% of RET 
expressing neurons. In conclusion, rapid postsynaptic effects of exogenously applied GDNF favor 
a role as a neuromodulator, although additional experiments using GDNF antagonists are urgently 
needed to see whether the rapid effects from exogenous GDNF parallel those from endogenous 
GDNF release in response to physiological stimuli.
The fifth criterion states that after a putative neurotransmitter is released from a neuron, it 
should be inactivated, e.g. through a reuptake mechanism or by an enzyme that stops the action 
of the transmitter. In order to satisfy this criterion for GDNF in the context of spinal nociception 
there must be a mechanism in place, which terminates its actions, following release from primary 
afferent terminals in the dorsal horn. Generally, there are three ways in which GDNF may be 
inactivated after release. Firstly, GDNF may simply diffuse away from the site of release and 
become functionally inactive by dilution, which was actually shown in Chapter 3. Secondly, 
GDNF’s actions may be terminated by uptake from soluble GFRα-1. Soluble GFRα-1 is involved 
in so called in-trans signaling (Paratcha and Ibanez, 2002) (Chapter 5), which is thought of as 
a way to increase sensitivity for GDNF signaling (Paratcha et al., 2001). Alternatively it may 
speculated that these soluble receptors contribute to removal of GDNF from synapses, just as it 
has been suggested that BDNF may be inactivated by truncated Tyrosine kinase B (TrkB) receptors 
(Pezet et al., 2002). Finally, GDNF may be inactivated by enzymatic degradation. Although such a 
mechanism is commonly accepted for small molecule neurotransmitters such as acetylcholine, it 
is not regarded a general principle for neuropeptides and proteins like BDNF (Pezet et al., 2002). 
In conclusion, although inactivation through diffusion has been shown for exogenously applied 
GDNF and this may fit its role as a neuromodulator, it is currently not clear which mechanisms 
contribute to endogenously released GDNF inactivation.
When reviewing the criteria as they were applied to GDNF, it may be concluded that evidence 
so far is consistent with a role of GDNF as a neuromodulator in spinal pain transmission and, 
equally important, that none of the data argue directly against a neuromodulator role of GDNF. 
However, additional data are urgently needed to make this claim unambiguously. Firstly, detection 
of GDNF mRNA is necessary to prove synthesis of GDNF in DRG neurons. Secondly, actual release 
of GDNF from primary afferent terminals in response to nociceptive stimuli and demonstration 
of biological effects from endogenously released GDNF is another prerequisite to firmly establish 
GDNF as a neuromodulator in spinal pain transmission.
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IS GDNF AN ANALGESIC OR A HYPERALGESIC COMPOUND?
Neurotrophic factors have different roles in the nervous system. They may act as trophic factors, 
in which case they are taken up from the environment and transported retrogradely towards the 
cell soma to exert their effects on the neuron. Alternatively, they may be produced by the neuron, 
transported anterogradely towards the nerve terminal and be released to exert their effects as 
a transmitter on the next neuron. As stated in the introduction of this thesis, the trophic effect 
of neurotrophic factors is evident from its role in survival and differentiation of neurons during 
development and its regenerative effects on damaged neurons in adulthood. Thus, exogenous 
application of NGF and BDNF can reverse pathological changes that occur after damage to 
nociceptive fibers, by virtue of their retrograde trophic actions. Since neuropathic pain is one of 
the main consequences of damage to nociceptive fibers, it is not surprising that NGF and BDNF 
have been shown to reverse neuropathic pain behavior (Apfel et al., 1994; Apfel et al., 1991; 
McArthur et al., 2000; Mitsumoto et al., 1994; Ren et al., 1995). NGF and BDNF may therefore 
be considered analgesic factors in neuropathic pain, by virtue of their capacity to counteract the 
pathological hyperalgesic effects that occur after nerve lesion. 
In inflammatory conditions, the roles of NGF and BDNF are entirely different from those in 
neuropathic pain. In this case, when there is no damage to nociceptive fibers, NGF is released from 
peripheral inflammatory cells, acting as a pro-inflammatory cytokine, and is both necessary and 
sufficient for the induction of hyperalgesia (Shu and Mendell, 1999). BDNF, produced by spinal 
ganglion cells and released from their terminals in the spinal cord, acting as a neurotransmitter, 
also induces inflammatory hyperalgesia (Zhao et al., 2006). NGF and BDNF may therefore be 
considered hyperalgesic factors in inflammatory pain, considering their net effect on nociceptive 
transmission.
A similar situation applies to the role of GDNF in nociception. GDNF determines the 
phenotype of primary afferent neurons in the early postnatal period and acts as a survival 
factor for axotomized nociceptors in adult animals. It was shown that intrathecal application of 
GDNF reverses phenotypical changes induced by peripheral axotomy (Bennett et al., 1998) and 
neuropathic pain behavior (Boucher et al., 2000), by virtue of its trophic effects. Thus, GDNF 
may be considered an analgesic factor in neuropathic pain. In contrast to the trophic effects of 
GDNF in pathological situations like neuropathic pain, we have provided evidence in this thesis 
that the physiological role of GDNF during adulthood is that of a neuromodulator involved in 
spinal nociceptive transmission. Supposing such a role for GDNF, the question immediately arises 
whether GDNF in these situations acts as an analgesic or a hyperalgesic compound? In chapter 4 
of this thesis we have demonstrated increased c-Fos expression in superficial dorsal horn neurons 
that express RET, the receptor for GDNF, following intrathecal GDNF injection. C-Fos is considered 
a marker of neuronal excitation and such an excitatory effect of GDNF on spinal neurons is in line 
with excitatory effects of GDNF elsewhere in the nervous system (Wang et al., 2003; Yang et al., 
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2001). Since in lamina I RET colocalizes with NK-1 to a high degree and since the majority of 
neurons in lamina I are known to be nociceptive specific neurons, increased c-Fos expression in 
SDH neurons following GDNF injection suggests a hyperalgesic action for GDNF. In a rat model 
of arthritis pain, an intrathecally applied GDNF function-blocking antibody resulted in attenuation 
of pain behavior (Fang et al., 2003). However it was also postulated (Malcangio et al., 2002) 
that GDNF has an analgesic effect during inflammation, through an indirect effect on dorsal horn 
somatostatin release. 
It may be concluded that the findings on the effects of GDNF regarding the modulation of 
nociceptive information in the spinal cord are limited and inconclusive. Based on the findings 
provided in this thesis, it seems most likely that GDNF exerts an excitatory effect on nociceptive 
neurons, in other words GDNF acts as a hyperalgesic transmitter in the spinal cord. Further 
experiments are needed to substantiate this conclusion.
FROM EXPERIMENTAL NOCICEPTION TO CLINICAL PAIN
As stated in the introduction where the organization of the nociceptive system was discussed, 
most of our knowledge regarding pain relates to the initial stages of pain processing, while the 
later stages, including the affective-motivational aspect of pain, have only recently begun to be 
explored, with the help of functional MRI and other imaging techniques. Furthermore, by far the 
greatest part of our knowledge of the pain system is based on experiments using cells, tissues 
and laboratory animals. So the question soon arises, what can cells, tissues and animals teach 
us about pain processing and the treatment of pain? The answer is: a lot, but not everything. To 
illustrate this, three examples of advances in the treatment of pain and how they relate to basic 
research will be discussed.
The leaves from willow trees were already known to have analgesic efficacy to animals and 
to the ancient Greeks when the active ingredient became commercially available to humans as 
Aspirin® in 1899. However, it was not until the 1960s-1970s that its exact mechanism of action 
became known. Aspirin® turned out to be an inhibitor of the cyclo-oxygenase (Cox) enzyme, which 
is responsible for the conversion of arachnidonic acid into prostaglandins, which are powerful 
proinflammatory agents. The experimental work leading to this discovery was awarded with the 
Nobel prize in Medicine or Physiology for Bergstrom, Samuelsson and Vane in 1982 (Oates, 1982) 
and stimulated pharmaceutical companies to develop new Non-Steroidal Anti Inflammatory Drugs 
(NSAIDs) and later, following the discovery of two different Cox-enzymes (Hla and Neilson, 1992), 
a whole new group of analgesics, called the Cox inhibitors (Coxibs). The second example is opium, 
which has been used as a treatment for pain since ancient times in different cultures. In the early 
19th century morphine was extracted as the single analgesic compound in the poppy. Although 
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most of our knowledge regarding the clinical pharmacology of opioids results from experiments on 
humans and clinical observations, the discovery of opioid receptors in guinee-pig gut in the 1960s 
(Gyand and Kosterlitz, 1966) and the subsequent discovery of the periaqueductal grey (Tsou and 
Jang, 1964) and spinal cord (Gouarderes et al., 1985; Yaksh and Rudy, 1976) as sites of action 
of morphine in rats spurred a large amount of basic experimental work that led to the development 
of new pharmacological compounds with various affinities for the three opioid receptors, such 
as oxycodone and fentanyl, and the application of novel techniques of analgesia, such as spinal 
analgesia. The third example is the identification of the anterolateral system and more recently 
the dorsal column pathway for visceral pain (Willis et al., 1999) in animals, that paved the way 
for new treatments in cancer patients. Nowaydays cordotomy for intractable somatic pain and 
midline myelotomy for visceral pain in patients with advanced cancer has become a standard 
procedure in tertiary cancer centers.
Thus, experimental pain research has contributed tremendously to the development of 
analgesics and physical analgetic treatments. However, there are still many conditions which 
are refractory to current pain treatment, the most obvious being cancer pain and neuropathic 
pain. Certainly, animal models of cancer pain (Halvorson et al., 2005; Medhurst et al., 2002; 
Schwei et al., 1999) and neuropathic pain (Bennett and Xie, 1988; Decosterd and Woolf, 2000; 
Kim and Chung, 1992) may reveal underlying mechanisms of these pain states, but unraveling 
a particular pain mechanism holds no promise that this will result in an effective treatment. It is 
well known that new treatments that were effective in experimental animals ultimately failed in 
clinical trials. There are several explanations for this: firstly, a particular pain inducing mechanism 
is almost never the simple cause of a pain syndrome. Usually multiple redundant mechanisms 
act in concert and intervening in one mechanism will be compensated by another. Secondly, it 
is virtually impossible to assess spontaneous pain in experimental animals, basically because 
animals cannot communicate their experiences in much detail. Pain in animals is generally 
assessed by measuring changes in pain thresholds, i.e. evoked pain and not spontaneous pain. In 
the clinic and outpatient clinic, however, patients complain mostly about their spontaneous pain. 
Thirdly, it is more and more acknowledged that the affective-motivational aspect of pain has an 
important contribution to the overall pain experience. In clinical pain trials nowadays therefore 
pain unpleasantness (Gracely and Dubner, 1987), affective pain scores (Richter et al., 2005) and 
mood (Lesser et al., 2004) are considered equally important outcome measures as pain intensity. 
This quality of pain is hard to determine in experimental animals.
How do the above contemplations relate to the current thesis on the involvement of 
neurotrophic factors in spinal pain transmission? It is true that so far all clinical trials with delivery 
of neurotrophic factors to patients with diabetic neuropathy (Apfel et al., 1998), amyotrophic 
lateral sclerosis and Parkinson’s disease (Nutt et al., 2003; Gill et al., 2003; Lang et al., 2006) 
have not shown any clinical efficacy. Therefore one may conclude that the clinical application of 
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neurotrophic factors is not worth pursuing (Apfel, 2002), but not before potential causes for failure 
of neurotrophic factors have been critically evaluated. One possible explanation is a practical 
one: since neurotrophic factors are large molecules subject to degradation and poor penetration, 
they may not reach their targets during systemic or intrathecal application and novel routes of 
administration have to be developed to explore their full therapeutic potential. A second reason 
relates to the fact that no clear distinction between the trophic effects and the rapid modulatory 
effects of neurotrophic factors were made. So far, clinical trials were initiated to counteract 
neurodegenerative conditions. However, neurotrophic factors do not act exclusively as trophic 
factors but may also act as neuromodulators as is argued in this thesis. NGF is now generally 
accepted as an important mediator of inflammatory hyperalgesia, BDNF as a neuromodulator in 
spinal nociceptive transmission and GDNF may be added to this list. Based on sound evidence 
from numerous experimental animal studies showing a strong effect of NGF antagonists in both 
inflammatory (Lewin et al., 1993; McMahon et al., 1995) and cancer pain (Halvorson et al., 
2005; Sevcik et al., 2005), a phase I clinical trial has recently been started to evaluate the efficacy 
of intraarticular injection of a monoclonal antibody against NGF in osteoarthritis. Thus, based on 
experimental studies with neurotrophic factors, it becomes clear that the clinical application of 
neurotrophic factors or its antagonists should be aimed at their fast modulatory effects rather 
than at their trophic effects. It is true that neurotrophic factors are just one of many classes of 
substances that are involved in pain sensation. However they constitute a unique class since 
they act on tyrsine kinase receptors, which may be targeted without affecting the other classes 
of transmitters and receptors involved in pain transmission. So far compounds targeting tyrosine 
kinase receptors are used in oncology and pharmaceutical companies will undoubtedly expand 
application of thesekinds of compounds for use in pain conditions, e.g. when anti-NGF trials will 
prove successful. In this way research on neurotrophic factors in xperimental animals may not 
only give insight in important pain mechaniss, but may also identify new target for the treatment 
of chronic pain.
131
General discussion
REFERENCES
Apfel SC. 2002. Is the therapeutic application of neurotrophic factors dead? Ann Neurol 51(1):8-11.
Apfel SC, Arezzo JC, Brownlee M, Federoff H, Kessler JA. 1994. Nerve growth factor administration protects 
against experimental diabetic sensory neuropathy. Brain Res 634(1):7-12.
Apfel SC, Kessler JA, Adornato BT, Litchy WJ, Sanders C, Rask CA. 1998. Recombinant human nerve growth 
factor in the treatment of diabetic polyneuropathy. NGF Study Group. Neurology 51(3):695-702.
Apfel SC, Lipton RB, Arezzo JC, Kessler JA. 1991. Nerve growth factor prevents toxic neuropathy in mice. 
Ann Neurol 29(1):87-90.
Bar KJ, Saldanha GJ, Kennedy AJ, Facer P, Birch R, Carlstedt T, Anand P. 1998. GDNF and its receptor 
component Ret in injured human nerves and dorsal root ganglia. Neuroreport 9(1):43-47.
Behrstock S, Ebert A, McHugh J, Vosberg S, Moore J, Schneider B, Capowski E, Hei D, Kordower J, Aebischer 
P, Svendsen CN. 2005. Human neural progenitors deliver glial cell line-derived neurotrophic factor to 
parkinsonian rodents and aged primates. Gene Ther.
Bennett DL, Michael GJ, Ramachandran N, Munson JB, Averill S, Yan Q, McMahon SB, Priestley JV. 1998. 
A distinct subgroup of small DRG cells express GDNF receptor components and GDNF is protective for these 
neurons after nerve injury. J Neurosci 18(8):3059-3072.
Bennett GJ, Xie YK. 1988. A peripheral mononeuropathy in rat that produces disorders of pain sensation like 
those seen in man. Pain 33(1):87-107.
Boucher TJ, Okuse K, Bennett DL, Munson JB, Wood JN, McMahon SB. 2000. Potent analgesic effects of 
GDNF in neuropathic pain states. Science 290(5489):124-127.
Decosterd I, Woolf CJ. 2000. Spared nerve injury: an animal model of persistent peripheral neuropathic pain. 
Pain 87(2):149-158.
Del Fiacco M, Quartu M, Serra MP, Follesa P, Lai ML, Bachis A. 2002. Topographical localization of glial 
cell line-derived neurotrophic factor in the human brain stem: an immunohistochemical study of prenatal, 
neonatal and adult brains. J Chem Neuroanat 23(1):29-48.
Dong ZQ, Ma F, Xie H, Wang YQ, Wu GC. 2005a. Changes of expression of glial cell line-derived neurotrophic 
factor and its receptor in dorsal root ganglions and spinal dorsal horn during electroacupuncture treatment in 
neuropathic pain rats. Neurosci Lett 376(2):143-148.
Dong ZQ, Wang YQ, Ma F, Xie H, Wu GC. 2005b. Down-regulation of GFRalpha-1 expression by 
antisense oligodeoxynucleotide aggravates thermal hyperalgesia in a rat model of neuropathic pain. 
Neuropharmacology.
Fang M, Wang Y, He QH, Sun YX, Deng LB, Wang XM, Han JS. 2003. Glial cell line-derived neurotrophic factor 
contributes to delayed inflammatory hyperalgesia in adjuvant rat pain model. Neuroscience 117(3):503-512.
Gill SS, Patel NK, Hotton GR, O’Sullivan K, McCarter R, Bunnage M, Brooks DJ, Svendsen CN, Heywood 
P. 2003. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 
9(5):589-595.
Glazner GW, Mu X, Springer JE. 1998. Localization of glial cell line-derived neurotrophic factor receptor alpha 
and c-ret mRNA in rat central nervous system. J CompNeurol 391:42-49.
132
Chapter 6
Golden JP, Baloh RH, Kotzbauer PT, Lampe PA, Osborne PA, Milbrandt J, Johnson EM, Jr. 1998. Expression 
of neurturin, GDNF, and their receptors in the adult mouse CNS. J CompNeurol 398:139-150.
Gouarderes C, Cros J, Quirion R. 1985. Autoradiographic localization of mu, delta and kappa opioid receptor 
binding sites in rat and guinea pig spinal cord. Neuropeptides 6(4):331-342.
Gracely RH, Dubner R. 1987. Reliability and validity of verbal descriptor scales of painfulness. Pain 
29(2):175-185.
Gyand EA, Kosterlitz HW. 1966. Agonist and antagonist actions of morphine-like drugs on the guinea-pig 
isolated ileum. Br J Pharmacol Chemother 27(3):514-527.
Halvorson KG, Kubota K, Sevcik MA, Lindsay TH, Sotillo JE, Ghilardi JR, Rosol TJ, Boustany L, Shelton DL, 
Mantyh PW. 2005. A blocking antibody to nerve growth factor attenuates skeletal pain induced by prostate 
tumor cells growing in bone. Cancer Res 65(20):9426-9435.
Hammarberg H, Piehl F, Cullheim S, Fjell J, Hokfelt T, Fried K. 1996. GDNF mRNA in Schwann cells and DRG 
satellite cells after chronic sciatic nerve injury. Neuroreport 7(4):857-860.
Hla T, Neilson K. 1992. Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci U S A 89(16):7384-7388.
Hokfelt T, Johansson O, Ljungdahl A, Lundberg JM, Schultzberg M. 1980. Peptidergic neurones. Nature 
284(5756):515-521.
Hokfelt T, Kellerth JO, Nilsson G, Pernow B. 1975. Substance p: localization in the central nervous system 
and in some primary sensory neurons. Science 190(4217):889-890.
Holstege JC, van Rooijen-Boot A, Jongen JLM, Haasdijk E, Neuteboom RF, Vecht CJ. 1999. Localization of 
BDNF and GDNF protein in rat spinal cord using light and electron microscopy immunocytochemistry. Soc 
Neurosci Abstr 25:1272.
Honda T, Takahashi M, Sugiura Y. 1999. Co-localization of the glial cell-line derived neurotrophic factor and its 
functional receptor c-RET in a subpopulation of rat dorsal root ganglion neurons. Neurosci Lett 275(1):45-48.
Jongen JL, Haasdijk ED, Sabel-Goedknegt H, van der Burg J, Vecht Ch J, Holstege JC. 2005. Intrathecal 
injection of GDNF and BDNF induces immediate early gene expression in rat spinal dorsal horn. Exp Neurol 
194(1):255-266.
Josephson A, Widenfalk J, Trifunovski A, Widmer HR, Olson L, Spenger C. 2001. GDNF and NGF family 
members and receptors in human fetal and adult spinal cord and dorsal root ganglia. J Comp Neurol 
440(2):204-217.
Kim SH, Chung JM. 1992. An experimental model for peripheral neuropathy produced by segmental spinal 
nerve ligation in the rat. Pain 50(3):355-363.
Klein SM, Behrstock S, McHugh J, Hoffmann K, Wallace K, Suzuki M, Aebischer P, Svendsen CN. 2005. 
GDNF delivery using human neural progenitor cells in a rat model of ALS. Hum Gene Ther 16(4):509-521.
Lang AE, Gill S, Patel NK, Lozano A, Nutt JG, Penn R, Brooks DJ, Hotton G, Moro E, Heywood P, Brodsky MA, 
Burchiel K, Kelly P, Dalvi A, Scott B, Stacy M, Turner D, Wooten VG, Elias WJ, Laws ER, Dhawan V, Stoessl AJ, 
Matcham J, Coffey RJ, Traub M. 2006. Randomized controlled trial of intraputamenal glial cell line-derived 
neurotrophic factor infusion in Parkinson disease. Ann Neurol 59(3):459-466.
Lesser H, Sharma U, LaMoreaux L, Poole RM. 2004. Pregabalin relieves symptoms of painful diabetic 
neuropathy: a randomized controlled trial. Neurology 63(11):2104-2110.
133
General discussion
Lever IJ, Bradbury EJ, Cunningham JR, Adelson DW, Jones MG, McMahon SB, Marvizon JC, Malcangio M. 
2001. Brain-derived neurotrophic factor is released in the dorsal horn by distinctive patterns of afferent fiber 
stimulation. J Neurosci 21(12):4469-4477.
Lewin GR, Ritter AM, Mendell LM. 1993. Nerve growth factor-induced hyperalgesia in the neonatal and adult 
rat. J Neurosci 13(5):2136-2148.
Malcangio M, Getting SJ, Grist J, Cunningham JR, Bradbury EJ, Charbel Issa P, Lever IJ, Pezet S, Perretti M. 
2002. A novel control mechanism based on GDNF modulation of somatostatin release from sensory neurones. 
Faseb J 16(7):730-732.
Matsuo A, Nakamura S, Akiguchi I. 2000. Immunohistochemical localization of glial cell line-derived 
neurotrophic factor family receptor alpha-1 in the rat brain: confirmation of expression in various neuronal 
systems. Brain Res 859(1):57-71.
McArthur JC, Yiannoutsos C, Simpson DM, Adornato BT, Singer EJ, Hollander H, Marra C, Rubin M, Cohen 
BA, Tucker T, Navia BA, Schifitto G, Katzenstein D, Rask C, Zaborski L, Smith ME, Shriver S, Millar L, Clifford 
DB, Karalnik IJ. 2000. A phase II trial of nerve growth factor for sensory neuropathy associated with HIV 
infection. AIDS Clinical Trials Group Team 291. Neurology 54(5):1080-1088.
McMahon SB, Bennett DL, Priestley JV, Shelton DL. 1995. The biological effects of endogenous nerve growth 
factor on adult sensory neurons revealed by a trkA-IgG fusion molecule. Nat Med 1(8):774-780.
Medhurst SJ, Walker K, Bowes M, Kidd BL, Glatt M, Muller M, Hattenberger M, Vaxelaire J, O'Reilly T, Wotherspoon 
G, Winter J, Green J, Urban L. 2002. A rat model of bone cancer pain. Pain 96(1-2):129-140.
Meng X, Lindahl M, Hyvonen ME, Parvinen M, de Rooij DG, Hess MW, Raatikainen-Ahokas A, Sainio K, 
Rauvala H, Lakso M, Pichel JG, Westphal H, Saarma M, Sariola H. 2000. Regulation of cell fate decision of 
undifferentiated spermatogonia by GDNF. Science 287(5457):1489-1493.
Mitsumoto H, Ikeda K, Klinkosz B, Cedarbaum JM, Wong V, Lindsay RM. 1994. Arrest of motor neuron 
disease in wobbler mice cotreated with CNTF and BDNF. Science 265(5175):1107-1110.
Nutt JG, Burchiel KJ, Comella CL, Jankovic J, Lang AE, Laws ER, Jr., Lozano AM, Penn RD, Simpson RK, 
Jr., Stacy M, Wooten GF. 2003. Randomized, double-blind trial of glial cell line-derived neurotrophic factor 
(GDNF) in PD. Neurology 60(1):69-73.
Oates JA. 1982. The 1982 Nobel Prize in Physiology or Medicine. Science 218(4574):765-768.
Ohta K, Inokuchi T, Gen E, Chang J. 2001. Ultrastructural study of anterograde transport of glial cell line-
derived neurotrophic factor from dorsal root ganglion neurons of rats towards the nerve terminal. Cells Tissues 
Organs 169(4):410-421.
Ren K, Thomas DA, Dubner R. 1995. Nerve growth factor alleviates a painful peripheral neuropathy in rats. 
Brain Res 699(2):286-292.
Shu XQ, Mendell LM. 1999. Neurotrophins and hyperalgesia. Proc Natl Acad Sci U S A 96(14):7693-7696.
Wang J, Chen G, Lu B, Wu CP. 2003. GDNF acutely potentiates Ca2+ channels and excitatory synaptic 
transmission in midbrain dopaminergic neurons. Neurosignals 12(2):78-88.
Yang F, Feng L, Zheng F, Johnson SW, Du J, Shen L, Wu CP, Lu B. 2001. GDNF acutely modulates excitability 
and A-type K(+) channels in midbrain dopaminergic neurons. Nat Neurosci 4(11):1071-1078.
Zhao J, Seereeram A, Nassar MA, Levato A, Pezet S, Hathaway G, Morenilla-Palao C, Stirling C, Fitzgerald M, 
McMahon SB, Rios M, Wood JN. 2006. Nociceptor-derived brain-derived neurotrophic factor regulates acute 
and inflammatory but not neuropathic pain. Mol Cell Neurosci.
134
Chapter 6
Paratcha G, Ibanez CF. 2002. Lipid rafts and the control of neurotrophic factor signaling in the nervous 
system: variations on a theme. Curr Opin Neurobiol 12(5):542-549.
Paratcha G, Ledda F, Baars L, Coulpier M, Besset V, Anders J, Scott R, Ibanez CF. 2001. Released GFRalpha1 
potentiates downstream signaling, neuronal survival, and differentiation via a novel mechanism of recruitment 
of c-Ret to lipid rafts. Neuron 29(1):171-184.
Pezet S, Malcangio M, McMahon SB. 2002. BDNF: a neuromodulator in nociceptive pathways? Brain Res 
Brain Res Rev 40(1-3):240-249.
Purves D. 2004. Neuroscience. Purves D, editor. Massachusets: Sinauer Associates, Inc.
Quartu M, Serra MP, Bachis A, Lai ML, Ambu R, Del Fiacco M. 1999. Glial cell line-derived neurotrophic 
factor-like immunoreactivity in human trigeminal ganglion and nucleus. Brain Res 847(2):196-202.
Richter RW, Portenoy R, Sharma U, Lamoreaux L, Bockbrader H, Knapp LE. 2005. Relief of painful diabetic 
peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J Pain 6(4):253-260.
Rind HB, von Bartheld CS. 2002. Anterograde axonal transport of internalized GDNF in sensory and motor 
neurons. Neuroreport 13(5):659-664.
Schwei MJ, Honore P, Rogers SD, Salak-Johnson JL, Finke MP, Ramnaraine ML, Clohisy DR, Mantyh PW. 
1999. Neurochemical and cellular reorganization of the spinal cord in a murine model of bone cancer pain. J 
Neurosci 19(24):10886-10897.
Sevcik MA, Ghilardi JR, Peters CM, Lindsay TH, Halvorson KG, Jonas BM, Kubota K, Kuskowski MA, 
Boustany L, Shelton DL, Mantyh PW. 2005. Anti-NGF therapy profoundly reduces bone cancer pain and the 
accompanying increase in markers of peripheral and central sensitization. Pain 115(1-2):128-141.
Tsou K, Jang CS. 1964. Studies on the Site of Analgesic Action of Morphine by Intracerebral Micro-Injection. 
Sci Sin 13:1099-1109.
von Bartheld CS, Wang X, Butowt R. 2001. Anterograde axonal transport, transcytosis, and recycling of 
neurotrophic factors: the concept of trophic currencies in neural networks. Mol Neurobiol 24(1-3):1-28.
Wang J, Chen G, Lu B, Wu CP. 2003. GDNF acutely potentiates Ca2+ channels and excitatory synaptic 
transmission in midbrain dopaminergic neurons. Neurosignals 12(2):78-88.
Widenfalk J, Lundstromer K, Jubran M, Brene S, Olson L. 2001. Neurotrophic factors and receptors in the 
immature and adult spinal cord after mechanical injury or kainic acid. J Neurosci 21(10):3457-3475.
Widenfalk J, Widmer HR, Spenger C. 1999. GDNF, RET and GFRalpha-1-3 mRNA expression in the developing 
human spinal cord and ganglia. Neuroreport 10(7):1433-1439.
Willis WD, Al-Chaer ED, Quast MJ, Westlund KN. 1999. A visceral pain pathway in the dorsal column of the 
spinal cord. Proc Natl Acad Sci U S A 96(14):7675-7679.
Yaksh TL, Rudy TA. 1976. Analgesia mediated by a direct spinal action of narcotics. Science 
192(4246):1357-1358.
Yang F, Feng L, Zheng F, Johnson SW, Du J, Shen L, Wu CP, Lu B. 2001. GDNF acutely modulates excitability 
and A-type K(+) channels in midbrain dopaminergic neurons. Nat Neurosci 4(11):1071-1078.
135
General discussion
FIGURES
Fig. 1. Otto Loewi’s experiment: Two frog hearts were perfused with and kept in warm Ringer’s 
solution. In this condition the hearts continued to beat for a couple of hours. He then stimulated 
the vagus nerve to heart #1. As a consequence there was a strong inhibition in this heart beats. 
When the perfusion fluid of heart  #1 was transferred to heart #2, exactly the same effect was 
achieved. Loewi rightly concluded that this must be due to a chemical released from the vagus 
nerve into the perfusion fluid, which he called “Vagusstoff”.
Fig. 2. Electron-microscopical image showing dense-cored vesicles (arrowheads) containing GDNF 
immunoreactive product in a primary afferent terminal in the superficial dorsal horn of an adult rat. 

Chapter 7
Summary / Samenvatting
138
Chapter 7
SUMMARY
The aim of this thesis was to investigate the involvement of glial cell line-derived neurotrophic 
factor (GDNF) in spinal pain transmission. In Chapter 1 some recent developments regarding the 
organization of the nociceptive system are discussed, followed by a description of the involvement of 
neurotrophic factors in sensory transmission. This information provides the necessary background 
for the interpretation of the findings in the chapters to follow.
In Chapter 2 immunocytochemistry was used to identify GDNF in rat spinal cord. Strong 
GDNF labeling was found in fibers and terminals in laminae I and IIouter and to a lesser extent in the 
remaining laminae. A few spinal ganglion cells also contained GDNF. After dorsal root transection 
GDNF disappeared from the dorsal horn and after dorsal root ligation there was accumulation of 
GDNF only on the ganglion side of the ligation. These findings demonstrate anterograde transport 
of GDNF within primary afferent fibers, which constitute the only source of GDNF labeling in the 
dorsal horn. The strong presence of GDNF in the superficial dorsal horn may indicate that GDNF 
has a role in pain transmission in the adult rat spinal cord.
 In Chapter 3 the effect of sciatic nerve axotomy on the expression of GDNF protein in 
the dorsal horn was investigated, using immunohistochemistry. Image analysis showed a 44% 
decrease relative to the non-transected side after 5 days survival, progressing to more than 80% 
decrease after 10 days and remaining so for at least 100 days. This rapid and strong decrease 
suggests active downregulation of the expression of GDNF protein after peripheral axotomy. The 
observed downregulation of GDNF is compared with changes observed for other substances in 
primary afferents after peripheral axotomy and is discussed in light of its presumed trophic or 
transmitter role in nociception.
In Chapter 4 the effect of GDNF and brain-derived neurotrophic factor (BDNF) injected by 
lumbar puncture, on the expression of the immediate early gene (IEG) products c-Fos, c-Jun and 
Krox-24 in the adult rat dorsal horn, was investigated. In the dorsal horn of S1 spinal segments, 
GDNF and BDNF induced a strong increase in IEG expression, which was most pronounced in 
laminae I and II (2.9-4.5 fold). More distal from the injection site, in the dorsal horn of L1/L2 
spinal segments, the increase in IEG expression was less pronounced, suggesting a concentration-
dependent effect. In order to explain the effects of intrathecally injected GDNF, we investigated 
whether lumbo-sacral dorsal horn neurons expressed RET protein, the signal-transducing element 
of the receptor complex for GDNF. It was found that several of these neurons contained RET 
immunoreactivity and that some of the RET-immunoreactive neurons had the appearance of 
nociceptive specific cells, confirming their presumed role in pain transmission. These results 
demonstrate that intrathecally applied GDNF and BDNF induce IEG expression in dorsal horn 
neurons in the adult rat, supposedly by way of their cognate receptors, which are present on these 
neurons. It is suggested that the endogenous release of GDNF and BDNF, triggered by nociceptive 
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stimuli, is involved in the induction of changes in spinal nociceptive transmission as in various 
pain states.
RET (REarranged during Transfection) is a transmembrane tyrosine kinase signaling receptor 
for members of the GDNF family of ligands. In Chapter 5 RET immunohistochemistry (IHC), 
double labeling immunofluorescence (IF) and in situ hybridization (ISH) was used in adult naïve 
and nerve injured rats, to study the distribution of RET in the spinal cord. In the dorsal horn, 
strong RET-immunoreactive (-ir) fibers were abundant in lamina IIinner (IIi) and clusters of varicose 
fibers were found in the deeper layers, although this labeling was preferentially observed after an 
antigen unmasking procedure. Following dorsal rhizotomy, the fibers in lamina IIi and the varicose 
fibers completely disappeared from the dorsal horn, indicating that they were all primary afferents. 
Following peripheral axotomy, RET-ir in primary afferents decreased in lamina IIi and appeared 
to slightly increase in lamina III and IV. RET-ir was also observed in neurons and dendrites 
throughout the dorsal horn. Some RET-ir neurons in lamina I had the morphological appearance of 
nociceptive projection neurons, which was confirmed by the finding that 54% of RET-ir neurons in 
lamina I colocalized with neurokinin-1. In the ventral horn, RET-immunoreactivity (-ir) was strongly 
expressed by motoneurons, with the strongest staining in small, presumably gamma-motoneurons, 
since they did not express cholinergic boutons and m2 muscarinic acetylcholine receptor-ir on 
their plasma membrane, in contrast to alpha-motoneurons. Increased RET expression following 
peripheral axotomy was most pronounced in alpha-motoneurons. The expression and regulation 
pattern of RET in the spinal cord is in line with its involvement in regenerative processes following 
nerve injury. The presence of RET in dorsal horn neurons, including nociceptive projection neurons, 
suggests that RET also has a role in signal transduction at the spinal level. This role may include 
mediating the effects of GDNF released from nociceptive afferent fibers.
In Chapter 6 we have applied the criteria that are generally used to define a neurotransmitter, on 
the currently available data on GDNF with respect to its involvement in nociceptive transmission. 
It was concluded that these data are in agreement with a role of GDNF as a neuromodulator in 
spinal pain transmission, although synthesis in the DRG and biological effects from endogenously 
released GDNF should be demonstrated to establish such a role unambiguously.
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SAMENVATTING
Het doel van dit proefschrift was de betrokkenheid van Glial Cell Line-Derived Neurotrophic Factor 
(GDNF) bij spinale pijntransmissie te bestuderen. In Hoofdstuk 1 worden enkele recente ontwikkelen 
betreffende de organisatie van het nociceptieve systeem besproken, gevolgd door een beschrijving van 
de betrokkenheid van neurotrofe factoren in sensibele transmissie. Dit is de achtergrondinformatie die 
nodig is om de bevindingen in de volgende hoofdstukken te kunnen interpreteren.
In Hoofdstuk 2 wordt gebruik gemaakt van immunocytochemie om GDNF in het ruggenmerg van 
de rat aan te tonen. Sterke GDNF labeling werd gevonden in vezels en eindigingen in lamina I, in het 
buitenste gedeelte van lamina II (IIouter) en in mindere mate in de overige lagen van het ruggenmerg. 
Enkele spinale ganglion cellen bevatten ook GDNF. Na doorsnijding van de dorsale wortel was GDNF 
niet meer zichtbaar in de dorsale hoorn van het ruggenmerg en na onderbinding van de dorsale wortel 
accumuleerde GDNF alleen aan de ganglion zijde van de onderbinding. Deze bevindingen tonen dus 
anterograad transport van GDNF in primair afferente vezels aan, welke laatstgenoemde vezels de enige 
bron van GDNF labeling in de dorsale hoorn vormen. De sterke labeling van GDNF in de oppervlakkige 
dorsale hoorn doet vermoeden dat GDNF een rol speelt bij de pijntransmissie in het ruggenmerg van 
de volwassen rat.
In Hoofdstuk 3 werd het effect van doorsnijding van de nervus ischiadicus op de expressie 
van GDNF eiwit onderzocht, met behulp van immunohistochemie. Beeldanalyse van foto’s van de 
ruggenmergcoupes toonde een afname aan van 44% ten opzichte van de contralaterale niet-doorsneden 
kant na 5 dagen. Dit verschil nam toe tot meer dan 80% na 10 dagen en bleef zo groot tot 100 dagen 
na de doorsnijding. De snelle en sterke afname suggereert een actieve downregulatie van GDNF eiwit 
na perifere axotomie. De door ons waargenomen afname van GDNF labeling werd vergeleken met de 
regulatie van andere peptiden en eiwitten in primaire afferenten en werd bediscusseerd in het kader 
van een rol van GDNF hetzij als neurotrofe factor of als neurotranmitter.
In Hoofdstuk 4 werd het effect van GDNF en Brain-Derived Neurotrophic Factor (BDNF) injecties 
door middel van lumbaalpuncties onderzocht, op de expressie van de Immediate Early Gene (IEG) 
products c-Fos, c-Jun en Krox-24, in de dorsale hoorn van de volwassen rat. In de dorsale hoorn 
van S1-ruggenmergsegmenten veroorzaakten GDNF en BDNF een sterke toename van het aantal 
neuronen dat gelabeled was met de verschillende IEGs, welke toename het meest uitgesproken was 
in lamina I en II (met een factor 2,9-4,5). Meer distaal van de injectieplaats, in de dorsale hoorn van 
L1/L2 segmenten, was de toename minder uitgesproken, wat een concentratie-afhankelijk effect doet 
vermoeden. Om de effecten van door middel van een lumbaalpunctie geinjecteerd GDNF te kunnen 
verklaren, onderzochten we of neuronen in de dorsale hoorn van het lumbo-sacrale ruggenmerg RET 
tot expressie brachten. RET is het signaal-transducerende element van het receptor-complex voor 
GDNF. RET immunoreactiviteit bleek aanwezig te zijn in een beduidend aantal neuronen in de dorsale 
hoorn en sommige RET-immunoreactieve neuronen hadden het morfologische aspect van nociceptief-
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specifieke cellen, wat in overeenstemming is met een veronderstelde rol van GDNF in pijntransmissie. 
De resultaten in dit hoofdstuk tonen aan dat intrathecale GDNF en BDNF IEG expressie in dorsale 
hoorn neuronen induceren, zeer waarschijnlijk via activatie van hun respectievelijke receptoren die 
aanwezig zijn op deze neuronen. De suggestie dringt zich daarom op dat endogeen released GDNF en 
BDNF uit primaire afferenten, welke wordt uitgelokt door nociceptieve stimulatie, betrokken zijn bij de 
inductie van veranderingen in spinale nociceptieve transmissie die optreden bij verschillende soorten 
chronische pijn.
RET (REarranged during Transfection) is een transmembraan tyrosine kinase receptor die de 
signaal transductie voor leden van de GDNF familie verzorgt. In Hoofdstuk 5 wordt de distributie van 
RET in het ruggenmerg bestudeerd in normale volwassen ratten en ratten met een zenuwbeschadiging, 
met behulp van immunohistochemie, double-labeling immuunfluorescentie en in situ hybridisatie. In 
de dorsale hoorn waren sterk gelabelde RET-immunoreactieve (-ir) vezels in ruime mate aanwezig in 
het binnenste gedeelte van lamina II (IIinner) en clusters van variceuze vezels werden aangetroffen in 
de diepere lagen. Dit labeling patroon werd voornamelijk gezien na een antigen-unmasking methode. 
Na doorsnijding van de dorsale wortel, verdween de RET labeling in lamina IIinner en in de variceuze 
vezels volledig, wat impliceert dat al deze vezels primaire afferenten zijn. Na doorsnijding van de nervus 
ischiadicus verminderde RET labeling in lamina IIinner en was er een geringe toename in lamina III en 
IV. RET werd ook waargenomen in neuronen en dendrieten in de gehele dorsale hoorn. De bevinding 
dat sommige RET neuronen het morfologische aspect van nociceptieve projectieneuronen hadden 
werd bevestigd door het gegeven dat 54% van de RET-ir neuronen in lamina I ook neurokinin-1 tot 
expressie brachten. In de ventrale hoorn werd RET-ir sterk tot expressie gebracht in motoneuronen, 
met de sterkste labeling in kleine, zeer waarschijnlijk gamma-motoneuronen. Dat het gaat om 
gamma-motoneuronen werd ondersteund door het feit dat deze kleine RET-ir neuronen geen m2 
muscarine aceylcholine receptor-ir en cholinerge boutons op hun celmembraan tot expressie brachten, 
in tegenstelling tot grote alfa-motoneuronen. De toename van RET-ir na doorsnijding van de nervus 
ischiadicus was het meest uitgesproken in alfa-motoneuronen. Het expressie en regulatie patroon 
van RET in het ruggenmerg stemt overeen met de bekende betrokkenheid van RET bij regeneratieve 
processen na zenuwbeschadiging. De aanwezigheid van RET-ir in dorsale hoorn neuronen, waaronder 
nociceptieve projectie neuronen, suggereert dat RET ook een rol speelt bij signaaltransductie op spinaal 
niveau, waaronder het mediëren van effecten van GDNF released uit nociceptieve primaire afferente 
vezels.
In Hoofdstuk 6 zijn de criteria die worden gebruikt om een neurotransmitter te definiëren vergeleken 
met de data die tot op heden bekend zijn over GDNF voor zover het diens rol in nociceptieve transmissie 
betreft. Er werd geconcludeerd dat deze data in overeenstemming zijn met een rol van GDNF als 
neuromodulator in spinale pijntransmissie. Om deze claim ontegenzeggelijk te bewijzen is het echter 
nodig om synthese van GDNF mRNA in het dorsale ganglion en biologische effecten van endogeen 
released GDNF aan te tonen.
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